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Bluetongue is a disease of domestic and wild ruminants caused by Bluetongue virus (BTV).  
It has caused several serious outbreaks, the most recent occurring in Northern Europe in 2006 
during which high mortality rates of livestock were reported.  The only vaccines currently 
approved and commercially available for use are live-attenuated or inactivated virus strains 
and although these are effective, there is the risk of reversion in the case of live-attenuated 
strains to more virulent forms by recombination.  Another drawback associated with the use 
of live-attenuated virus vaccines is that they are not DIVA (differentiate infected from 
vaccinated animals) compliant, this means that naturally infected animals cannot be 
distinguished from vaccinated animals.  Recombinantly produced vaccines would be 
preferable to minimize the risks associated with live-attenuated virus vaccines and also enable 
the development of candidate vaccines that are DIVA-compliant.   
A number of recombinant vaccine candidates have been developed against BTV, with the 
most promising vaccine consisting of BTV virus-like particles (VLPs).   BTV VLPs were 
successfully produced in insect cells by the co-expression of the four BTV capsid proteins 
(VP2, VP3, VP5 and VP7).  Sheep vaccinated with insect cell-produced BTV VLPs were 
shown to be protected against challenge with wild type virus. However, the high costs 
associated with the production and scale-up of BTV VLPs in insect cells has possibly limited 
their widespread application.  Plants – such as N. benthamiana – provides a safe, efficient 
and cost effective system for the production of recombinant proteins.   
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In this study the best plant expression vector with which to co-express the four BTV serotype 
8 (BTV-8) VPs – which direct formation of BTV-8 VLPs – was identified.  Expression and 
purification of the BTV-8 VLPs was optimised with the aim of producing a VLP-based vaccine 
for BTV-8.  It was further undertaken to develop two novel second generation plant-produced 
protein body (PB) vaccines that are DIVA compliant.  Mice were immunised with the plant-
produced VLP and PB vaccines in order to analyse their ability to elicit humoral immune 
responses.  
Agrobacterium-mediated transient heterologous co-expression of the BTV-8 capsid proteins 
in N. benthamiana was optimised by comparing co-expression profiles obtained using different 
plant expression vectors that were available to us.  Successful co-expression of the four capsid 
proteins was achieved using the pEAQ-HT vector.  Expression of BTV-8 VPs using 
recombinant pEAQ-HT constructs was further optimised and it was shown to direct the 
assembly of VLPs which were successfully purified using discontinuous gradient 
ultracentrifugation.  In situ localisation of assembled particles was investigated by using 
transmission electron microscopy (TEM) and it was shown that a mixed population of core-
like particles (CLPs, consisting of VP3 and VP7) and VLPs were present as paracrystalline 
arrays in the cytoplasm of plant cells co-expressing all four capsid proteins.     
Although VLPs are effective vaccine candidates that lack the viral genome and therefore the 
inherent drawbacks associated with live-attenuated virus vaccines, the BTV-8 VLPs are not 
DIVA compliant using current diagnostic techniques.  Moreover, these VLPs provide 
protection against only one of the 26 serotypes of BTV.  A second approach to BTV vaccine 
design was applied by initiating the development of two novel second generation PB plant-
produced vaccines, Zera®-VP2 and Zera®-VP2ep.  Zera®-VP2 contained the full-length BTV-
8 VP2 codon-optimised sequence and Zera®-VP2ep contained predicted B-cell epitope 
sequences of multiple BTV serotypes that were predicted for VP2.  In addition to fulfilling the 
DIVA requirement of a vaccine, Zera®-VP2ep was aimed at being multivalent with the ability 
to stimulate an immune response to several BTV serotypes.  Both these candidate vaccines 
were successfully expressed in N. benthamiana and in situ TEM analysis showed that the 
expressed proteins accumulated within the cytoplasm of plant cells in dense membrane-
defined PBs called StorPro® organelles.  It was shown that the multi-epitope included in Zera®-
VP2ep contained regions that were able to bind to the antibodies produced against native 
VP2.  It was further shown that the PBs were easy to purify due to their dense nature and 
more importantly they were extremely stable, making them ideal vaccine candidates.   
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Preliminary immunogenicity studies of the VLP and PB candidate vaccines were carried out 
in BALB/c mice.  The VLP-based vaccine was found to be unstable as only antibodies to the 
core components, VP3 and VP7, could be detected in the mice serum.  The Zera®-VP2ep and 
Zera®-VP2 vaccine candidates both elicited significant anti-VP2 immune responses in the 
vaccinated mice without the use of adjuvant.  These results demonstrate that Zera®-VP2ep 
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1.1.  Introduction 
Bluetongue (BT) is a non-contagious, arthropod-borne viral disease that affects cattle, sheep, 
goats and wild ruminants (Roy, 2004). BT was first recognised and described in South Africa 
after the introduction of fine-wool sheep from Europe over 200 years ago (Maclachlan and 
Mayo, 2013; Vellema, 2008).  The classical form of BT is seen in sheep; however cattle are 
also a natural reservoir for the virus (Roy, 2004).  The causative agent of BT is the Bluetongue 
virus (BTV), the type species of the genus Orbivirus in the family Reoviridae (Mertens et al., 
2004). BTV is mostly transmitted by adult females of the haematophagous midges that belong 
to the genus Culicoides (du Toit, 1944).   
BTV is endemic in tropical and sub-tropical regions and prior to 1998, outbreaks of BT in 
Southern European countries were rare (Mellor and Boorman, 1995).  However, since 1998 
BTV has become one of the most widespread animal pathogens as it has spread to areas that 
were previously free of the virus (Purse et al., 2005).  Outbreaks of BT occur when susceptible 
sheep are introduced into BTV-endemic regions or when the virus spreads to naïve sheep 
populations at the interface of endemic and non-endemic regions (MacLachlan, 2004).  In 
2006 BTV serotype 8 (BTV-8) was detected in northern Europe (Netherlands, Belgium, 
Germany and the north of France); this was the first time that BTV had been detected beyond 
the latitude of 52 °N.  In subsequent outbreaks the northernmost limits of BTV moved beyond 
54 °N (Vellema, 2008; Wilson and Mellor, 2009).  
In 1996 worldwide economic losses due to BT were estimated to exceed 3 billion US dollars 
per year (Tabachnick, 1996).  These losses are both direct (weight loss, abortions, death, 
reduction in milk production etc.) and indirect, such as trade restrictions, surveillance, 
vaccination, vector control and the treatment of affected animals (MacLachlan and Osburn, 
2006; Wilson and Mellor, 2008). The BTV-8 outbreak in Europe in 2006 is significant as it is 
believed to have caused greater economic damage than any other single-serotype outbreak 
(Wilson and Mellor, 2009).  Due to its ability to rapidly spread, the serious economic 
consequences associated with outbreaks and the impact of the disease on animals (Purse et 




1.2.  Bluetongue virus 
1.2.1.  Classification and variation of BTV 
BTV is a virus with a ten-component double stranded ribonucleic acid (dsRNA) genome that 
causes an insect-borne, infectious non-contagious disease of both domesticated and wild 
ruminants; it is the type species of the genus Orbivirus that is classified into the family 
Reoviridae.  Reoviridae is one of the largest families of virus that includes major human 
pathogens, such as rotavirus, as well as pathogens of insects, reptiles, fish, plants and fungi 
(Mertens et al., 2004).  Orbiviruses differ from other members of the Reoviridae family in that 
they can multiply in both arthropod and vertebrate cells, causing severe disease and high 
mortality (Roy, 2004).  BTV is transmitted between its hosts by Culicoides spp., causing 
disease in ruminants worldwide (Mellor et al., 2008).   
BTV virions are complex three-layered icosahedral structures that are ~80 nanometres (nm) 
in diameter.  The virions are composed of a core of ten segments of dsRNA encapsulated by 
seven structural proteins (four major and three minor proteins) that are arranged into three 




Figure 1.1:  A schematic of the BTV particle showing the four structural proteins, the transcriptase 
complex and the dsRNA genome (Mertens et al., 2004).  Image used with permission from the publisher.  
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The three minor proteins (viral protein [VP] 1, VP4 and VP6) are enclosed by the sub-core that 
is made up of VP3. The core-surface layer consists of VP7, both VP3 and VP7 are major 
proteins.  The outer capsid is composed of major proteins VP2 and VP5 which is laid onto the 
foundation provided by the core. The minor proteins together with genomic RNA form the virus 
replication complex, whereas the four major proteins make up the capsid of the virus (Mertens 
and Diprose, 2004; Mertens et al., 2004; Roy, 1992; Roy, 2004).   
In addition to the structural proteins BTV has four non-structural (NS) proteins (NS1, NS2, 
NS3 and NS3a) which are involved in virus replication and assembly in BTV-infected cells 
(Roy, 2004).  
VP2 is the most variable of the BTV capsid proteins and contains the epitopes involved in virus 
neutralisation and serotype determination (DeMaula et al., 2000; Huismans and Erasmus, 
1981). Twenty six distinct serotypes of BTV have been identified based on neutralisation 
activity of VP2 as well as with BTV specific real time reverse transcriptase polymerase chain 
reaction [RT-PCR, (Hofmann et al., 2008; Maan et al., 2011a; Orru et al., 2006)]. Each 
serotype shows variation that is associated with the geographical origins of the virus from 
around the world (Darpel et al., 2007).  Recent molecular studies on BTV isolates from 
different geographic regions have further divided BTV into two major topotypes, namely the 
eastern lineage which includes BTV isolates from South East Asia, India, China and Australia, 
and the western lineage which includes virus isolates from Africa and North or South America  
(Maan et al., 2012; Maan et al., 2011a; Maan et al., 2008). 
 
1.2.2.  Three-dimensional (3-D) structure of BTV 
The 3-D structure of BTV cores and virions has been determined by cryoelectron microscopy 
(Cryo-EM) and reconstructed using computational methods. Cryo-EM of the BTV core showed 
that it has a diameter of 69 nm, with the surface exhibiting icosahedral symmetry (Grimes et 
al., 1997). Figure 1.2 B and C show that the core is divided into two layers (VP3 and VP7) that 
enclose the ten dsRNA segments and the proteins that are responsible for replication (Figure 
1.2 A).  A total of 120 molecules of VP3 (Figure 1.2 B) provide a smooth scaffold for the VP7 
trimers to associate with (Figure 1.2 C).  The surface of the core consists of clusters of VP7 
trimers that have knob-like protrusions organised into pentameric and hexameric units with 
channels between them. In total there are 780 VP7 molecules per particle.  The layer formed 




Analysis of cryoelectron micrographs of BTV virions show that the two outer capsid proteins, 
VP2 and VP5 (Figure 1.2 D), attach in an orderly fashion to the foundation provided by the 
surface (VP7) of the core. (Roy, 2004).  The capsid is icosahedral and the two outer capsid 
proteins have very distinctive morphologies.  VP5 is globular and 120 of these proteins sit in 
the channels that are formed by the VP7 trimers.  The sail-shaped VP2 spikes are located 
above 180 of the VP7 trimers and form triskelion-type motifs that cover most of the VP7 
molecules.  The VP2 spikes protrude 4 nm above the globular proteins and contain the virus 
neutralising epitopes.  VP2 and VP5 form a continuous layer around the core, except for holes 
on the five-fold axis (Hewat et al., 1992a; Hewat et al., 1992b; Roy, 2004).   
 
Figure 1.2:  A surface representation of a cryoelectron micrograph of BTV, adapted from Roy (2004).  
(A) The RNA genome and the replication complex that is formed by VP1, VP4 and VP6, (B) the smooth 
inner layer formed by 120 molecules of VP3 and (C) protrusions of the 260 VP7 trimers in the outer 
layer.  Together A, B and C form the BTV core. (D)  The topography of the globular-shaped VP5 and 
the sail-shaped VP2 displayed on a whole virus particle.  Image used with permission from the 
publisher.  
 
1.2.3.  Virus Proteins 
The BTV core contains the 10 dsRNA segments, each one encoding a single viral protein, 
except for the smallest RNA segment, S10. The three minor protein components; VP1 (RNA 
dependent RNA polymerase, 150 kilodalton [kDa]), VP4 (capping enzyme, 76 kDa) and VP6 
(helicase, 36 kDa) constitute the transcriptase complex (Mertens et al., 1984; Roy, 1992; 
Singh et al., 2004) .   
The two major proteins that make up the core - VP3 (102 kDa) and VP7 (38 kDa) - are both 
hydrophobic (Roy, 1992).  VP3 is highly conserved among BTV serotypes as well as different 
genera of the Reoviridae family.  VP3 has an important functional role in the structural integrity 
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of the virus core (Huismans and Van Dijk, 1990; Mertens et al., 2004).  VP7 is highly conserved 
among the BTV serotypes and contains the group-specific antigenic determinants.  VP7 is 
often used in current diagnostic serological tests - such as the commercially available 
competitive enzyme linked immunosorbent assays (cELISA) - as the BTV serogroup antigen 
for the detection of BTV (MacLachlan, 1994; MacLachlan, 2004; Roy, 1992; Roy, 1996; 
Vellema, 2008).   
The core of BTV is surrounded by a diffuse outer capsid layer which comprises of VP2 (110 
kDa) and VP5 (58 kDa).  These proteins are the least conserved among virus serotypes (Roy, 
1992; Roy, 1996) and together they are involved in cell attachment and viral entry during 
initiation of infection (Hassan et al., 2001). Specificity of interactions between the proteins of 
the outer capsid (especially VP2) and neutralising antibodies can be evaluated by serum 
neutralisation assays, which distinguish between the different virus serotypes (Singh et al., 
2004). VP2 is the most variable, serotype-specific protein, the viral haemagglutinin and the 
cellular receptor binding protein (Hassan and Roy, 1999; Nason et al., 2004; Roy, 1992). 
Antibodies to VP2 elicit virus neutralisation properties and confer resistance to reinfection with 
a homologous serotype (MacLachlan, 1994; Roy, 1992; Vellema, 2008).  VP5 binds to the 
surface of cells and plays a role in membrane destabilisation in order for the core to gain 
access to the cytoplasm (Forzan et al., 2004; Hassan et al., 2001). 
In addition to the seven structural proteins there are four non-structural proteins, NS1, NS2, 
NS3 and NS3a, that can be found in infected cells.  In contrast to the structural proteins, the 
sequences of the four NS proteins are highly conserved among serotypes (Roy et al., 1990a). 
These proteins are involved in virus replication and assembly (Roy, 1992; Roy, 2004).  NS1 
and NS2 form two virus-specific structures in the cytoplasm of infected cells - tubules and 
granular viral inclusion bodies (VIBs), respectively (Cromack et al., 1971; Lecatsas, 1968).  
The BTV sub-core and core particles are assembled within the VIBs in the cytoplasm of 
infected cells (Mertens et al., 2004).  NS3 and NS3a are both encoded by the same gene 
segment and are associated with intracellular, smooth-surfaced vesicles and the plasma 
membrane.  These proteins mediate the release of BTV from infected cells (Mertens et al., 
2004; Roy, 1992).  
The evolutionary rate (genetic drift) of the multi-segmented RNA viruses is very high as they 
have no proof-reading activity and their genomes are able to reassort, resulting in antigenic 
shift (Gale et al., 2009).  During reassortment, different strains of BTV that infect the same cell 
can exchange their genome segments.  This process is enabled by the segmented nature of 
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the BTV genome and plays a significant role in the generation of new virus strains that have 
different serological and biological properties (Roy et al., 2009; Singh et al., 2004). 
 
1.2.4.  Replication 
BTV can replicate in both wild and domestic ruminants. Replication takes place in both the 







Figure 1.3 shows a schematic representation of the replication cycle of BTV (Mertens, 2002). 
BTV interacts with the cell surface via the VP2 trimers and enters the cell via a clathrin-
dependent endocytosis pathway (Forzan et al., 2004; Hyatt et al., 1993).  The reduction of pH 
in the endosome induces the association of VP5 with the endosomal membrane and the 




delivery of the transcriptionally active core into the cytoplasm (Forzan et al., 2004; Mertens et 
al., 2004). The transcriptase function of the core particle is activated by the removal of VP2 
and VP5 during cell entry (Mertens and Diprose, 2004).   
Positive sense single stranded (ss) RNA copies that act as messenger RNAs are transcribed 
by the VP1 molecules in the BTV core from each of the ten genome segments (Boyce et al., 
2004).  The RNA molecules are capped by the guanylyl-transferase and transmethylase 
activities of VP4 and exit the particles via channels that are situated at the five-fold axes of the 
core particle (Mertens and Diprose, 2004).  Viral RNA is directed to the VIB, where 
encapsidation of different segments within the VP3 shell involves interactions with VP6 
(helicase), NS2 (ssRNA binding protein), VP1 and VP4.  DsRNA is synthesized from the 
positive strand RNA by VP1 (Boyce et al., 2004); each dsRNA segment associates with a 
different transcriptase complex (Nason et al., 2004). 
The fragile VP3 sub-cores act as a scaffold for the addition of VP7 trimers, thereby forming 
stable cores (Grimes et al., 1997; Tanaka and Roy, 1994).  VP2 and VP5 are added to the 
core surface at the periphery of the VIB upon entry of the host cytoplasm.  The mature particles 
are transported within the cytoplasm on microtubules that involve the interaction of VP2 with 
vimentin (Bhattacharya et al., 2007).  The virions are released from infected cells when NS3 
mediates the destabilisation of the cell membrane; budding and cell death/lysis also play a 
role in release of the virions (Mertens et al., 2004).  
 
1.3.  Bluetongue Disease 
1.3.1.  Clinical signs 
BTV can infect all known species of domestic and wild ruminants.  Severe disease usually 
occurs in the fine-wool and mutton breeds of sheep as well as some species of deer (Mellor 
and Boorman, 1995).  BTV infection of cattle, goats and wild ruminant species is mostly 
asymptomatic or subclinical.  In BTV endemic areas BTV-infected sheep develop only mild or 
no obvious disease (MacLachlan, 2004).  The blue tongue after which the disease is named 
is seen only in serious clinical cases (Wilson and Mellor, 2009). 
Onset of the disease in sheep is typically characterised by high fever lasting 5 - 7 days (Roy, 
2004). Clinical signs of disease can include fever, depression, excessive salivation, nasal 
discharge, facial oedema, hyperaemia and ulceration of the oral mucosa, coronitis, lameness 
and death (Darpel et al., 2007; Mellor and Boorman, 1995).  Abortion can occur in pregnant 
8 
 
animals as well as teratogenic defects in calves (Roy, 2004).  The severity of clinical disease 
and mortality rate is influenced by the breed and age of the animal as well as the virus strain 
that causes the infection (Mellor and Wittmann, 2002). In acute phases of BT, clinical signs in 
sheep are mainly associated with damage to microvascular endothelial cells (Singer et al., 
2001).   
Those animals that do recover from BT may suffer from a number of long-lasting secondary 
effects, such as reductions in milk production, weight gain, wool break and temporary infertility 
(Wilson and Mellor, 2009). 
 
1.3.2.  Pathogenesis in ruminants 
Pathogenesis of BTV infection is similar in sheep and cattle as well as other species of 
ruminants.  After an animal is infected with BTV through the bite of a Culicoides vector, the 
virus travels to the regional lymph node where initial replication takes place (Barratt-Boyes et 
al., 1995; Maclachlan et al., 2009).  The virus then spreads throughout the body to a variety 
of tissues, where replication occurs mainly in mononuclear phagocytic and endothelial cells 
(MacLachlan, 2004; Maclachlan et al., 2009).   
Viraemia is cell-associated and can be prolonged in domestic ruminants. During viraemia BTV 
is associated with all blood cells, but late in the course of infection the virus becomes 
associated with the erythrocytes.  The longer lifespan of erythrocytes facilitate prolonged 
infection of ruminants, as well as the infection of the haematophagous insect vectors that feed 
on viraemic ruminants (Barratt-Boyes et al., 1995; MacLachlan, 2004; Maclachlan et al., 2009; 
Singer et al., 2001).  Infectious virus can co-circulate with neutralising antibodies for several 
weeks (Maclachlan et al., 2009).  The maximum period of viraemia in sheep is about 50 days 
and in cattle about 100 days (Mellor and Wittmann, 2002).   
 
1.3.3.  BTV insect vector 
Arthropods of the genus Culicoides classified into the family Ceratopogonidae within the order 
Diptera are the vectors responsible for transmission of BTV (du Toit, 1944).  These small (3 
mm) haematophagous midges occur throughout the world (Figure 1.4) on all large land 
masses, except for Antarctica, New Zealand, Patagonia and the Hawaiian Islands (Mellor, 
2000; Purse et al., 2005; Walton, 2004; Wilson and Mellor, 2009).  Culicoides are spread by 
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the wind over long distances, and movement of infected midges has been implicated as the 
most likely source of a number of BT outbreaks (Wilson and Mellor, 2008). Culicoides that are 
of veterinary importance breed in organically rich, damp soil that is found near their hosts 




Approximately 50 of the 1500 species of Culicoides play a role in BTV transmission worldwide.  
For Culicoides species to be effective vectors of BTV, they must occur in large numbers and 
feed almost only on ruminants.  
Males do not feed on blood, but adult females undertake flight activity to seek a blood meal.  
After ingestion, infected blood is directed to the hind part of the mid-gut where BTV replicates 
in the gut cells, progeny of the virus particles escape into the hemocoel and infect a range of 
secondary target organs, including salivary glands.  After replication in the salivary gland cells, 
BTV is available for transmission during biting activity (Mellor, 2000). The insects can only 
transmit BTV after this extrinsic incubation period of 4 - 20 days, depending on the temperature 
and serotype (MacLachlan, 2004; Mellor et al., 2000; Purse et al., 2005). BTV infection of 
Culicoides persists for the remainder of their lifetime, where adults survive approximately 20 
Figure 1.4:  Distribution map of BTV and Culicoides vectors.  Image adapted from Purse et al. (2005).  
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days (MacLachlan, 2004).  The extrinsic incubation period can be shorter at higher 
temperatures indicating an increased rate of virogenesis, therefore compensating for the 
shorter lifespan of the vector at higher temperatures (Gale et al., 2009). 
Peak populations of adult Culicoides occur in the late summer and autumn, when BT is usually 
detected in ruminants (Mellor and Boorman, 1995).  Midges of C. obsoletus and C. pulicaris, 
which are indigenous to the north Palearctic, have been identified as new vectors of BTV-8 
since the outbreaks occurred in northern Europe in 2006.  Northern Europe recently 
experienced higher temperatures which increased the competence of these indigenous 
midges to serve as vectors for BTV (Gale et al., 2009).   
 
1.3.4.  Epidemiology 
Prior to 1998 outbreaks of BT in Europe were sporadic and it was considered an exotic 
disease.  However from 1998 to 2005 several countries in the Mediterranean basin were 
affected by different BTV strains.  In 2006 BTV-8 was detected in the Netherlands after which 
it spread to neighbouring countries, causing a devastating epidemic in 2007.  The BTV-8 
epidemic was believed to have caused greater economic damage than any other single-
serotype outbreak (Wilson and Mellor, 2009).   
The distribution of BTV is limited to areas where Culicoides vector species are present (Mellor 
et al., 2000) and transmission occurs during the time of the year when climatic conditions are 
favourable for adult vector activity (Mellor, 2000).  In a phenomenon termed “overwintering” it 
is possible that BTV can be maintained in the host or vector, and after months of no detection, 
BT outbreaks can reappear (Takamatsu et al., 2003; Wilson and Mellor, 2008).  Adult 
Culicoides can survive for more than three months at 10 °C (Lysyk and Danyk, 2007), while 
virus replication may effectively stop.  Once temperatures are favourable, the latent virus can 
replicate again (Mullens et al., 1995).  It is possible that this phenomenon contributed to the 















On rare occurrences some strains of BTV can be transmitted by secondary mechanisms, such 
as oral or transplacental transmission within ruminant populations (Figure 1.5), however these 
mechanisms are not important in the long-term survival and spread of the virus (Mellor et al., 
2008; Mellor and Wittmann, 2002; Wilson and Mellor, 2009).    
In regions of the world where enzootic BTV infection occurs throughout the year, BT is 
uncommon.  This can be attributed to population immunity or it can be a result of co-evolution 
of the animal host and the virus (Huang et al., 2009).  
 
1.3.5.  Global distribution of BTV 
BTV occurs world-wide in a broad band, from about 35 °S to 40 °N, that covers much of the 
Americas, Africa, southern Asia, northern Australia and occasionally the southern fringes of 
Europe (Figure 1.4).  In North America, Asia and most recently in northern Europe, the 
Figure 1.5:  Transmission routes of BTV.  Possible secondary transmission routes (oral and 
transplacental) are also indicated.  Adapted from Wilson and Mellor (2009). 
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occurrence of BTV can extend up to 50 °N (Gibbs and Greiner, 1994; Mellor et al., 2008; Purse 
et al., 2005).  Existence of BTV in these areas is a reflection of Culicoides distribution and the 
temperature required for BTV replication and transmission by these vectors.  
In 2006 BTV-8 extended northwards into areas of Europe that has never before been affected 
by the virus, and persisted in these areas causing the greatest outbreak of BT on record.  The 
reasons for the change in BT epidemiology are linked to extensions in the distribution of its 
vector species C. imicola and the involvement of novel Culicoides vectors, likely a result of 
climate change (Mellor et al., 2008; Purse et al., 2005). 
In Europe prior to 1998, only transient and limited incursion of single BTV serotypes into the 
Mediterranean were documented (Maclachlan and Mayo, 2013).  However, since 1998 
multiple BTV serotypes (1, 2, 4, 6, 8, 9, 11 and 16) have been detected in Europe (Mellor et 
al., 2008).  BTV-8 which was first identified in northern Europe in 2006 has spread upwards 
throughout the Mediterranean basin above 50 °N right up to regions of Scandinavia 
(Saegerman et al., 2008; Wilson and Mellor, 2008).  All the BTV serotypes that have invaded 
the Mediterranean basin after 1998, except for BTV-8, were shown to have originated from 
the adjacent regions of Africa or Asia (Purse et al., 2005).   
BTV serotypes 10, 11, 13 and 17 are endemic to extensive areas of North America.  BTV-2 
was documented in America 30 years ago and in recent years an additional 10 serotypes have 
been identified in the south eastern United States (MacLachlan, 2010).  It is assumed that 
these viruses originated in the adjacent Caribbean ecosystem after which they spread to North 
America (Maclachlan, 2011). 
In Australia and Israel novel serotypes have been identified in recent years.  Historically BTV 
serotypes 2, 4, 6, 10 and 16 were present in Israel, but recently BTV serotypes 8, 15 and 24 
emerged in this country (Shimshony, 2004).  In Australia eight serotypes (1, 3, 9, 15, 16, 20, 
21 and 23) were identified previously, with only serotypes 1 and 21 spreading into eastern 
Australia annually. However, in 2007/2008 BTV serotypes 2 and 7 were detected for the first 
time in the Northern Territory of Australia (MacLachlan, 2010). 
New BTV serotypes (BTV-25 and 26) were recently identified with RT-PCR in Switzerland and 
the Middle East (Hofmann et al., 2008; Maan et al., 2011a). It is difficult to interpret the BTV 
status of other regions in the world, especially the Middle East and Asia, due to the lack of 




1.3.6.  Disease surveillance and diagnosis  
Control of endemic or emerging BT in certain regions relies on the rapid detection of either the 
virus (virological surveillance) or the disease (clinical surveillance).  This is best accomplished 
by on-going field surveillance for infection and not only disease surveillance, as infections can 
be mild or subclinical. Surveillance should include evaluation of livestock as well as that of 
potential vector species present in the region.  Sensitive and specific diagnostic assays should 
be used for virus detection (Maclachlan and Mayo, 2013; Souza Monteiro et al., 2012). 
Traditional detection and typing methods such as virus isolation and serum/virus neutralisation 
assays can take weeks and depend on the availability of reference virus-strains and antisera 
(Jeggo, 1986).  Serum neutralisation tests can show a heterotypic response to multiple BTV 
serotypes, especially if the animal was previously infected or vaccinated with more than one 
type of BTV, thereby obtaining inconclusive results (Maan et al., 2012).   
The most conserved protein among the BTV serotypes, VP7, contains the serogroup-specific 
antigenic determinants and is often used in current diagnostic serological tests, such as 
cELISAs, as the antigen for the detection of BTV (MacLachlan, 1994; Vellema, 2008).  
However, since these cELISAs rely on the detection of anti-VP7 antibodies, they cannot be 
used to determine virus serotype.   
An indirect ELISA was developed by Barros et al. (2009) to facilitate differentiation between 
vaccinated and infected animals.  This assay is based on a differential antibody response to 
NS3 observed between naturally infected and vaccinated animals.  The theory is that 
inactivated vaccines contain mainly capsid proteins, therefore they are less likely to elicit 
antibody responses against non-structural proteins.  In the study it was shown that animals 
infected with BTV had greater levels of NS3 antibodies than animals that were immunised with 
inactivated BTV vaccines (Barros et al., 2009).  However, this diagnostic method is not 
commercially used, possibly since the presence of non-structural proteins within vaccine 
preparations could vary from batch to batch, thereby skewing the results obtained.  
Nucleic-acid based typing assays are available for the detection of BTV, such as the group-
reactive quantitative RT-qPCR assays and sequencing that can reliably detect all BTV 
serotypes with sensitivity and specificity (Hofmann et al., 2008; Mayo et al., 2010).  These 
methods are advantageous as they are fast, sensitive and more specific than the established 
serological assays. Individual virus lineages can be identified by comparing the sequence data 
of strains that had previously been analysed.  Full-length sequence data of VP2 (segment 2) 
from multiple isolates of individual types of BTV, including eastern and western strains, has 
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become available and a complete set of “serotype-specific” primers for all 26 BTV serotypes 
have been designed and evaluated.  The assays using these primers have been shown to 
provide rapid and reliable BTV serotype and strain identification in less than 24 hours (Maan 
et al., 2012).   
 
1.3.7.  Prevention and control 
Hypothetically, BTV infection of wild and domestic animals can be controlled either by 
elimination of the midge vector or by protecting the animal hosts from infection and disease 
(Maclachlan and Mayo, 2013).  
Vector-based control strategies to limit the spread of BTV are aimed at either reducing or 
eradicating populations of either Culicoides adults or larvae.  These strategies are challenging 
considering the enormous midge populations in many regions and their extensive breeding 
sites (Maclachlan and Mayo, 2013).  Control of the immature life-stages (larvae) by removing 
breeding sites and using pesticides (mature midges) can be employed to reduce populations 
of adult Culicoides at a local level (Carpenter et al., 2008; Holbrook, 1986; Mintiens et al., 
2008). The efficacy of this strategy is limited in areas that require broad application and there 
are concerns with regards to the effects of the insecticides on the environment. Decoys such 
as repellents and attractants have been evaluated to lure midges and reduce the biting rate 
among animals; however their use is complicated and requires a daily application regimen 
(Maclachlan and Mayo, 2013).   
Animal-based control strategies include stabling of livestock, movement restrictions, culling of 
infected animals and vaccination.  The use of protective housing is mostly impractical 
considering extensive livestock production systems and the sheer number of livestock that 
need to be stabled (Huang et al., 2009; Napp et al., 2011).  The implementation of movement 
restrictions can be logistically challenging and economically devastating (Papadopoulas et al., 
2009).  Arboviral diseases are not easily managed by culling of animals as infections can be 
subclinical and the vector midges harbouring the virus can spread widely. Furthermore, there 
is also societal resistance to the large-scale slaughter of healthy animals (Maclachlan and 
Mayo, 2013).  
Vaccination is central to the response of BT outbreaks.  However, vaccination is difficult given 
that there are 26 serotypes of BTV; this, together with serotype-specific immunity in livestock 
can make vaccination problematic (Noad and Roy, 2009b; Zientara et al., 2010). 
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1.4.  Vaccines against BTV 
The most effective means to protect animals against disease and to reduce spread of the virus 
after infection is vaccination.  To combat the direct losses incurred with BTV outbreaks and to 
minimize the circulation of BTV, vaccination of livestock was implemented by various countries 
according to their individual national policies, the serotype of virus and the availability of 
vaccines (Caporale and Giovannini, 2010; Savini et al., 2008).   
A number of vaccines have been developed against BT.  These include inactivated whole 
virus vaccines, live attenuated virus vaccines (modified live virus vaccines), recombinant 
vaccines and virus-like particle (VLP) vaccines.  While these vaccines have various 
advantages and disadvantages, only attenuated virus vaccines and some inactivated vaccines 
are presently commercially available (Niedbalski, 2011; Noad and Roy, 2009b; Osburn et al., 
1996; Savini et al., 2008).  The most important reasons for BT vaccination are to prevent 
clinical disease, to reduce environmental spread of BTV, and to protect susceptible animals 
during movement between affected and BTV-free zones (Niedbalski, 2011).  Ideally a vaccine 
for BT should protect against more than one serotype, should not revert to virulence or 
recombine with circulating strains of the virus, and should not be able to replicate in the field 
(Roy et al., 2009). It is also important that vaccines against BT are safe to use and allow for 
differentiation between naturally infected and vaccinated animals [DIVA, (Niedbalski, 2011)]. 
 
1.4.1.  Inactivated vaccines 
Inactivated vaccines are prepared by treating cell-cultured BTV with beta-propiolactone, 
gamma radiation or binary ethylenimine.  Vaccines prepared in this way are commercially 
available and have shown good immunogenicity and safety. The risks of reassortment of 
genes with field strains, reversion to virulence and teratogenicity are avoided with the use of 
inactivated vaccines (Di Emidio et al., 2004; Roy et al., 2009).   
The first inactivated vaccine to be developed and used in the field after an outbreak of BT in 
Europe was the vaccine against BTV-2, which was used to vaccinate sheep in 2005 in Corsica 
(France).  In 2005-2006 monovalent BTV-4 and bivalent BTV-2 and BTV-4 inactivated 
vaccines were developed and used in Corsica, Spain, Portugal and Italy (Rodriguez-Sanchez 
et al., 2008; Savini et al., 2008).   
The disadvantages of using inactivated vaccines is that a single dose produces only transient 
neutralising antibodies and does not provide sufficient long-lasting immunity, therefore booster 
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immunisations are required, which increases costs.  These vaccines are also expensive to 
produce and require that large amounts of infectious virus be grown before inactivation.  In 
addition, there are no strategies available at present for regular diagnostic purposes that can 
differentiate infected animals from vaccinated animals (Savini et al., 2008). 
 
1.4.2.  Modified live virus (MLV) vaccines  
MLVs are produced by adapting BTV field isolates to in vitro growth through serial passaging 
in tissue culture or embryonated chicken eggs.  A strong antibody response is directly 
correlated with the MLVs’ ability to replicate in a vaccinated host and can last up to one year. 
These vaccines are more affordable to produce in large quantities than inactivated vaccines, 
protective immunity is stimulated after a single inoculation and they have proven effective in 
the prevention of clinical BT in the areas where they are used (Dungu et al., 2004a; Savini et 
al., 2008).   
The first egg-adapted attenuated BTV vaccine was developed in South Africa in the early 
1950’s (Alexander and Haig, 1951) and since then MLV vaccines for many serotypes of BTV 
have been developed and are available outside of Europe.  These countries include the United 
States of America, Turkey, South Africa and India (Savini et al., 2008).   
Despite the apparent success of MLVs for controlling BTV, a number of documented or 
potential drawbacks have been reported.  These include depressed milk production in lactating 
sheep as well as abortion/embryonic death and teratological effects after the vaccination of 
pregnant ewes with MLV vaccines (Monaco et al., 2004; Osburn et al., 1971; Schultz and 
Delay, 1955; Young and Cordy, 1964).  
The vaccine virus can cause viraemia for over two weeks in vaccinated sheep and the 
viraemia has been reported to be sufficient for transmission of the vaccine strain to the insect 
vector (Schwartz-Cornil et al., 2008; Veronesi et al., 2010; Veronesi et al., 2005).  In both 
North America and Europe studies have shown that live, attenuated BTV vaccine viruses (or 
its individual gene segments) used to vaccinate animals, can be acquired and transmitted by 
Culicoides in the field thereby contributing to the genetic diversity of circulating viruses (Batten 
et al., 2008a; Osburn et al., 1996).  Of particular concern is the reassortment of MLV genes 
with those of wild-type virus strains that co-infect the same animal.  In Italy, 2002, a circulating 
BTV-16 strain was found to be generated by reassortment between BTV-2 and BTV-16 MLV 
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strains (Batten et al., 2008b).  As with inactivated vaccines, there is the inability to serologically 
distinguish naturally infected from MLV vaccinated animals (Savini et al., 2008).   
 
1.4.3.  Recombinant vaccines 
A number of experimental recombinant vaccines have been investigated which aim to meet 
the requirements for an effective BT vaccine.  These requirements include low cost of 
production, DIVA compliance, protective immunity against multiple serotypes, no risk for 
reversion/reassortment and long term protective immunity after a single dose (Roy et al., 2009; 
Schwartz-Cornil et al., 2008). 
 
1.4.3.1.  Recombinant subunit protein vaccines 
It has been demonstrated that VP2 purified from BTV was able to elicit protective immune 
responses in sheep (Huismans et al., 1987).  VP2 alone and in combination with other viral 
proteins have been tested in small-scale animal experiments to analyse the protective efficacy 
using different approaches. These include purified recombinant VP2 and VP5 which were 
successful in eliciting neutralising antibodies in sheep when used together  (Roy et al., 1990b), 
a recombinant vaccinia BTV vaccine expressing VP2 and VP5 which afforded protection 
against homologous challenge (Lobato et al., 1997), as well as other recombinant poxvirus-
based systems where the poxvirus is used as a vector for the transfer of BTV genes into host 
cells, resulting in the expression of BTV proteins (Boone et al., 2007).  A capripox vector 
expressing VP2, VP7, NS1 and NS2 provided only partial protection against heterotypic BTV 
challenge (Perrin et al., 2007; Wade-Evans et al., 1996).  A recombinant canarypox virus 
vaccine co-expressing VP2 and VP5 was described that elicited neutralising antibodies and 
protected sheep against challenge with BTV (Boone et al., 2007).  A major advantage of this 
vaccine in terms of BTV is that the existing VP7 competitive diagnostic ELISA assay would 
distinguish vaccinated from naturally infected animals. This vaccine is still in the 




1.4.3.2.   Virus-like particles (VLPs) as vaccines 
VLPs are structures that resemble the authentic conformation of native viruses and are formed 
when multiple subunits of protein complexes interact with each other in such a way that it 
results in self-assembly (Grgacic and Anderson, 2006).  BTV VLPs contain only the four 
structural proteins - VP2, VP3, VP5 and VP7 - of BTV and mimic the structure of authentic 
virus particles.  They are readily recognised by the immune system and present viral antigens 
in a conformation that is more authentic than other subunit vaccines, making them excellent 
immunogens (Noad and Roy, 2003).  VLPs have been shown to be non-infectious and unable 
to replicate as they contain no viral genetic material (Rodriguez-Limas et al., 2013).  Since 
BTV VLPs do not contain the non-structural proteins or virus RNA, it is possible to distinguish 
between vaccinated and infected animals using molecular diagnostic techniques (Niedbalski, 
2011).  VLPs are excellent vaccine candidates as there is no risk of reversion to virulence or 
reassortment with wild virus strains as they contain only structural proteins (Roy et al., 2009).  
The repetitive, high density display of epitopes on VLPs render them more immunogenic than 
subunit vaccines or chemically inactivated vaccines. The particulate nature of VLPs combined 
with epitope display enhance the humoral, cell-mediated and mucosal immune responses 
(Grgacic and Anderson, 2006; Noad and Roy, 2003; Roy and Noad, 2008).  VLPs are excellent 
candidates for BTV vaccines, since both humoral and cellular immunity is important for 
protection against BTV (Calvo-Pinilla et al., 2012). In addition to the above-mentioned 
advantages of using VLPs as a vaccine, they are also safe to produce and handle and the 
host cells for their production do not necessarily come from mammalian sources, and therefore 
would not contain mammalian derived pathogens (Roy, 1996).    
VLPs for BTV serotype 10 were first produced in insect cells using a baculovirus-based protein 
expression system; this system was shown to efficiently produce large amounts of proteins 
with the correct folding and assembly of large complexes (French et al., 1990).  BTV VLPs are 
formed by the co-expression of the four major structural proteins of the virus (VP2, VP3, VP5 
and VP7); these proteins self-assemble into triple-layered VLPs.  Sheep vaccinated with the 
insect cell expressed BTV-10 VLPs developed neutralising antibodies and were protected 
against challenge with a homologous serotype, these studies showed that VLPs are both safe 
and effective to use as potential vaccines for BTV (Roy et al., 1990b; Stewart et al., 2012).  In 
other experiments it was shown that low doses of VLPs were sufficient to give complete 
protection from virus challenge and none of the vaccinated animals developed clinical signs 
or viraemia.  Furthermore, sheep vaccinated with VLPs that were made separately from two 
different serotypes were shown to have complete protection against the vaccine serotypes as 
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well as partial protection against related non-vaccine serotypes.  It was also demonstrated 
that vaccination with VLPs provided long lasting protective efficacy over 14 months (Noad and 
Roy, 2003; Roy et al., 1994; Roy et al., 2009).  Despite their efficacy, however, the cost of 
producing VLPs in insect cells is very high, which has hindered further development and 
commercialisation of these vaccine candidates, alternative methods of production would be 
desirable to facilitate large-scale development of these vaccines.  
Recently BTV-8 VLPs were successfully expressed and assembled in Nicotiana benthamiana 
(N. benthamiana) plants using a transient plant expression vector.  The plant-expressed VLPs 
elicited an immune response in sheep providing protective immunity against challenge with a 
BTV-8 field isolate (Thuenemann et al., 2013). 
 
1.5.  Plant expression systems 
Over the last 20 years, plant-based expression of heterologous proteins has attracted much 
interest as it has many advantages over other eukaryotic expression systems for the 
expression of proteins.  These include high biomass, ease of scale up, cost effectiveness and 
a low risk of contamination (Lai and Chen, 2012; Sainsbury and Lomonossoff, 2008). Plant-
based expression now represents a viable platform for the production of medical and industrial 
proteins.  Furthermore, plant-based expression systems are safe to use as they do not contain 
the human and animal pathogens that are potentially an issue when using mammalian cell-
based production systems (Fischer et al., 2012; Pogue et al., 2010; Rybicki, 2010; Xu et al., 
2012).   
Several classes of recombinant proteins have been produced in plants.  These include 
monoclonal antibodies, vaccine antigens, therapeutic enzymes, growth hormones, industrial 
enzymes (hydrolases and proteases) and biopolymers such as spider silk proteins, elastin-
like polypeptides and collagen (Tiwari et al., 2009; Xu et al., 2012).  Recently, good 
manufacturing practice (GMP) procedures have been established for the production of 
recombinant proteins in whole transgenic plants and transient expression systems; this should 
lead to an increase in the number of plant-derived pharmaceutical proteins and rapid-response 
vaccines that enter clinical development stages (Fischer et al., 2012).  
A wide variety of plants has been utilised for the expression of human and animal vaccines, 
with the hepatitis B surface antigen expressed in transgenic tobacco being one of the first VLP 
candidate vaccines (Mason et al., 1992; Rybicki, 2010).  Ever since 1992 well-characterised 
viruses such as human immunodeficiency virus, human papilloma virus, influenza virus, foot 
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and mouth disease virus and rotavirus, to name but a few, have been successfully investigated 
for the formation of VLPs in plants (Scotti and Rybicki, 2013).   
Nicotiana spp. is one of the most popular candidates for the commercial production of 
recombinant proteins (Fischer et al., 2004; Twyman et al., 2003).  The continual use of tobacco 
makes it a well-established expression host, and furthermore the high biomass yields, rapid 
scalability and the fact that it is a non-food crop make it suitable for commercial molecular 
farming (Fischer et al., 2004; Stoger et al., 2002).   
Limitations associated with plant expression systems include low yields of recombinant 
protein, which is most likely a result of protein instability, low levels of expression and lack of 
post-translational modifications (Fischer et al., 2004).  Several advances for yield increase 
have been made toward addressing these shortcomings.  These include maximising the rate 
of transcription and translation by using strong plant promoters (Twyman et al., 2003), codon-
optimisation of the gene of interest, co-expression with viral silencing suppressors (Takeda et 
al., 2002; Voinnet et al., 2003), targeting of the recombinant proteins to different subcellular 
compartments within the plant cell (Fischer et al., 2012; Maclean et al., 2007; Twyman et al., 
2003) and fusion of the protein of interest to signal sequences that drive sequestration of the 
recombinant protein into large protein bodies (PBs) that are protected from degradation by 
host cell enzymes (Torrent et al., 1994).  
PBs are organelles derived from the endoplasmic reticulum (ER) that are able to store stable 
amounts of zeins - prolamin-type storage proteins that are used as a source of nitrogen during 
early germination of maize seeds (Müntz, 1998).  These zein polypeptides can oligomerise 
into larger complexes that ultimately self-associate into PBs (Galili, 2004).  γ-Zein, one of the 
maize prolamin storage proteins, has been shown to be naturally accumulated at high levels 
in PBs in the ER.  Heterologous plant-based expression of the Zera® sequence (ERA Biotech, 
Spain), generated from the N-terminal proline-rich domain and Pro-X sequence of γ-zein 
results in ER retention and formation of membrane-delineated PBs in non-seed tissues (Geli 
et al., 1994; Torrent et al., 2009a; Torrent et al., 2009b).  Expression of the Zera® domain 
fused to target proteins has been shown to result in the high-level accumulation of recombinant 
proteins in large, stable PBs called StorPro® (ERA Biotech, Spain) organelles that are 
protected from degradation and are easy to purify (Geli et al., 1994; Torrent et al., 2009a).   
Currently, most of the vaccines that are available on the market are manufactured using 
strategies such as chemical inactivation and attenuation of pathogens, or subunit vaccines 
that are produced using cell culture techniques.  Plant-produced vaccines provide relatively 
inexpensive and safe alternatives to the abovementioned methods (Santi, 2009).  There are 
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three ways in which industrial-scale recombinant vaccines can be produced in plants:  (i) 
stable transgenic or transplastomic expression, (ii) transient expression and (iii) in vitro culture 
systems where plant biomass is cultured in bioreactors under sterile conditions (Xu et al., 
2012). 
Extensive research has been carried out using stably transformed plants; however the 
reduced development and production times associated with transient expression (3-9 months 
for transgenic versus a few days for transient expression) make it a more viable option for the 
production of proteins of commercial and academic interest (Sainsbury and Lomonossoff, 
2008).  Transient expression is mediated by either binary plant vectors or recombinant viral 
vectors based on RNA plant viruses that are hosted in Agrobacterium tumefaciens [A. 
tumefaciens, (Sainsbury and Lomonossoff, 2008; Xu et al., 2012)].   
Agrobacterium is a gram-negative plant pathogen that is known for its natural ability of trans-
kingdom DNA transfer.  Although Agrobacterium is used mainly for plant genetic engineering 
it can transfect virtually any living cell, from prokaryotes, yeast and fungi to human cells (Tzfira 
et al., 2004).  During the process of agroinfiltration foreign genes are introduced into the 
abaxial air spaces of intact plants by vacuum or syringe infiltration of recombinant A. 
tumefaciens, which contains the gene of interest within its transfer DNA (T-DNA) region. The 
production of recombinant proteins within the leaves starts within 24 hours and can continue 
for several days (Xu et al., 2012).   
Transient expression mediated by recombinant viral vectors is one of the most effective means 
of achieving high-level transient expression of foreign proteins in plants (Giritch et al., 2006; 
Lindbo, 2007), as these systems make use of the ability of RNA viruses to replicate to high 
titres within infected cells. There are a number of drawbacks using virus-directed replication 
of RNA, which include restrictions on the insert size, genetic stability of the constructs during 
viral replication and vectors that are based on full-length replicons can move from cell to cell 
through a plant, resulting in bio-containment issues. As alternatives, non-replicating viral 
vectors have been developed that allow for the high-level and rapid transient expression of 
proteins, these include potato virus X and the Cowpea mosaic virus (CPMV)-based expression 
system as well as deconstructed viral vectors based on bean yellow dwarf virus and the 
tobacco mosaic virus based magnICON®  expression system (Huang et al., 2009; Regnard et 
al., 2010; Sainsbury and Lomonossoff, 2008; Santi et al., 2006).  Transient expression using 
binary plant and non-replicating virus based vectors is limited to the tissue which has been 
infiltrated with a recombinant Agrobacterium suspension (Sainsbury et al., 2009),  thereby 
circumventing the bio-containment problem.  
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Previously, Agrobacterium-mediated transient expression was most commonly used as a 
method to assess gene expression and to test expression cassette arrangements before 
continuing with the stable expression of proteins (Fischer et al., 2004; Sainsbury et al., 2009).  
However, in recent years transient expression in N. benthamiana has been shown to be a 
highly efficient process for both developmental research and the large-scale production of 
recombinant proteins (D'Aoust et al., 2010; D’Aoust et al., 2008).   
A few plant-derived pharmaceutical products have been produced via transient expression 
using GMP-approved processes.  These products include the rapid response influenza VLP 
vaccine produced by Medicago Inc. (D'Aoust et al., 2010; D’Aoust et al., 2008; Vicente et al., 
2011), the influenza virus haemagglutinin subunit vaccine produced by the Fraunhofer 
Institute (Shoji et al., 2009; Shoji et al., 2011) and the MAPP66 antibody produced by 
Bayer/ICON that can be used as a combination Herpes simplex virus (HSV) and human 
immunodeficiency virus (HIV) microbicide.  All of these vaccines have either completed, or are 
in phase I clinical trials (Fischer et al., 2012). 
 
1.6.  Concluding remarks 
BTV is an economically significant disease that affects ruminants; the most recent outbreak 
(BTV-8) occurred in northern Europe in 2006 where high mortality rates of livestock were 
reported (Toussaint et al., 2006; van Wuijckhuise et al., 2006).  The most effective means of 
controlling or protecting susceptible animals against circulating serotypes of BTV is 
vaccination (Coetzee et al., 2012).  
Vaccines against animal viral diseases, such as BTV, are usually either chemically inactivated 
or “killed” viruses, or attenuated “live” viruses.  These vaccines are, however, associated with 
significant risks, such as incomplete inactivation of killed virus, or the ability of the attenuated 
virus strain to revert to a more virulent strain capable of causing disease in the vaccinated 
animals.  In the case of BTV with its segmented genome, there is the added risk of genetic 
exchange of segments (reassortment) between the vaccine strain and field strains, which can 
result in the production of new strains of the virus (Noad and Roy, 2003; Savini et al., 2008).  
Moreover, attenuated vaccines have been associated with significant side effects, including 
abortion and teratological effects (Osburn et al., 1971; Schultz and Delay, 1955; Young and 
Cordy, 1964).  Another problem associated with attenuated vaccines is the requirement for 
strict biosafety measures in their production and also the inability to differentiate between 
vaccinated and naturally infected animals, as all of the gene products are made in both cases 
(Stewart et al., 2010).   
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It is therefore desirable to develop vaccines for BTV that are DIVA-compliant and safe to use.  
Furthermore, producing these vaccines in a system that does not require strict biosafety 
measures will be advantageous.  Transient protein expression in plants is an effective method 
for rapid small- and large-scale production of proteins, providing a cost-effective alternative 
for the production of subunit and/or VLP BTV vaccines.   
 
1.7.  Aims and objectives of the study 
The broader objective of this study was to develop plant-based vaccine candidates for BTV.  
In order to achieve this, the specific aims of the study were four-fold:  
 
(i) Transient expression of recombinant proteins in plants can be enhanced by using 
expression vectors that target the recombinant protein to different organelles within the 
plant cells (Maclean et al., 2007).  Furthermore, transient expression allows for rapid 
evaluation of the expression of numerous constructs.  Therefore, transient co-
expression of the four plant codon optimised capsid genes (VP2, VP3, VP5 and VP7) 
of BTV-8 was carried out using the pTRA vector suite that targets heterologous protein 
expression to different subcellular compartments.  Expression levels obtained with the 
pTRA vector suite were compared to expression of the capsid genes obtained with the 
Cowpea mosaic virus-based HyperTrans (CPMV-HT) pEAQ vector system in N. 
benthamiana.  The pEAQ-HT expression system was used for comparison with our in-
house pTRA vectors as it was a stipulated objective of the EU FP7 grant that funded 
this project. 
 
(ii) The second objective was to further optimise co-expression and subsequent 
purification of BTV-8 VLPs with the plant expression vector that allowed for the most 
efficient expression of all four capsid proteins.  The production of VLP vaccines against 
BTV in planta abrogates the need for high biosafety levels required with insect cell 
produced VLPs, thereby reducing the costs involved in vaccine production. Recently 
BTV VLPs were successfully produced in N. benthamiana using a transient expression 
system. Sheep vaccinated with the plant-expressed VLPs were protected against 
challenge with a field strain of BTV-8 (Thuenemann et al., 2013).   
 
(iii) The third objective of this study was to develop two second generation plant-produced 
BTV PB vaccines by fusing a predicted synthetic VP2 multi-epitope and the full-length 
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codon optimised BTV-8 VP2 to Zera® (ERA Biotech, Spain), which drives PB 
formation.  The epitope-based candidate vaccine is proposed to be multivalent, 
thereby obviating the need for multiple serotype-specific vaccination.  The particulate 
vaccine consisting of the full-length VP2 could be used in animals to protect against a 
single serotype of BTV; this vaccine could also be produced as a rapid-response 
vaccine to circulating serotypes of BTV.  Both PB vaccine candidates are aimed at 
being DIVA compliant.   
 
(iv) The final objective of this study was to analyse the immunogenicity of the plant-






Agrobacterium-mediated transient expression of BTV-8 plant codon optimised 
capsid genes in N. benthamiana using different expression vectors 
 
2.1.  Introduction 
BTV virions are architecturally complex, multi-layered particles that consist of seven structural 
proteins. Figure 1.1 (Chapter 1) shows that the four major structural proteins are organised 
into three layers.  The outer shell of the virion contains two major proteins, VP2 and VP5 that 
are laid onto the foundation provided by the assembly of VP3 and VP7 (French et al., 1990; 
Roy, 1996).     
When VP3 and VP7 are co-expressed in an insect cell/baculovirus expression system, they 
form core-like particles (CLPs).  Using the same expression system, the co-expression of VP2 
and VP5 together with VP3 and VP7 leads to the assembly of VLPs that are devoid of nucleic 
acid (French et al., 1990; Roy, 1996).  However, the cost associated with the production of 
VLPs in insect cells is very high and alternative methods of production would be desirable 
(Thuenemann et al., 2013).  Despite the proven efficacy of the attenuated vaccine in South 
Africa (Coetzee et al., 2012), it is desirable to replace these attenuated vaccines with 
recombinant VLP vaccines, as this would negate the possibility of the emergence of new 
reassortant viruses of unknown virulence due to co-circulation of vaccine and wild-type viruses 
in the same herds. 
In recent years the heterologous expression of complex high-value proteins in plants has 
attracted much interest. There are many advantages of using plants over other eukaryotic 
expression hosts, including their high yield of biomass, ease and affordability of scale-up and 
lack of the risk of contamination by human pathogens (Rybicki, 2010; Tzfira and Citovsky, 
2006).  Transient expression systems are flexible and allow for rapid expression of high 
concentrations of recombinant protein in a matter of days (Fischer et al., 1999).  Transient 
expression can be achieved by the use of infective plant virus-based vectors where the gene 
of interest is cloned into the genome of a viral plant pathogen which is used to infect the plant, 
or by infiltration of plants with recombinant Agrobacterium containing the transgenes of interest 
inserted into the T-DNA region of the bacterial tumour-inducing plasmid [pTi, (Fischer et al., 
1999; Tzfira et al., 2004)].  The Agrobacterium vir (virulence)-system processes and transfers 
the T-DNA from the bacterium to the plant cell nucleus where it is transcribed and translated 
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using host cell enzymes, resulting in transient expression of recombinant protein (Kapila et al., 
1997; Tzfira et al., 2004; Zupan et al., 2000).   
As a defence mechanism against virus infection plants have an RNA silencing system known 
as post-transcriptional gene silencing (PTGS), which can suppress the transient expression 
of foreign proteins. Several plant viruses encode silencing suppressors that counteract PTGS 
(Takeda et al., 2002; Voinnet et al., 2003).  The NSs protein of tomato spotted wilt virus 
(TSWV) and P19 of tomato bushy stunt virus (TBSV) are examples of such proteins (Takeda 
et al., 2002; Voinnet et al., 2003).  A. tumefaciens-mediated transient expression of 
recombinant proteins can be enhanced and extended by co-infiltrating plants with recombinant 
A. tumefaciens cells that encode the silencing suppressor gene (Maclean et al., 2007).  
Expression levels of heterologous proteins in plants can be increased by using signal peptides 
that target the expressed protein to different organelles within the plant cell.  It was shown that 
the Human papilloma virus (HPV) major capsid protein, L1, was expressed at higher levels 
when recombinant protein was targeted to the chloroplast compared to cytoplasmic 
localisation or retention in the endoplasmic reticulum [ER, (Maclean et al., 2007)].  Moreover, 
targeting of the recombinant proteins to different subcellular compartments may facilitate 
easier purification when production is scaled up.  
BTV-8 VLPs have been successfully produced in N. benthamiana using a Cowpea mosaic 
virus-based HyperTrans (CPMV-HT) and associated pEAQ transient expression system which 
targets expression to the cytoplasm (Thuenemann et al., 2013).  In this chapter transient co-
expression of the four BTV-8 VPs in N. benthamiana was compared by using the binary A. 
tumefaciens pTRA suite of vectors pTRAc-HT, pTRAkc-AH and pTRAkc-rbcs1-cTP, which 
target recombinant protein to the cytosol, apoplast and chloroplast respectively, in order to 
determine whether the expression yields could be improved by targeting the recombinant 
proteins to different subcellular compartments (Maclean et al., 2007).  The pTRA vectors used 
in this study were available in-house at UCT.  In addition to the pTRA vectors, the VPs were 
also co-expressed using pEAQ-HT which has the P19 silencing suppressor sequence of TBSV 
incorporated into the T-DNA, enabling expression of the gene of interest and the silencing 
suppressor from a single plasmid (Sainsbury et al., 2009), to compare which system best co-




2.2.  Materials and Methods 
2.2.1.  PCR amplification of the BTV-8 capsid (VP) genes 
The BTV-8 VP2, VP3, VP5 and VP7 capsid gene sequences (Genbank accession numbers:  
AM498052, AM498053, AM498056 and AM498057, respectively) were codon optimised for 
Nicotiana spp. translation and synthesized by GeneArt (Germany).    
The four codon optimised genes were modified by Eva Thuenemann (John Innes Centre, UK) 
using the primers listed in Table 2.1 to facilitate directional cloning of the genes into the AgeI 
and XhoI sites of the pEAQ-HT vector (Figure 2.1 A, obtained from G. Lomonossoff, John 
Innes Centre, UK) to yield four different constructs.  The four pEAQ-HT plasmids (pEAQ-
HTVP2co, pEAQ-HTVP3co, pEAQ-HTVP5co and pEAQ-HTVP7co) were used as template 
DNA in subsequent PCR DNA amplifications to modify the 5’ and 3’ termini of the four BTV-8 
capsid genes to facilitate cloning into the pTRA vector suite.  The primers used for the various 
PCR reactions are listed in Table 2.1. 
PCR amplification of the capsid genes was performed with the primers listed in Table 2.1.  The 
PCR reactions consisted of 50 ng of the appropriate template DNA, 200 μM dNTPs, 1 μM of 
each primer, 1x Buffer A and 1 unit (U) KAPA Taq DNA Polymerase (KAPA Biosystems).  For 
modification of VP2 and VP3 the reactions were amplified with an initial denaturation step at 
94 °C for 5 min. Twenty seven cycles of denaturation at 94 °C for 30 s, annealing at 53 °C for 
60 s and elongation at 72 °C for 90 s were carried out followed by a final elongation step at 72 
°C for 5 min. For amplification of VP5 and VP7 the cycling conditions were modified by 
annealing at 55 °C for 60 s and elongation at 72 °C for 45 s. The amplified products were 
separated on 0.8% w/v TBE (89 mM Tris base, 89 mM boric acid and 2 mM EDTA [pH 8]) 
agarose gels containing 2.5 mg/mL ethidium bromide and visualised under short wavelength 
ultraviolet (UV) illumination.   
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Figure 2.1:  From the previous page. A flow diagram displaying the strategy that was followed to modify 
the BTV-8 capsid genes and their subsequent cloning into the pTRA vector suite. The capsid genes 
were directionally cloned and subcloned into the plant expression vectors:  (A) pEAQ-HT, (B) pTRAc-
HT, (C) pTRAkc-AH and (D) pTRAkc-rbcs1-cTP.   The vector elements that are necessary to achieve 
expression using the pEAQ-HT and pTRA vectors in planta are shown in the figure.             (A) pEAQ-
HT:  RB and LB: right and left borders for T-DNA integration, 35S promoter from Cauliflower mosaic 
virus (CaMV), 5’UTR:  modified 5’ UTR from CPMV RNA-2, 3’UTR from CPMV RNA-2, NosT: nopaline 
synthase terminator, P19:  suppressor of gene silencing from TBSV, 35S terminator from CaMV, nptII:  
kanamycin resistance gene, OriV:  pRK2 origin of replication, TrfA:  replication essential locus and 
ColEI; the pBR322 E. coli origin of replication (Sainsbury et al., 2009).  (B-D) pTRA vectors:  P35SS:  
CaMV 35S promoter with a duplicated transcriptional enhancer, CHS:  chalcone synthase 5’ UTR, 
pA35S: CaMV 35S polyadenylation signal that enables foreign gene expression, SAR: the expression 
cassettes are flanked by two copies of the Rb7 scaffold attachment region, ColEI ori:  origin of 
replication for E. coli, RK2 ori:  Agrobacterium origin of replication, bla:  gene for ampicillin / carbenicillin 
resistance.  pTRAc-HT (B) contains a 6x histidine tag at the N-terminal, pTRAkc-rbcs1-cTP (C) contains 
chloroplast-transit peptide sequence of the potato rbcS1 gene (rbcs1-cTP) and pTRAkc-AH (D) 
contains a plant codon optimised signal peptide sequence from the murine mAB24 heavy chain gene 
(LPH). In addition, both (C) and (D) contain nptII,the gene for kanamycin resistance and pNos/pAnos 
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XhoI See note 2 below Apoplast 
pTRAkc-AHVP2co 
VP3 ~2.7 pTRAkc-AHVP3co 
VP5 ~1.5 pTRAkc-AHVP5co 










VP3 ~2.7 cTPVP3coF GTGGACGCGTTAGGTGCATGGCTGCTCAAAATGAGCAAAG 59 pTRAkc-rbcs1-cTPVP3co 
VP5 ~1.5 cTPVP5coF GTGGACGCGTTAGGTGCATGGGAAAGATTATTAAGTCCCTCTC 55 pTRAkc-rbcs1-cTPVP5co 





pEAQ-HTVP2F GCACCGGTATGGAAGAACTCGCTATCCCAA 56 
Cytoplasm 
pEAQ-HTVP2co 
VP3 ~2.7 pEAQ-HTVP3F GCACCGGTATGGCTGCTCAAAATGAGCAAAG 59 pEAQ-HTVP3co 
VP5 ~1.5 pEAQ-HTVP5F GCACCGGTATGGGAAAGATTATTAAGTCCCTCTC 55 pEAQ-HTVP5co 
VP7 ~1 pEAQ-HTVP7F GCACCGGTATGGATACAATTGCTGCTAGGG 54 pEAQ-HTVP7co 
1 The restriction sites are underlined and in bold. 
2 The 5’ and 3’ termini were modified using the same primers that were used to modify the genes for cloning into pTRAc-HT. 





2.2.2.  Cloning of amplified genes into pGEM®-T-Easy for sequence analysis 
DNA was purified from the agarose gels using the QIAquick® Gel Extraction kit (Qiagen) 
following the manufacturer’s instructions.  The purified DNA was ligated into the pGEM®-T-
Easy Vector system (Promega) according to the manufacturer’s instructions and incubated 
overnight (O/N) at 4 °C. 
The ligated plasmid constructs were used to transform DH5-α chemically competent E. coli 
cells (E. cloni™, Lucigen) according to the method described by Sambrook et al. (1989).  The 
transformed cells were selected on Luria Bertani (LB) media plates supplemented with 
ampicillin (100 μg/mL), X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, [80 μg/mL]) 
and IPTG (Isopropylthio-β-D-galactoside, [0.5 mM]) that were incubated for 16 hrs at 37 °C.   
White colonies were inoculated into 5 mL LB broth supplemented with 50 μg/mL ampicillin and 
incubated with agitation for 16 hrs at 37 °C.  Plasmid isolations were performed using the 
QIAprep® Spin Miniprep kit (Qiagen) according to instructions provided by the manufacturer.  
Recombinant pGEM®-T-Easy clones were verified by restriction enzyme digestion.   
Recombinant DNA (~500 ng) was digested for 1 hr at 37 °C using 1 U XhoI (Fermentas) per 
reaction according to the manufacturer’s instructions.  Linearized DNA was separated on 0.8% 
w/v TBE agarose gels containing 2.5 mg/mL ethidium bromide.   
After verification of the clones with restriction digests the plasmid DNA was sequenced 
(Macrogen Inc., Netherlands) using the M13 forward and reverse primers.  Gene-specific 
internal primers (Table 2.2) were designed for sequencing in order to obtain sequence data 









Table 2.2:  The gene-specific internal primers used to sequence the entire length of the genes 
of interest. 























2.2.3.  Sub-cloning of the BTV-8 capsid genes into the pTRA vector suite1 
The capsid genes were sub-cloned into the three different pTRA binary vectors (Figure 2.1):  
pTRAc-HT, pTRAkc-AH and pTRAkc-rbcs1-cTP (kindly provided by Dr Rainer Fischer, 
Fraunhofer Institute, Aachen, Germany).  These vectors are designed to target recombinant 
proteins to the cytosol, apoplast and chloroplast, respectively (Maclean et al., 2007).  The VP2 
and VP3 genes modified for cloning into pTRAc-HT, pTRAkc-AH and pTRAkc-rbcs1-cTP were 
excised from the pGEM®-T-Easy backbone by first digesting the plasmid DNA with either NcoI 
or MluI and ScaI for 1 hr at 37 °C after which the DNA was gel-purified with the QIAquick® Gel 
Extraction kit (Qiagen). The entire volume of purified DNA was subsequently digested with 
XhoI for 1 hr at 37 °C and gel-purified.  This two-step digestion from pGEM®-T-Easy yielded 
VP2 and VP3 genes with 5’ NcoI or MluI sites and 3’ XhoI sites. VP5 and VP7 were excised 
from pGEM®-T-Easy by double digesting with either NcoI or MluI and XhoI, yielding genes 
flanked by 5’ NcoI or MluI sites and 3’ XhoI sites.  
The pTRAc-HT and pTRAkc-AH (Figure 2.1 B and C) expression vectors were linearized by 
restriction digestion with NcoI and XhoI and pTRAkc-rbcs1-cTP (Figure 2.1 D) was linearized 
with MluI and XhoI.  The vector DNA was dephosphorylated using 1 U rapid alkaline 
phosphatase (Roche) according to the manufacturer’s instructions. The BTV-8 genes were 
                                               
1 All restriction enzymes used in the section were obtained from Fermentas and digests were carried 
out according to the manufacturer’s instructions.  
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directionally sub-cloned into the pTRA plant expression vectors yielding the constructs listed 
in Table 2.1.   
DH5-α chemically competent E. coli cells were transformed (Sambrook et al., 1989) with the 
plasmid constructs and recombinant clones were selected on LB media plates supplemented 
with ampicillin (100 μg/mL) O/N at 37 °C.  Colonies were inoculated into 5 mL LB broth 
supplemented with 50 μg/mL ampicillin and incubated with aeration for 16 hrs at 37 °C. Small 
scale plasmid isolations were performed on the cultures using the QIAprep® Spin Miniprep kit 
(Qiagen).  
For confirmation of the recombinant pTRA constructs 500 ng - 1 µg plasmid DNA was digested 
for 1 hr at 37 °C with 1 U each of the restriction enzymes (5’ NcoI/MluI and 3’ XhoI) that flank 
the genes of interest (Table 2.1).   Digested DNA was separated on 0.8% w/v TBE agarose 
gels containing 2.5 mg/mL ethidium bromide.  
 
2.2.4. Transformation of A. tumefaciens 
A. tumefaciens LBA4404 and A. tumefaciens GV3101::pMP90RK cells were made 
electrocompetent using the method described by Shen and Forde (1989).  Fifty to 100 ng of 
the pEAQ-HT and pTRA recombinant plasmids were electroporated into A. tumefaciens 
LBA4404 and A. tumefaciens GV3101::pMP90RK, respectively.  Transformation of the A. 
tumefaciens strains was carried out by electroporation according to the method described by 
Maclean et al. (2007).  Recombinant pEAQ-HT clones were selected on LB media plates at 
27 °C containing 30 μg/mL kanamycin and 50 μg/mL rifampicin.  The pTRA clones were 
selected under the same conditions except that the plates were additionally supplemented 
with 50 μg/mL carbenicillin.   
Successful transformation was confirmed by colony PCR (as in Section 2.2.1) using the gene-
specific primers listed in Table 2.1, as well extracting plasmid DNA (QIAprep® Spin Miniprep 
kit, Qiagen) from O/N liquid cultures of putative recombinant clones and back-transformation 
of the DNA into DH5-α chemically competent E. coli cells. Transformed E. coli was plated onto 




2.2.5.  A. tumefaciens-mediated transient expression 
Starter cultures of recombinant pEAQ-HT and pTRA A. tumefaciens cells, including A. 
tumefaciens LBA4404 containing pBIN-NSs, the plasmid carrying the TSWV NSs silencing 
suppressor gene (Prins et al., 1996), were supplemented with the relevant antibiotics and 
grown in LB broth as described by Maclean et al. (2007).  To prevent clumping of the 
recombinant LBA4404 A. tumefaciens cells, the medium was supplemented with 2 mM 
magnesium sulphate (MgSO4).   
The starter cultures were used to inoculate induction medium (Maclean et al., 2007) with the 
addition of the appropriate antibiotics, including 20 μM acetosyringone and the cultures were 
incubated O/N at 27 °C with agitation.  The cells were harvested from the O/N cultures by 
centrifugation at 1 000 x g for 5 min and resuspended in infiltration medium (10 mM 
magnesium chloride [MgCl2], 10 mM 2-morpholinoethanesulfonic acid [MES], 3% sucrose and 
150 μM acetosyringone in water, pH 5.6).  The cell suspensions were incubated at 22 °C for 
2 hrs to allow for expression of the vir genes prior to infiltration.  After incubation the cultures 
were diluted to the required optical density (OD600) in infiltration medium.  The cell densities 
(OD600) used for co-infiltration of the constructs were varied in order to find the optimal cell 
concentration where all four capsid proteins were successfully co-expressed.      
For each one of the expression vectors used, the relevant recombinant A. tumefaciens 
constructs were co-infiltrated into six-week-old N. benthamiana leaves by injecting the 
suspension into the abaxial spaces using a blunt-ended syringe (Maclean et al., 2007).  
Recombinant A. tumefaciens pTRA constructs were co-infiltrated with pBIN-NSs, the pEAQ-
HT recombinant strains did not require co-infiltration with the silencing suppressor as it already 
has the P19 silencing suppressor integrated on the T-DNA of the plasmid under control of the 
CaMV 35S promoter (Sainsbury et al., 2009).  As a negative control the plants were infiltrated 
with infiltration medium.  Time-trials were conducted to evaluate and compare co-expression 
of VP2, VP3, VP5 and VP7 with the different vectors.  The plants were grown at 22 °C under 
16hrs/8hrs light/dark cycles until harvested.     
 
2.2.6.  Protein extraction and western blot analysis  
Three leaf discs (cut by using the cap of a microcentrifuge tube) were harvested for each 
vector co-expressing recombinant proteins at 1, 3, 5 and 7 days post infiltration (dpi) and 
ground up in liquid nitrogen.  The leaf material was resuspended in 70 μL per disc of bicine 
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buffer (50 mM bicine [pH 8.4], 20 mM sodium chloride [NaCl], 0.1% N-lauroyl-sarcosine [NLS], 
1 mM DL-dithiothreitol [DTT] and 1x Complete Mini EDTA-free protease inhibitor cocktail 
[Roche]) by vortexing.  The crude leaf extracts were clarified by centrifugation at    15 000 x g 
for 5 min in a bench top centrifuge. 
For western blot analysis, the crude plant extracts were incubated at 90 °C for 10 min in 
sample application buffer (Sambrook et al., 1989).  The proteins were separated on 8% SDS 
polyacrylamide gels where equal amounts of total protein were loaded in each lane.  For all 
the western blots PageRuler™ Prestained Protein Ladder (Thermo Scientific) was used as 
molecular weight marker.  After electrophoresis the proteins were transferred onto 
nitrocellulose membranes at 15 volts (V) for 1 hr using a Trans-blot®SD semi-dry transfer cell 
(Bio-Rad).  After electroblotting the membranes were blocked in blocking buffer (5% non-fat 
dairy milk [NFDM] and 1x PBST [137 mM NaCl, 10 mM disodium hydrogen phosphate 
(Na2HPO4), 2.7 mM potassium chloride (KCl), 2 mM potassium dihydrogen phosphate 
(KH2PO4) at pH 7.4 and 0.1% Tween-20]).  The membranes were probed O/N at 4 °C with  1: 
2000 sheep serum containing antibodies that reacted equally with all four VPs (Thuenemann 
et al., 2013) diluted in blocking buffer.  The membranes were washed four times with blocking 
buffer for 15 min each and afterward incubated in a 1: 10 000 dilution of anti-goat/sheep 
alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich) in blocking buffer for 1 
hr at   37 °C.  After incubation in secondary antibody the membranes were washed four times 
with 1x PBST, with 15 min for each wash.  Detection was performed with 5-bromo-4-chloro-3-
indolyl-phosphate (BCIP) and nitroblue tetrazolium (NBT) phosphatase substrate (BCIP/NBT 
1-component, KPL).        
Protein extraction and western blot analysis was repeated at least three times to confirm co-




2.3.  Results 
2.3.1.  PCR amplification of the BTV-8 codon optimised capsid genes 
The BTV-8 capsid genes, VP2, VP3, VP5 and VP7 were successfully amplified with the 
primers listed in Table 2.1 to modify the 5’ and 3’ termini for cloning into the pTRA vectors.  
PCR amplification of the genes with the different primer sets were expected to yield the 
following fragments:  VP2:  2.8 kb, VP3:  2.7 kb, VP5:  1.5 kb and VP7:  1 kb.   
Figure 2.2 shows the results of PCR amplification, indicating that all four genes were 
successfully amplified.  Figure 2.2 A shows bands at the expected sizes for all four capsid 
genes that were amplified with the pTRAc-HT primer sets.  These genes were modified to 
contain 5’ NcoI and 3’ XhoI restriction enzyme sites to facilitate cloning into the pTRAc-HT and 
pTRAkc-AH expression vectors.   
Figure 2.2 B shows the four genes at the expected sizes that were modified with the gene-
specific pTRAkc-rbcs1-cTP forward and pTRAc-HT reverse primers to contain 5’ MluI and 3’ 
XhoI restriction enzyme sites.   
 
 
The relevant bands on the gel were purified using the QIAquick® Gel Extraction kit (Qiagen) 
and subsequently cloned into the pGEM®-T-Easy vector.   
 
Figure 2.2:  PCR amplification of the BTV-8 capsid genes using (A) the pTRAc-HT gene-specific primer 
sets containing the 5’ NcoI and 3’ XhoI restriction enzyme sites and (B) the pTRAkc-rbcs1-cTP gene-
specific forward primers containing the 5’ MluI enzyme site and the pTRAc-HT gene-specific reverse 
primers with the 3’ XhoI enzyme sites.  The negative controls (-) containing water instead of DNA 
template were amplified with the appropriate primer sets.  Lanes M represents the molecular weight 
marker, O’GeneRuler™1kb DNA ladder (Fermentas).   
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2.3.2.  Verification of pGEM®-T-Easy clones 
The PCR-modified genes were successfully cloned into the pGEM®-T-Easy vector and 
transformed into E. coli, yielding the constructs listed in Table 2.3.   
 
Table 2.3:  Table showing the constructs created by cloning of the PCR-modified genes into 
pGEM®-T-Easy. 
Gene Construct 
Restriction sites (5’ / 
3’) 
VP2 cVP2GEM®-T-Easy NcoI / XhoI 
VP3 cVP3GEM®-T-Easy NcoI / XhoI 
VP5 cVP5GEM®-T-Easy NcoI / XhoI 
VP7 cVP7GEM®-T-Easy NcoI / XhoI 
VP2 cTPVP2GEM®-T-Easy MluI / XhoI 
VP3 cTPVP3GEM®-T-Easy MluI / XhoI 
VP5 cTPVP5GEM®-T-Easy MluI / XhoI 
VP7 cTPVP7GEM®-T-Easy MluI / XhoI 
 
The pGEM®-T-Easy recombinant clones were verified by restriction enzyme digestion using 
the XhoI sites which flank the 3’ ends of all the genes of interest.  Figure 2.3 A and B show 
that both the cVP- and cTPVPGEM®-T-Easy clones contained the genes of interest as 
linearized fragments were obtained after restriction digestion of the recombinant DNA at ~5.8 
kb, ~5.7 kb, ~4.6 kb and ~4 kb for modified VP2, VP3, VP5 and VP7, respectively. 
The recombinant pGEM®-T-Easy clones were sequenced with M13 forward and reverse 
primers as well as gene-specific internal primers (Table 2.2) to obtain sequence data for the 
entire sequence of each individual gene. The sequences were analysed in DNAMAN (Lynnon 
Biosoft) by multiple alignment of the sequence data with theoretical sequences of the different 












2.3.3.  Sub-cloning into the pTRA vector suite 
2.3.3.1.  Excision of the capsid genes from the pGEM®-T-Easy vector backbone 
Digestion of cVP2- and cVP3GEM®-T-Easy with NcoI and XhoI resulted in fragments at ~3 kb 
consisting of either VP2 and VP3 and the pGEM®-T-Easy backbone.  As these fragments were 
indistinguishable on agarose gels, the genes could not be excised using this strategy.  
Therefore, the cVP2- and cVP3GEM®-T-Easy plasmid DNA was first restriction digested using 
NcoI and ScaI (which cuts the pGEM®-T-Easy backbone); this yielded fragments at ~4.8 kb 
and ~1.1 kb for cVP2 and ~4.6 kb and ~1.1 kb for cVP3.  In both instances the larger fragment 
was purified from the gel and subsequently digested with XhoI, yielding cVP2 and cVP3 with 
NcoI and XhoI 5’ and 3’ restriction sites.  In the case of cVP5- and cVP7GEM®-T-Easy, the 
genes were excised from the pGEM®-T-Easy backbone by double digesting with NcoI and 
XhoI.  Bands at ~1.5 kb for cVP5 and ~1 kb for cVP7 were gel-purified yielding genes flanked 
with 5’ NcoI and 3’ XhoI restriction sites (results not shown). 
Figure 2.3: Recombinant pGEM®-T-Easy clones were verified by linearizing the plasmid DNA with XhoI 
restriction enzyme digestion.  (A) Shows the pGEM®-T-Easy clones with the genes modified to contain 
5’ NcoI and 3’ XhoI restricting sites and (B) shows the clones containing 5’ MluI and 3’ XhoI restriction 
sites.  Clones containing the genes of interest yielded bands at ~5.8 kb, ~5.7 kb, ~4.6 kb and ~4 kb for 
modified VP2, VP3, VP5 and VP7, respectively.  Lanes M represent the molecular weight marker.     
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The same strategy was followed to excise the genes from cTPVP2-, VP3-, VP5- and VP7 
GEM®-T-Easy, however MluI was used instead of NcoI yielding genes flanked by 5’ MluI and 
3’ XhoI restriction sites (results not shown).  
 
2.2.3.2.  Verification of recombinant pTRA clones 
The capsid genes were successfully cloned into the pTRAc-HT, pTRAkc-AH and pTRAkc-
rbcs1-cTP plant expression vectors and transformed into E. coli. 
Recombinant pTRA clones were screened by small scale plasmid isolations on O/N cultures 
and the subsequent restriction enzyme digestion of the plasmid DNA with NcoI and XhoI for 
the pTRAc-HT and pTRAkc-AH clones and MluI and XhoI for pTRAkc-rbcs1-cTP clones 
(Figure 2.4). Restriction enzyme digestion resulted in ~6.2 kb, ~7.6 kb and ~7.7 kb bands that 
constitute linearized pTRAc-HT, pTRAkc-AH and pTRAkc-rbcs1-cTP vector backbones, 
respectively (Figure 2.4, black arrows).  In all cases the insert VP DNA resulted in bands at 
~2.8 kb, ~2.7 kb, ~1.5 kb and ~1 kb for VP2, VP3, VP5 and VP7 respectively (Figure 2.4, white 
arrows).  These restriction profiles confirmed that the VP genes were successfully sub-cloned 







Figure 2.4:  pTRAc-HT (A) and pTRAkc-AH (B) recombinant clones were verified by NcoI / XhoI 
restriction enzyme digestion, whereas pTRAkc-rbcs1-cTP (C) recombinant clones were verified by 
restriction enzyme digestion with MluI and XhoI.  Black arrows indicate the linearized vector backbone 
at ~6.2 kb, ~7.6 kb and ~7.7 kb for pTRAc-HT, pTRAkc-AH and pTRAkc-rbcs1-cTP respectively.  White 
arrows indicate the insert DNA at ~2.8 kb, ~2.7 kb, ~1.5 kb and ~1 kb for VP2, VP3, VP5 and VP7 
respectively.  The molecular marker is represented by lanes M.  
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2.3.4.  Confirmation of successful A. tumefaciens transformation 
The recombinant pTRA constructs were transformed into A. tumefaciens GV3101::pMP90RK 
and recombinant pEAQ-HT constructs were transformed into A. tumefaciens LBA4404.  
Successful transformation was confirmed by colony PCR and back-transformation of the 
plasmid DNA extracted from the transformed A. tumefaciens into E. coli.  
 
2.3.5.  Transient expression of BTV-8 VPs in N. benthamiana 
To evaluate whether recombinant pTRA and pEAQ-HT A. tumefaciens constructs expressed 
the BTV-8 VPs in plants, individual recombinant constructs were infiltrated into N. 
benthamiana at an OD600 value of 0.25 per construct.  All the vectors successfully expressed 
the individual capsid proteins; VP2, VP3, VP5 and VP7 (results not shown) and subsequent 
experiments were carried out to optimise co-expression of the four VPs with each vector set, 
as the aim was to eventually produce assembled BTV-8 VLPs.  
Recombinant A. tumefaciens constructs harbouring the pEAQ-HT plasmids was initially co-
infiltrated into N. benthamiana leaves using a blunt-ended syringe with a relative vector 
concentration ratio of 1:1:1:1 (VP2:VP3:VP5:VP7), at an OD of 0.25 for each construct.  
Preliminary screening at 1, 3, 5 and 7 dpi of the pEAQ-HT infiltrated leaf tissue using western 
blot analysis showed that although VP2, VP3 and VP7 were present in the crude extracts, 
VP5 was not co-expressed (results not shown).  The lack of expression of VP5 could possibly 
have been a result of the low A. tumefaciens cell concentration used for infiltration.  It has 
been shown by Wroblewski et al. (2005) that an increase in the cell concentration used for 
infiltration can lead to an increase of transgene expression, therefore the concentration of the 
recombinant A. tumefaciens constructs encoding VP5 was subsequently doubled (for both the 
pTRA and pEAQ-HT constructs) and infiltration was carried out at a relative vector 
concentration ratio of 1:1:2:1 (VP2:VP3:VP5:VP7). 
Figure 2.5 shows the expression results after each set of four recombinant constructs were 
co-infiltrated into N. benthamiana using a relative vector concentration of 1:1:2:1 (VP2, VP3, 
VP5:VP7), at an OD600 of 0.25 for each construct and an OD600 of 0.5 for the construct carrying 
VP5.   
Co-expression of the VPs cloned into the pTRAc-HT plant expression vector (Figure 2.5 A), 
resulted in the detection of expected bands from 3 dpi onwards for VP3 (~102 kDa) and VP7 
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(~38 kDa), respectively.  A very faint ~59 kDa band (red arrow) constituting VP5 was barely 
detected at 1 dpi, however detection of this protein was not very convincing as non-specific 
protein bands were also detected on this day and the band at ~59 kDa could possibly have 
been due to non-specific binding of the antibody.  The expected band at ~111 kDa for VP2 
was not detected over the course of the 7 day time-trial.   
Co-infiltration with the pTRAkc-AH set of constructs (Figure 2.5 B) resulted in very low-level 
accumulation of VP5 at 1, 3 and 5 dpi (red arrow).  VP7 was detected at ~38 kDa from 3 dpi, 
onwards.  No VP2 or VP3 was detected with western blot analysis.   
When N. benthamiana was co-infiltrated with the pTRAkc-rbcs1-cTP set of constructs (Figure 
2.5 C), accumulation of VP7 (~38 kDa) was detected at 3 and 5 dpi, with VP3 (~102 kDa) and 
VP5 (~59 kDa) barely visible at 5 dpi (green arrow) and 1 dpi (red arrow), respectively. 
Co-infiltration with the pEAQ-HT set of constructs resulted in the successful co-expression of 
all four VPs at 5 and 7 dpi (Figure 2.5 D).  Expected band sizes of 111 kDa, 102 kDa, 59 kDa 
and 38 kDa corresponding to VP2, 3, 5 and 7 respectively, were visualized with the most 








Wroblewski et al. (2005) showed that an increase in the concentration of A. tumefaciens cells 
used for infiltration could increase transgene expression and subsequent levels of expressed 
protein.  These findings were found to be applicable to heterologous expression in N. 
benthamiana as it was shown above (Figure 2.5) that expression of VP5 was achieved after 
doubling the A. tumefaciens cell concentration used for infiltration.  Therefore, to determine 
whether an increase in cell density would affect co-expression of the BTV-8 VPs with the pTRA 
Figure 2.5:  Co-expression of the BTV-8 VPs (VP2, VP3, VP5 and VP7) over 7 days using four different 
plant expression vectors: (A) pTRAc-HT, (B) pTRAkc-AH, (C) pTRAkc-rbcs1-cTP and (D) pEAQ-HT.  
Equal amounts of total protein were loaded in each lane.  Each set of recombinant constructs was co-
infiltrated at OD600 of 0.25 for VP2,VP3, VP7 and 0.5 for the VP5-carrying construct, with a relative 
vector concentration of 1:1:2:1 (VP2:VP3:VP5:VP7).  VPs that were expressed are indicated by the 
white arrows.  Red and green arrows indicate faint bands obtained for VP5 and VP3 expression, 
respectively (A-C).  The negative controls are crude leaf extracts of plants infiltrated with infiltration 
medium. Lanes M indicate the molecular weight size marker.          
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and pEAQ-HT sets of constructs, infiltration of N. benthamiana using increased concentrations 
of all the recombinant A. tumefaciens constructs were tested.  
Infiltration of N. benthamiana with the pTRAc-HT constructs at an OD600 of 0.5 for each 
construct carrying VP2, VP3 and VP7 and OD600 of 1.0 for VP5, resulted in the co-expression 
of VP2, VP3 and VP7 (Figure 2.6 A).  Expression of VP7 (~38 kDa,) was detected throughout 
the time-trial, with VP3 (~102 kDa) detected from 3 dpi onward.  VP2 (~111 kDa) was detected 
on the western blot at 3 and 5 dpi, after which expression ceased.  With pTRAkc-AH (Figure 
2.6 B) the increased cell concentration used for co-infiltration resulted in the high level 
accumulation of VP7 from 1 dpi onward, with VP2 and VP3 detected from 3 dpi until the end 
of the time-trial.   VP5 was not expressed using either pTRAc-HT or pTRAkc-AH.   
The increase in cell density used for co-infiltration of the pTRAkc-rbcs1-cTP constructs 
resulted in expression of all four VPs (Figure 2.6 C).  Bands representing VP2, VP3 and VP7 
was detected at ~111 kDa, 102 kDa and 38 kDa, respectively from 1 dpi onward, whereas 
VP5 (~59 kDa) was barely detected at 1 dpi (red arrow).  Even though an increase in the A. 
tumefaciens cell concentration used for infiltration of the pTRA constructs enhanced 
expression of the VPs, all four proteins were rarely co-expressed on the same day.  Western 
blot analysis of the pTRAkc-AH and pTRAkc-rbcs1-cTP constructs infiltrated at higher cell 
concentrations (Figure 2.6 B and C, grey arrows) showed the presence of an unknown protein 
at ~80 kDa that was co-expressed with the VPs.   
On the other hand, co-expression of the VPs with the pEAQ-HT vector was enhanced with the 
increase in the cell concentration used for infiltration (Figure 2.6 D).  The presence of all four 
VPs was shown by western blotting from 1 dpi onward, although bands representing VP2 and 
VP5 were very faint at 1 and 3 dpi (blue and red arrows, respectively).  The accumulation of 
these proteins increased over the course of the time-trial with the most intense bands for all 

















Figure 2.6:  Co-expression of the BTV-8 VPs (VP2, VP3, VP5 and VP7) over 7 days using:  (A) 
pTRAc-HT, (B) pTRAkc-AH, (C) pTRAkc-rbcs1-cTP and (D) pEAQ-HT.  Each set of recombinant 
constructs was co-infiltrated at OD600 of 0.5 for each individual construct (OD600=1.0 for VP5), with 
a relative vector concentration of 1:1:2:1 (VP2:VP3:VP5:VP7).  Expressed proteins are indicated by 
the white arrows.  Red and blue arrows indicate bands representing VP5 and VP2, respectively (C 
and D).  Grey arrows (B and C) indicate an unknown protein at ~80 kDa.  The negative controls are 
crude leaf extracts of plants infiltrated with infiltration medium. Lanes M represent the molecular 
weight size marker.  
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Increasing the cell density to OD600 of 1.0 for each construct did not enhance co-expression 
of the capsid proteins using the pTRA vectors, as a comparison of corresponding bands on 
the western blots were found to be similar to those found on blots developed using samples 
from expression using an OD600 of 0.5 for each construct (results not shown).   
The increase in cell density to OD600 of 1.0 for infiltrating the pEAQ-HT constructs resulted in 
similar accumulation levels to those obtained when infiltrating at OD600 of 0.5 for each A. 
tumefaciens construct (results not shown).  
Infiltrated leaves were examined over the course of 7 days for the visible effects caused by 
increasing the cell density used for infiltration (Figure 2.7).  N. benthamiana infiltrated with 
infiltration medium served as a control for evaluating the effects caused by infiltration with the 
different recombinant constructs.  Leaves infiltrated with the pTRA constructs at OD600 of 0.5 
and 1.0 developed slight chlorosis from 3 dpi onward.  The chlorotic symptoms did not worsen 
as the time-trial progressed.  Plants infiltrated with the pTRAkc-AH and pTRAkc-rbcs1-cTP 
sets of constructs developed chlorosis at 3 dpi using an infiltration OD600 = 0.5, the leaves 
became more chlorotic over the last days of the time-trial, showing signs of necrosis at the 
injection sites (7 dpi). At 3 dpi chlorosis was observed in leaves infiltrated with the pTRAkc-
AH and pTRAkc-rbcs1-cTP sets of constructs at OD600 = 1.0.  The symptoms worsened 
progressively over the course of the time-trial, resulting in severely necrotic leaves at 7 dpi 
(Figure 2.7).  Leaves infiltrated with the pEAQ-HT set of constructs at both OD600 = 0.5 and 
1.0 were the healthiest with signs of chlorosis observed from 3 – 7 dpi, but no necrosis 





Figure 2.7:  Photographs of infiltrated leaves prior to protein extraction at 7 dpi. Four plant expression 
vectors were used to co-express the BTV-8 VPs:  pTRAc-HT, pTRAkc-AH, pTRAkc-rbcs1-cTP and 
pEAQ-HT.  Each set of recombinant constructs was co-infiltrated at either OD600 of 0.5 or 1.0 for each 
individual construct, with a relative vector concentration of 1:1:2:1 (VP2:VP3:VP5:VP7).  Plants 
infiltrated with infiltration medium served as an indicator of the effects caused by infiltrating with different 
cell concentrations with the expression vectors.  
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2.4.  Discussion 
In recent years, plants have become increasingly popular for the expression of recombinant 
proteins (Rybicki, 2009a; Rybicki, 2010).  Transient expression by means of agro-infiltration  
is a fast and convenient method for evaluating expression of heterologous proteins in plants 
(Fischer et al., 1999).  While the successful production of BTV-8 VLPs in N. benthamiana has 
been reported elsewhere (Thuenemann et al., 2013), this study – performed simultaneously – 
was aimed at comparing the ability of several different plant expression vectors to transiently 
co-express the four capsid proteins of BTV-8 (VP2, VP3, VP5 and VP7) in N. benthamiana 
leaves to determine whether expression levels could be increased by targeting the 
recombinant proteins to different subcellular compartments. 
Expression of the BTV-8 VPs with the pTRA plant expression vectors using a relative vector 
concentration ratio of 1:1:2:1 at an infiltration OD600 of 0.25 resulted in poor co-expression of 
the four VPs.  Only VP7 was expressed using an infiltration OD600 of 0.25 for all the pTRA 
expression vectors; little to no expression of VP2, VP3 and VP5 was achieved using these 
infiltration conditions (Figure 2.5 A, B and C).   
Expression was optimised by increasing the A. tumefaciens cell concentration used for co-
infiltrating, which resulted in the successful co-expression of three out of the four VPs.  VP2, 
VP3 and VP7 were co-expressed using the pTRAc-HT (Figure 2.6 A) vector which retains 
recombinant protein in the cytosol of plant host cells, these three proteins were also expressed 
using pTRAkc-AH and pTRAkc-rbcs1-cTP (Figures 2.6 B and C) which target recombinant 
proteins to the apoplast and chloroplast, respectively.  VP5 was only detected at 1 dpi using 
the pTRAkc-rbcs1-cTP expression vector (Figure 2.6 C, red arrow).  It has been found that 
VP5 is cytotoxic and degrades easily when expressed without being fused to another protein 
(Hassan et al., 2001).  Furthermore, research has shown that VP5 interacts strongly with VP7 
and assembly of VP5 precedes that of VP2 in the making of VLPs (Nason et al., 2004). It is 
possible that VP5 was expressed during the early stages of the time-trials using all the pTRA 
vectors; however it was degraded due to the absence of a CLP scaffold for it to interact with 
to form VLPs. The presence of the 6x histidine tag on all the pTRAc-HT constructs may have 
further prevented proper folding of the VPs to form CLPs.   
BTV core and sub-core particles assemble within viral inclusion bodies in the cytoplasm of 
infected cells (Boyce et al., 2004; Mertens et al., 2004); it is possible that assembly of 
recombinant CLPs and VLPs also takes place in the cytoplasm of the plant cell.  Furthermore 
the cytoplasm of both animal and plant cells have a pH of 7.0 - 7.5, whereas the apoplast and 
chloroplast have more acidic pH values of 5.8 and 4, respectively.  These lower pH values 
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could have resulted in failure of the BTV proteins to accumulate when expressed with the 
pTRAkc-AH and pTRAkc-rbcs1-cTP vectors, which target expressed proteins to the 
chloroplast and apoplast, respectively.  Thus, while the pTRA vectors were shown to be very 
useful in producing HPV VLPs at high yield (Maclean et al., 2007), they were not effective in 
the case of BTV VLP production.  
Further increasing the cell density of the recombinant pTRA constructs to an OD600 of 1.0 did 
not have any effect on increasing the VP co-expression.  In the case of pTRAkc-AH and 
pTRAkc-rbcs1-cTP it did, however, cause necrosis of the plant leaves which lower cell 
densities did not (Figure 2.7).  The necrosis seemed to correlate with the expression of an 
unknown protein at ~80 kDa (Figure 2.6 B and C, grey arrows) that was detected on the 
western blots.  It is possible that the higher concentration of A. tumefaciens cells may have 
played a detrimental part in normal plant regulatory functions (Wroblewski et al., 2005), 
causing the plant cells to die off and the subsequent expression of proteins involved in the 
process.   
In contrast to the pTRA vectors, all four capsid proteins of BTV-8 were successfully co-
expressed using the pEAQ-HT vector (Figures 2.5 and 2.6 D). This difference in expression 
observed between the pTRA vector suite and the pEAQ-HT vector could be attributed to the 
presence of the P19 silencing suppressor which is integrated into the T-DNA of the pEAQ-HT 
vector.  This ensures that both the gene of interest and the silencing suppressor are 
transferred to the same plant host cells, thereby ensuring concomitant post transcriptional 
gene silencing activity and expression of recombinant protein (Sainsbury et al., 2009).  In the 
case of the pTRA vectors, A. tumefaciens cells hosting the silencing suppressor plasmid 
(pBIN-NSs) were co-infiltrated with the plant expression vectors containing the genes of 
interest.  This does not necessarily guarantee the successful delivery and transfer of silencing 
suppressor T-DNA to the same host plant cells as the A. tumefaciens constructs containing 
the recombinant plasmids with the genes of interest (Sainsbury et al., 2009).  Successful co-
expression of the four BTV-8 VPs and the silencing suppressor from five separate A. 
tumefaciens constructs within the same plant cell, require five separate transfer events with 
the pTRA vectors – these factors taken together with the size of the larger VPs (VP2:  ~111 
kDa and VP3:  ~102 kDa) could possibly constitute a substantial bottleneck in co-expression 
of the four VPs. 
In conclusion, these results show that the pTRA vector suite only co-expressed some of the 
VPs, therefore these vectors are not suitable for the co-expression of the four BTV-8 VPs.  It 
was concluded from this work that pEAQ-HT is the most effective of all the vectors tested for 
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co-expression of the four BTV-8 VPs and it was decided to conduct further optimisation and 




Transient expression, characterisation and purification of BTV-8 VLPs  
 
3.1.  Introduction 
Virus-like particles (VLPs) resembling mature viral particles in size and shape are formed by 
the self-assembly of viral structural proteins.  It is advantageous to use VLPs as vaccines as 
they have been shown to stimulate both humoral and cellular immune responses (Grgacic and 
Anderson, 2006).  VLPs have the ability to stimulate a strong humoral immune response as B 
cells recognise the specific repetitive epitopes exposed on the surfaces of these particles 
(Jegerlehner et al., 2002; Mason et al., 1992; Whitehead et al., 2014).  Since VLPs are similar 
in size to native virions, they are able to be taken up by the dendritic cells which presents them 
to the major histocompatibility complex, resulting in the stimulation of a cellular immune 
response (Chackerian, 2007). 
BTV has a complex structure where the four major structural proteins – VP2, VP3, VP5 and 
VP7 – are concentrically arranged around the segmented genome and other minor structural 
and non-structural proteins.  In an effort towards making a safer vaccine for BTV, VLPs that 
lack the viral genome and that are identical to native BTV virions have been produced in insect 
cells using only the four outer capsid proteins of BTV (French et al., 1990; Roy, 1992).  
However, high production costs and contamination with host-associated products or viruses 
are just some of the drawbacks associated with the production of VLPs in insect cells (Kushnir 
et al., 2012).   
Agrobacterium-mediated transient expression in plants provides a more cost-effective, 
convenient and fast alternative for the production of vaccine candidates, including VLPs (Chen 
and Lai, 2013; Rybicki, 2010; Scotti and Rybicki, 2013).  Several reasons make plants a viable 
and appealing vehicle for the production of VLP vaccines; these include the cost-effectiveness 
and scalability of the production system as well as the possibility of producing rapid response 
plant-produced vaccines in response to pandemics.  For the production of influenza VLPs, 
Medicago Inc. (Canada) and the Fraunhofer Institute (USA) proved that it was possible to 
proceed from the acquisition of nucleic acid sequence data through to the purification of grams 
of protein within a month using an Agrobacterium-mediated transient expression system in 
tobacco (D'Aoust et al., 2010; D’Aoust et al., 2008; Rybicki, 2009b; Shoji et al., 2009; Shoji et 
al., 2011).   
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The plant expression platform has the possibility of providing a fast and scalable method for 
the production of BTV VLPs.  Recently, BTV-8 VLPs were successfully produced in N. 
benthamiana by using the pEAQexpress vector, where either VP2 and VP5 or VP3 and VP7 
were incorporated on the same T-DNA.  These VLPs were shown to protect sheep against 
lethal challenge with the virus (Thuenemann et al., 2013).   
In this study transient expression of BTV-8 VLPs using separate pEAQ-HT plasmids carrying 
the capsid genes to be expressed was further optimised and VLP assembly from the four 
separately expressed capsid proteins was analysed.  In situ localisation of the particles was 
investigated using transmission electron microscopy.  VLP purification using 
ultracentrifugation was optimised to achieve concentration of the VLPs, after which structural 
characterisation of the purified particles was carried out.  Purified VLPs were used for 





3.2.  Materials and Methods 
3.2.1.  Optimisation of BTV-8 co-expression using pEAQ-HT 
Since it was shown in Chapter 2 that the pEAQ-HT plant expression vector was the most 
successful at co-expressing the BTV-8 structural proteins, additional optimisation experiments 
using this set of constructs consisting of pEAQ-HTVP2co, pEAQ-HTVP3co, pEAQ-HTVP5co 
and pEAQ-HTVP7co were conducted.   
A. tumefaciens LBA4404 harbouring the abovementioned pEAQ-HT recombinant plasmids 
was cultured and prepared for syringe-infiltration as described in section 2.2.5.  Maintaining a 
cell concentration of OD600 of 0.5 per recombinant A. tumefaciens construct, the effects of 
different infiltration ratios of the four recombinant pEAQ-HT plasmids were tested.  In addition 
to the infiltration ratio of 1:1:2:1 (VP2:VP3:VP5:VP7) used in Chapter 2, the relative vector 
concentration infiltration ratios of 2:1:1:1 and 1.5:1:1:6.5 were also tested.  The 2:1:1:1 ratio 
was chosen at random and the ratio of 1.5:1:1:6.5 correlated to the ratio of the number of 
copies of each of the VPs on the BTV virion as determined by cryo-electron microscopy 
(Hassan and Roy, 1999; Roy, 1992; Roy, 2004).   
Three leaf discs were harvested for each infiltration ratio from 6 dpi to 9 dpi and protein was 
extracted and prepared for western blot analysis as described in section 2.2.6.     
 
3.2.2.  Transmission electron microscopy (TEM) of crude plant extracts 
TEM was carried out on crude plant extracts to determine at which ratio and dpi co-expression 
of the four BTV-8 VPs resulted in the formation of VLPs.  Copper grids (mesh size 200) were 
made hydrophilic by glow discharging at 25 mA for 30 s using a Model 900 SmartSet Cold 
Stage Controller (Electron Microscopy Sciences).  The grids were floated on a 1:200 dilution 
of BTV-8 sheep serum made against plant-produced VLPs (Thuenemann et al., 2013) for 2 
min and washed twice with sterile water.  Thereafter the grids were floated on a 1:10 dilution 
of crude plant extract for 5 min and washed three times with sterile water.  The samples were 
negatively stained for 1 min with 2% w/v uranyl acetate and viewed using a Technai G2 
transmission electron microscope (FEI).  Particles were measured using the Ruler tool in 




3.2.3.  Embedding of infiltrated leaf sections for in situ TEM 
The BTV-8 pEAQ-HTVP2co, pEAQ-HTVP3co, pEAQ-HTVP5co and pEAQ-HTVP7co 
constructs were cultured and combined (as described above) in a ratio of 1:1:2:1 
(VP2:VP3:VP5:VP7) and syringe-infiltrated into the abaxial surfaces of six-week-old N. 
benthamiana plants.   
At 9 dpi a whole leaf was picked from the infiltrated plant and a 3 cm x 3 cm piece was cut out 
with a scalpel blade in the presence of 2.5% gluteraldehyde (25% gluteraldehyde diluted in 
0.1 M phosphate buffer [20 mM sodium dihydrogen (ortho) phosphate (NaH2PO4) and 80 mM 
disodium hydrogen (ortho) phosphate (Na2HPO4), pH 7.4]). The leaf sample was soaked in 
2.5% gluteraldehyde for 6 hrs after which it was cut into 1 mm x 3 mm fragments, also in the 
presence of 2.5% gluteraldehyde. The leaf fragments were soaked in 2.5% gluteraldehyde 
O/N at 4 °C. The following day the leaf fragments were washed 3 times, 5 minutes for each 
wash, in 0.1 M phosphate buffer (pH 7.4).  The leaf fragments were fixed for 1 hr in one part 
2% osmium tetroxide and one part 0.2 M phosphate buffer (40 mM NaH2PO4 and 160 mM 
Na2HPO4, pH 7.4), after which it was washed twice for 5 min each with 0.1 M phosphate buffer 
followed by two washes of 5 min each with sterile water.  
After washing, the leaf fragments were sequentially dehydrated.  The leaf fragments were 
incubated for 5 min each in 30%, 50%, 70%, 80%, 90% and 95% ethanol. The fragments were 
incubated for 10 min in 100% ethanol; this step was repeated twice. After the ethanol series 
the leaf fragments were further dehydrated by 10 min incubation in 100% acetone, repeated 
twice.  The leaf fragments were mixed O/N in 1:1 acetone: Spurr’s (Agar Scientific) resin.   
The following day half of the 1:1 acetone: Spurr’s resin mixture was removed and replaced 
with 100% Spurr’s resin to yield a 1:3 acetone: Spurr’s resin mixture. The samples were mixed 
for 4 hrs at room temperature, after which the acetone/resin mixture was removed and 
replaced with 100% Spurr’s resin.  The leaf fragments were incubated in 100% Spurr’s resin 
for three days at 4 °C.  The 100% Spurr’s resin was replaced with fresh resin and incubated 
for 4 hrs at room temperature after which the resin was replaced again and incubated 
overnight at room temperature.  The following day the specimens were embedded in 100% 
Spurr’s resin and incubated for 24 hours at 60 °C.  
The embedded leaf specimens were cut into ultrathin sections with a diamond knife and 
collected onto copper grids (mesh size 200). The copper grids  were stained with uranyl 
acetate for 10 min after which they were washed five times, 15 seconds each, with water.  The 
55 
 
grids were blotted dry and transferred to lead citrate for 10 min after which the grids were 
washed with water and blotted dry.   
Grids were viewed and the particles measured as described above (Section 3.2.2).  
 
3.2.4.  Protein extraction and density gradient purification of BTV-8 VLPs 
Thirty six-week-old N. benthamiana plants were syringe infiltrated using a ratio of 1:1:2:1 of 
the recombinant A. tumefaciens strains containing the pEAQ-HT plasmids expressing VPs 2, 
3, 5 and 7.  The plants were grown for 8-9 days at 22 °C under 16hrs/8hrs light/dark cycle.  
Infiltrated leaves were harvested and immediately cut into fine pieces.  The plant material was 
thoroughly homogenised with a Waring-type blender in three volumes of ice cold bicine buffer 
(50 mM bicine [pH8.4], 20 mM sodium chloride [NaCl], and 1 x Complete Mini, EDTA-free 
protease inhibitor cocktail [Roche]) lacking NLS and DTT.  The homogenate was incubated at 
4 °C for 30 min with gentle agitation after which it was filtered through four layers of Miracloth™ 
(Merck) and further clarified by centrifugation at 1 000 x g for 10 min at 4 °C.   
The crude plant sap was overlaid onto 5 mL of a 30% iodixanol (Optiprep™, Sigma-Aldrich) 
cushion prepared in 50 mM Tris-HCl, pH 8.4 and 20 mM NaCl after which it was centrifuged 
for 2 hrs at 79 000 x g in a SW 32 Ti rotor (Beckman).  The 30% iodixanol cushion was 
collected after centrifugation from the bottom of the tube and diluted to 15% with 50 mM Tris-
HCl, pH 8.4 and 20 mM NaCl, after which it was overlaid onto a discontinous iodixanol gradient 
diluted in 50 mM Tris-HCl, pH 8.4 and 20 mM NaCl.  The discontinous gradient was centrifuged 
as described above and fractions were collected from the bottom of the tubes and analysed 
by western blotting (as described in Chapter 2). 
 
3.2.5.  TEM of purified BTV-8 VLPs 
Copper grids were glow discharged as described in section 3.2.2.  The grids were floated on 
the fractionated samples from the density gradients for 5 min, after which they were washed 
five times with sterile water.  The samples were negatively stained for 1 min with 2% w/v uranyl 




3.2.6.  Quantification of purified VLPs 
Purified fractions were resolved on SDS-Page gels and treated with Coomassie-blue stain to 
confirm that no contaminating plant proteins were co-purified on the iodixanol gradients (0.1% 
Coomassie Brilliant Blue R-250, 50% methanol and 10% glacial acetic acid).  Thereafter, the 
total soluble protein (TSP) present in the iodixanol fractions containing VLPs was determined 
using the Bio-Rad DC Protein Assay according to the manufacturer’s instructions.  Bovine 
serum albumin (BSA, Sigma-Aldrich) was used as protein standard and the absorbance was 
read at 750 nm using a Bio-Tek Powerwave XS spectrophotometer.   
 
3.3.  Results 
3.3.1.  Co-expression of the BTV-8 capsid proteins with pEAQ-HT  
Time-trials of the co-expression of the BTV-8 capsid proteins were extended to 9 dpi to 
determine if longer expression would lead to increased levels of co-expressed proteins.  Co-
infiltration of the recombinant A. tumefaciens harbouring the pEAQ-HT plasmids in a ratio of 
1:1:2:1 (Figure 3.1 A) resulted in the co-expression of VP2 (~111 kDa), VP3 (~102 kDa), VP5 
(~59 kDa) and VP7 (~38 kDa) from 6 dpi onward. The most intense bands for all four proteins 
were observed at 7 and 8 dpi, after which the recombinant protein levels appeared to be 
slightly less.  
Co-infiltration of the recombinant pEAQ-HT constructs in a ratio of 2:1:1:1 (Figure 3.1 B) 
resulted in the presence of VP2, VP3 and VP7 on the western blot at 6 dpi with no VP5 visible. 
At 7 and 8 dpi, all four VPs constituting the VLPs were observed, with VP5 becoming less 
visible after 9 dpi.  In comparison, infiltration at a cell density ratio of 1.5:1:1:6.5 (Figure 3.1 C) 
resulted in co-expression of all four capsid proteins at 6 dpi, with VP5 at very low levels (red 













3.3.2.  TEM of the crude plant extracts infiltrated with different ratios of 
recombinant A. tumefaciens constructs 
TEM was carried out on the crude leaf extracts of the 6 – 9 dpi pEAQ-HT samples that were 
infiltrated using the relative vector concentration ratios of 1:1:2:1 (VP2:VP3:VP5:VP7), 2:1:1:1 
and 1.5:1:1:6.5 to assess whether co-infiltration resulted in the assembly of intact CLPs or 
VLPs.  It was expected that the particles could be distinguished from each other by a difference 
Figure 3.1:  Western blot analysis of the BTV-8 capsid protein co-expression with different infiltration 
ratios of recombinant pEAQ-HT plasmids. (A) Infiltration using a relative vector concentration ratio of 
1:1:2:1 (VP2:VP3:VP5:VP7), (B) 2:1:1:1 and (C) 1.5:1:1:6.5, the red arrow indicates expression of VP5 
at 6 dpi.  The negative control was crude leaf extract of a plant infiltrated with infiltration medium and 
lanes M represent the molecular weight marker.  
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in size with CLPs ranging in diameter from 60 - 69 nm and VLPs having diameters ranging in 
size from 72 – 80 nm.   
A mixed population of both putative CLPs and VLPs was confirmed from 6 – 9 dpi using an 
infiltration ratio of 1:1:2:1 (Figure 3.2 A[i] and B[i]).  Sub-core (VP3 only) particles and CLPs 
were observed in crude N. benthamiana extracts infiltrated with all three ratios (results not 
shown for 7 and 8 dpi), however there were no putative VLPs visible in the leaves which were 
co-infiltrated using the ratios of both 2:1:1:1 (Figure 3.2 A[ii] and B[ii]) and 1.5:1:1:6.5 (Figure 
3.2 A[iii] and B[iii]) throughout the time-trial.  With the 2:1:1:1 and 1.5:1:1:6.5 infiltration ratios 
the amount of particles that were visible decreased after 6 dpi, with mostly protein aggregates 
visible at 9 dpi (results not shown for 7 and 8 dpi). No CLP or VLP-like structures were 
observed in the negative control sample that was infiltrated with infiltration medium only 




















3.3.3.  In situ TEM of BTV-8 capsid proteins co-expressed in N. benthamiana 
Leaves infiltrated with recombinant A. tumefaciens constructs using a relative vector 
concentration ratio of 1:1:2:1 (VP2:VP3:VP5:VP7) were harvested at 9 dpi, embedded in 
Spurr’s resin and subsequently viewed using TEM.   
Western blot analysis of the leaves harvested for in situ TEM showed that all four capsid 
proteins were successfully expressed at 9 dpi (results not shown).  Aggregates of spherical 
particles arranged in linear arrays were observed in the cytoplasm of the plant cells expressing 
VLPs (Figure 3.3).  The particles ranged from 61 – 83 nm in diameter, indicating the existence 
of a mixed population of particles consisting of both CLPs and VLPs.  Figure 3.3 (A[i] and B[i]) 
shows two fields of view at a magnification of 5700 x and 8000 x, respectively.  Figure 3.3 
(A[ii] and B[ii]) show the particles in more detail (17 000 x magnification).  TEM showed that 
CLPs and VLPs were not expressed in every plant cell (results not shown), but when a cell 
did produce the particles they were present in large numbers. Negative control samples 
infiltrated with infiltration media (Figure 3.3 C) were also evaluated using TEM.  No similar 
structures were observed in these control samples.  
 
  
Figure 3.2:  From the previous page.  Transmission electron micrographs of leaves infiltrated with the 
three different ratios - (i) 1:1:2:1, (ii) 2:1:1:1, (iii) 1.5:1:1:6.5 - tested of A. tumefaciens harbouring the 
recombinant pEAQ-HT plasmids at 6 dpi (A) and 9 dpi (B).  (C) A negative control crude extract of a 
plant infiltrated with infiltration medium only was also viewed.  The crude extracts were captured onto 
copper grids with sheep serum and viewed using a Technai G2 transmission electron microscope (FEI).  













3.3.4.  Density gradient purification of putative BTV-8 VLPs 
Since VLPs were observed in both the crude extracts and embedded sections of leaves 
infiltrated with pEAQ-HT constructs in the ratio of 1:1:2:1 (VP2:VP3:VP5:VP7), the number of 
plants infiltrated was scaled up to produce larger amounts of VLPs for purification with density 
gradient centrifugation.   
 
3.3.4.1.  Initial VLP purification 
Infiltrated leaf tissue was harvested at 6 and 9 dpi after which VLPs were immediately 
extracted by grinding leaves in liquid nitrogen and resuspending the leaf material in bicine 
buffer containing NLS and DTT.  The crude extracts were overlaid onto discontinuous 
iodixanol gradients consisting of 10 – 60% iodixanol (in 10% increments), followed by 
ultracentrifugation.  
Western blot analysis of undiluted iodixanol fractions collected from the bottom of the tubes 
showed smears in lane 4 (Figure 3.4 A) and lanes 4 and 5 (Figure 3.4 B) – representing 30 – 
40% iodixanol - for VLPs purified at 6 and 9 dpi, respectively.  At 6 dpi (Figure 3.4 A) only VP7 
(orange arrow) was detected in the pellet (P), with no protein present in fractions 1 – 3, 
representing 50 – 60% iodixanol.  Three distinct bands representing either VP2 or VP3 (purple 
arrow), VP5 (red arrow) and VP7 (orange arrow) was detected in fraction 4.  Analysis of 
fractions 1 – 3 at 9 dpi (Figure 3.4 B) showed no bands representing the VPs, however fraction 
3 showed a band at ~50 kDa (black arrow), which could possibly constitute degradation 
products.  No protein was detected in the pellet (P) collected after gradient centrifugation at 9 
dpi.   
Figure 3.3:  From the previous page.  (A) and (B): Transmission electron micrographs of leaf sections 
that were infiltrated with recombinant pEAQ-HT plasmids using an infiltration ratio of 1:1:2:1 
(VP2:VP3:VP5:VP7) and harvested at 9 dpi. A(i) and B(i) represent two fields of view at 5700 x and 
8000 x magnification, respectively.  A(ii) and B(ii) show the particles in more detail at 17 000 x 
magnification.  Particles were present in paracrystalline arrays.  Scale bars left panel:  0.5 µm, right 
panel: 0.2 µm (C) Negative control leaf infiltrated with infiltration medium at 17 000 x magnification 
(Scale bars:  0.2 µm).  CW:  cell wall, CPT:  chloroplast, CYT:  cytoplasm, V:  vacuole.  
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Two-fold serial dilutions using bicine buffer were made of fraction 4 and fractions 4 and 5, 
collected at 6 and 9 dpi respectively and analysed on western blots.  Western blot analysis 
(Figure 3.4 C) of the diluted 30 – 40% iodixanol fractions showed the presence of VP2, VP3, 
VP5 and VP7 (blue, green, red and orange arrows respectively) in the ½ dilution of fraction 4 
collected at 6 dpi, with no VP5 detected at the ¼ and 1/8 dilutions.  Serial dilutions of both 
fractions 4 and 5 collected at 9 dpi, show the presence of VP3, VP5 and VP7 (green, red and 
orange arrows respectively), but no VP2 was detected.  Dilutions of fraction 5 (9 dpi) show the 
presence of additional bands on the western blot.  These bands possibly constitute 











Fraction 4 collected at 6 dpi and fractions 4 and 5 collected at 9 dpi were fixed to copper grids 
and visualised using TEM.   
Transmission electron micrographs of fraction 4 (6 dpi) showed particles ranging in size from 
51 nm to 70 nm (Figure 3.5 A[ii]).  The smaller particles (~51 nm, black arrows) represent 
putative sub-core particles which consist of only VP3, these particles had a smooth surface 
and appeared to be either hexagonal, angular or round, depending on their orientation on the 
grid.  Larger particles representing putative CLPs (red arrows) closely resembled CLPs 
Figure 3.4:  Western blot analysis of fractions collected after density gradient purification of putative 
BTV-8 VLPs.  Iodixanol fractions ranging from 20 – 60% of VLPs purified at 6 and 9 dpi are shown in 
A and B, respectively.  Lanes P represent the pellets collected after gradient centrifugation and 
numbers 1 – 8 indicate the fraction numbers collected from the bottom of the tubes.  (C) Shows a 
dilution series of fraction 4 from 6 dpi and fractions 4 and 5 from 9 dpi.  Lanes M represent the 
molecular weight marker.  VP2:  blue arrow, VP3:  green arrow, VP5: red arrow and VP7:  orange 





produced in insect cells, the particles had a spiky appearance due to the layer of VP7 trimers 
arranged around the sub-core particles.   
TEM analysis of fractions 4 and 5 collected at 9 dpi (Figure 3.5 B[ii] and [iii]) showed similar 
results to those found at 6 dpi, with mostly putative sub-core particles and CLPs present in the 
iodixanol fractions.  Control samples Figure 3.5 A[i] and B[i]) collected from the top of the tubes 
after gradient ultracentrifugation were also analysed with TEM; no structures resembling sub-




Figure 3.5:  TEM analysis of iodixanol fractions 4 (A[ii]) collected at 6 dpi and fractions 4 and 5 (B[ii] 
and [iii]) collected at 9 dpi.  A (i) and B (i) are the negative controls collected from the top of the tube 
after ultracentrifugation.  Fractions from 6 and 9 dpi consisted of particles from 51 – 70 nm in size, 




3.3.4.2.  Optimisation of VLP purification 
Since the purification process appeared to be detrimental to the stability of the particles as 
indicated by western blot and TEM analysis of the iodixanol purified fractions (Figures 3.4 and 
3.5), several small modifications were made to the extraction method. Plant tissue was not 
ground up in liquid nitrogen, but thoroughly homogenised instead in ice cold bicine buffer 
lacking DTT and NLS.  DTT is a redox reagent that reduces disulphide bridges of proteins and 
prevents intra-molecular disulphide bonds from forming between cysteine residues, while NLS 
is a detergent that denatures proteins by reducing solvent-inaccessible disulphide bonds.  
Proteins were co-expressed for 9 days - since VLPs were detected in both the crude extract 
(Figure 3.2 B[i]) and in situ (Figure 3.3 A and B) - after which recombinant protein was 
immediately extracted from the leaf material.  The clarified crude plant extract was overlaid 
onto a 30% iodixanol cushion and centrifuged as described in section 3.2.4.  
Ultracentrifugation through the iodixanol cushion further clarified the crude plant extract by 
removing particulate matter and contaminating plant proteins that were co-extracted with the 
VLPs.  The 30% iodixanol cushion containing the VLPs could be stored O/N at 4 °C without 
adverse effects on the particles.   
The 30% iodixanol cushion was diluted to 15% in Tris buffer (pH 8.4) and overlaid onto either 
a discontinous gradient containing 20 – 60% iodixanol in 10% increments (1 mL of each step, 
total volume of 10 mL) or a continuous 20 – 60% gradient (total volume of 24 mL).  After 
centrifugation 1 mL fractions were collected from the bottom of the tubes containing both the 
discontinous gradient and the continuous gradient.  
Western blot analysis of the fractions collected from the discontinous iodixanol gradient 
(Figure 3.6 A) showed that no protein was detected in fractions 1 and 2, which represent ~50% 
and ~60% iodixanol respectively. Bands corresponding to the expected sizes of VP3 and VP7 
were detected in fraction 3 and all four VPs were detected from fraction 4 onward.  Fractions 
4 - 6 corresponds to approximately 30 - 40% iodixanol, where the VLPs were expected to be 
found.   
Transmission electron micrographs of fraction 4 (Figure 3.6 B [i] and [ii]) show that intact VLPs 
(green arrows) ranging from 73 – 80 nm in size were purified on the discontinous gradient. 
The fuzzy appearance of the outer layer of the particles is due to the assembly of VP2 and 
VP5 with the CLPs.  Less structured uniform particles (blue arrows) possibly representing 
assembly intermediates between CLPs and VLPs were co-purified with the putative VLPs.  
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The plant produced VLPs were similar to VLPs (Figure 3.6 B[iii]) produced using the 












Western blot analysis of the fractions collected of the continuous iodixanol gradient showed 
that no protein was present in the first 11 fractions (fractions 1-10: results not shown).  In 
Figure 3.7 A bands representing VP7 (orange arrow) were observed in fractions 13 – 14, with 
Figure 3.6:  (A) Western blot analysis of fractions collected from a discontinuous iodixanol gradient.  
Lane numbers indicate the fractions collected from the bottom of the tubes. Bands the size of VP2, VP3, 
VP5 and VP7 were seen from fraction 4 onward.  Lane M indicates the molecular weight marker.  B (i) 
and (ii) TEM of fraction 4 show both intermediate structures (blue arrows) and VLPs (green arrows).  
Scale bars are 200 nm.  B (iii) TEM of baculovirus-expressed VLPs (Roy, 2004).   
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VP3 (green arrow) also present in fractions 15 and 16.  VP3, VP5 and VP7 was detected in 
fraction 17 and all four VPs were detected from fraction 18 onward.  Even though all four VPs 
were detected on the western blot, TEM analysis of fraction 19 showed that only CLPs ranging 
from 60 – 69 nm in diameter were purified; no VLPs were observed (Figure 3.7 B).  The results 
indicate that even though VP2 and VP5 were co-purified with the CLPs, they were not 












Figure 3.7:  (A) Western blot analysis (two blots joined) of particles purified using a continuous iodixanol 
gradient.  Lanes 10 – 27 show the fractions collected from the bottom of the tubes.  Bands representing 
the four VPs can be seen from lane 17 onward.  Lane M represents the molecular weight marker.  VP3:  
green arrow and VP7:  orange arrow.  (B) TEM of fraction 19 shows that CLPs were purified on the 
continuous gradient.  Scale bar:  200 nm.   
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Particles produced for animal experiments (Chapter 5) were extracted as above and 
subsequently purified on an iodixanol cushion followed by ultracentrifugation through a 
discontinuous iodixanol gradient.  The discontinuous gradient was slightly modified to consist 
of 1 mL 60%, 2 mL 50%, 2 mL 40 %, 3 mL 30% and 2 mL 20% iodixanol.  The modifications 
were carried out to prevent overloading of the gradient with the sample and to allow for 
selection of VLPs in the ~30% iodixanol fraction.  The best fractions from the first round of 
centrifugation were pooled and applied to a second discontinous gradient consisting of half 
the volumes of appropriately diluted iodixanol and centrifuged as described above.  Three 
fractions of 500 µL each that contained VLPs were pooled (results not shown) and quantified.   
 
3.3.5.  Total soluble protein (TSP) quantification of VLPs 
Coomassie-stained SDS-Page gels (results not shown) showed that now contaminating plant 
proteins were co-purified with the VLPs on the gradient, however bands representing the four 
VPs could not be visualised on the gel due to the low levels of purified protein.  Therefore, the 
TSP of the pooled iodixanol fractions containing VLPs was determined using the Bio-Rad DC 
Protein Assay kit.  A standard curve was plotted using the average absorbance values 
obtained for the BSA standards (Figure 3.8).  Using the equation on the chart, the TSP was 
calculated at ~1.75 mg total protein in a volume of 1.5 mL.  The final yield of VLPs was 









Figure 3.8:  TSP quantification of the pooled iodixanol fractions containing VLPs using BSA as a 
standard.  The green triangle indicates the average absorbance obtained for the VLPs.  The error bars 
indicate the standard deviation. 





















3.4.  Discussion 
VLPs are excellent vaccine candidates as they combine the advantages of using whole-virus 
vaccines and subunit vaccines.  These advantages include:  a well-defined structure and 
uniformity with repetitive structures, the preservation of antigenic conformation, safety for use 
as they are non-infectious and non-replicating and the fact that they can be DIVA compliant 
when using diagnostic tests that are based on the detection of non-structural BTV proteins or 
antibodies (Barros et al., 2009; Crisci et al., 2012).  BTV is a structurally complex virus with a 
capsid made up of concentric layers of the four capsid proteins VP2, VP3, VP5 and VP7.  
Production of VLPs that contain multiple capsid proteins that interact with each other is 
technically challenging as all the capsid proteins must be co-expressed by the same cell in 
order for the VLP to be assembled (Noad and Roy, 2003).   
In this study, transient co-expression of the four BTV-8 capsid proteins in N. benthamiana was 
further optimised by varying the infiltration ratios of the recombinant A. tumefaciens constructs 
carrying the pEAQ-HT plasmids.  The infiltration ratios were varied in order to assess the effect 
on protein accumulation and the ability of the co-expressed proteins to assemble into VLPs.  
Expression using the 1:1:2:1 infiltration ratio was continued as it was shown to result in the 
successful co-expression of VP2, VP3, VP5 and VP7 (Chapter 2).   
Co-expression time-trials were extended to 9 days to ascertain if this would lead to increased 
levels of accumulation and samples were collected from 6 dpi onward.  Western blot analysis 
(Figure 3.1) of the expression time-trials using different ratios showed that all four capsid 
proteins were successfully expressed using the three infiltration ratios.  All four proteins were 
expressed from 6 – 9 dpi after infiltration using the 1:1:2:1 ratio (Figure 3.1 A).  Infiltration 
using the 2:1:1:1 (Figure 3.1 B) and 1.5:1:1:6.5 (Figure 3.1 C) ratios resulted in the co-
expression of the four capsid proteins at 7 – 8 dpi and 6 dpi, respectively.   
TEM analysis of the crude plant extracts from the time-trials showed that plants infiltrated with 
VP2:VP3:VP5:VP7 in a ratio of 1:1:2:1 resulted in the successful expression of VLPs (76 – 82 
nm) from 6 – 9 dpi (Figure 3.2 A[i] and B[i]).  TEM analysis further showed that co-infiltration 
with the four separate A. tumefaciens constructs resulted in the “spontaneous” assembly of 
separately expressed VPs into CLPs and VLPs.  
In contrast, TEM analysis of expression using the 2:1:1:1 and 1.5:1:1:6.5 ratios showed that 
sub-core like particles and CLPs were expressed at 6 dpi (Figure 3.2 A[ii-iii]) in the plants, 
however no VLPs were detected in the crude extracts from 6 – 9 dpi.  At 9 dpi (Figure 3.2 B[ii-
iii]) mostly protein aggregates and sub-core like particles were observed using TEM, indicating 
degradation of the particles over extended periods of expression.  The microscopy results 
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correlated with the expression profiles seen on western blots, where only VP2, VP3 and VP7 
were detected after 9 dpi (Figure 3.1 A and B).  The EM results indicated the importance of 
VP5 in the assembly of VLPs; it appeared that VP5 was not as readily expressed as the other 
VPs.  Therefore, increasing the infiltration volume of the recombinant A. tumefaciens 
harbouring VP5, increased the likelihood of VP5 being successfully co-expressed with the 
other VPs.   
Based on these results further expression studies were conducted by co-infiltrating plants with 
a 1:1:2:1 ratio of the recombinant A. tumefaciens constructs.   
Leaves co-expressing the capsid proteins were harvested at 9 dpi and embedded in Spurr’s 
resin to ascertain where in the plant cell the particles were assembled and also to determine 
the size of the particles in situ.  Electron micrographs of leaf sections co-expressing the four 
capsid proteins showed the presence of mixed populations of both CLPs and VLPs (measuring 
61 – 83 nm in size) present in paracrystalline arrays within the cytoplasm of plant cells (Figure 
3.3 A and B), indicating that particles were assembled by interactions of the expressed VPs.  
Similarly, work done by French and Roy (1990) showed that CLPs also aggregated as 
paracrystalline arrays within the cytoplasm of insect cells co-expressing VP3 and VP7.  BTV 
virions have been shown to assemble within the cytoplasm of infected host cells, where after 
virions are released from the cells in a process mediated by the non-structural protein, NS3 
(Boyce et al., 2004; Mertens et al., 2004).  The in situ results from this study and work done 
by French and Roy (1990) suggest that recombinantly-produced CLPs and VLPs assemble 
within the cytoplasm, similar to native BTV virions.  The absence of NS3 from recombinantly-
produced particles possibly keep them localised within the cytoplasm, resulting in the 
formation of paracrystalline arrays that consist of a multitude of CLPs and/or VLPs.  TEM 
analysis showed that not every plant cell expressed CLPs and/or VLPs.  These results were 
expected because for VLPs to be produced in a host cell, four transfer events – from each one 
of the four recombinant A. tumefaciens constructs – into the cell is required for co-expression 
of the four capsid proteins and subsequent VLP formation.   
In order to determine when VLPs could be effectively purified from crude plant extract, leaves 
co-expressing the four VPs were harvested at 6 and 9 dpi, and protein was extracted using 
bicine buffer containing NLS and DTT (as in Chapter 2).  After purifying these crude extracts 
on discontinuous iodixanol gradients, western blot analyses (Figure 3.4) and TEM (Figure 3.5) 
of the purified fractions showed that only sub-core like particles and CLPs were purified using 
this extraction buffer at both days.  For subsequent experiments, proteins were co-expressed 
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for 9 days as this expression time frame was shown to result in the formation of VLPs within 
the plant cell using TEM (Figure 3.3 A and B). 
Since the presence of NLS and DTT in the buffer used to extract these heteromultimeric 
complexes appeared to negatively affect the stability of the VLPs (Figures 3.4 and 3.5), these 
substances were omitted from further extraction processes.  In addition, the crude plant extract 
was centrifuged through a 30% iodixanol cushion which resulted in further clarification of the 
crude plant sap by removing contaminating plant proteins that were co-extracted with the 
VLPs, as well as any particulate matter that remained in the extract after low-speed 
centrifugation.   
Purification of VLPs was compared by overlaying the diluted 30% iodixanol cushion containing 
the particles onto either a discontinous gradient or a continuous gradient.  Both western blot 
analysis and TEM showed that centrifugation through a discontinous gradient resulted in the 
successful purification of intact VLPs measuring 73 – 80 nm in diameter (Figure 3.6 B[i-ii]).  
The purified plant produced VLPs were shown to be similar to VLPs produced by Roy (2004) 
in insect cells (Figure 3.6 B[iii]).  In contrast, the continuous gradient resulted in the purification 
of mostly CLPs (Figure 3.7 B) although all four proteins were detected on a western blot 
(Figure 3.7 A).  From these results it was found that although the four proteins constituting 
VLPs were still present in the purified iodixanol fractions, purification through the continuous 
gradient most likely resulted in the dissociation of the two outer capsid proteins, VP2 and VP5, 
from the CLPs.  It was determined that the discontinuous gradient was important for 
maintaining the structural integrity of VLPs during the purification process.  Similarly, it was 
also shown that the centrifugation of insect cell produced VLPs through a discontinuous 
sucrose gradient was important for the purification of structurally intact VLPs (Stewart et al., 
2010).  It is possible that the less steep continuous gradient results in dilution of the VLPs 
throughout the gradient, causing the outer capsid proteins to dissociate from the more stable 
CLPs whereas selection for VLPs on the discontinuous gradient is more stringent.  
VLPs that were produced for animal experiments (Chapter 5) were purified on a discontinuous 
iodixanol gradient and the best fractions obtained from the first gradient were subjected to a 
second round of ultracentrifugation through a smaller gradient to concentrate the particles.   
The final yield of VLPs that was purified after 9 dpi from plants co-infiltrated with four different 
A. tumefaciens constructs using a ratio of 1:1:2:1 (VP2:VP3:VP5:VP7) was determined to be 
~27 mg TSP per kilogram of fresh leaf tissue (Figure 3.8).  It was shown by Thuenemann et 
al. (2013)  that increased yields (up to ~70 mg [TSP] VLPs per kilogram of fresh weight plant 
material) of BTV-8 VLPs were obtained by using the pEAQexpress vectors where VP3 and 
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VP7 or VP2 and VP5 were expressed from the same T-DNA.  In this approach VP3 was under 
control of the wild type CPMV 5’ UTR which resulted in down-regulation of CLP synthesis and 
a shift towards higher levels of VLP expression.  Furthermore, the fact that two proteins were 
carried on the same T-DNA halved the number of A. tumefaciens constructs that needed to 
be co-infiltrated into plants and also reduced the number of transfer events that were 
necessary to result in VLP expression from plant cells (Thuenemann et al., 2013).  
In conclusion, it has been shown that co-infiltration of the A. tumefaciens constructs harbouring 
the pEAQ-HT plasmids using a relative vector concentration ratio of 1:1:2:1 resulted in the 
expression of intact VLPs in plants.  To the best of our knowledge this is the first work 
demonstrating the presence of assembled BTV-8 VLPs in paracrystalline arrays within the 
cytoplasm of plant cells.  The importance of using a discontinuous gradient for the purification 
of structurally intact VLPs was also demonstrated.  The expression approach used here, is 
flexible in terms of being able to vary individual A. tumefaciens construct densities for “fine-
tuning” protein expression.  This may be necessary for making vaccines for different BTV 
serotypes, as there is no guarantee that the individual VPs of these will express in the same 
way as has been shown for BTV-8.  On the other hand, the expression approach used by 
Thuenemann et al. (2013) - where two proteins are expressed from a single T-DNA - could 
have the potential to be used as a rapid response production system for production of BTV 
VLPs where VP3, VP5 and VP7 serve as a “universal core” and the serotype specific VP2 is 






Design, expression and purification of BTV protein body vaccines 
 
4.1.  Introduction 
The most efficient means of controlling Bluetongue disease (BT) in sheep is through 
vaccination.  A vaccine produced by Onderstepoort Biological Products (OBP, Pretoria) that 
consists of attenuated field strains is widely used in South Africa.  The vaccine is sold as three 
bottles each containing five different BTV serotypes (Bottle A:  serotypes 1, 4, 6, 12 and 14; 
Bottle B:  serotypes 3, 8, 9, 10 and 11 and finally Bottle C:  serotypes 2, 5, 7, 13 and 19).  The 
most attenuated virus strains are administered first, thereby reducing the possible side effects 
caused by the less attenuated virus strains in the remainder of the vaccine preparations 
(Coetzee et al., 2012; Roy et al., 1990b).  Several side effects including the development of 
mild clinical symptoms (Veronesi et al., 2010), decreased milk production (Savini et al., 2008) 
and transplacental infection (MacLachlan et al., 2000; Osburn et al., 1971) have been 
documented with the use of these vaccines.   
VLP vaccines have been produced using insect cell and plant-based expression systems.  The 
VLP-based vaccines were shown to be safe and effective, with vaccinated sheep protected 
against virus challenge (Roy et al., 1990a; Stewart et al., 2012; Thuenemann et al., 2013).  A 
disadvantage of these however, is that they are protective against only one of the 26 BTV 
serotypes, unless they are administered as a combination of VLPs produced against different 
serotypes.  In South Africa 22 of the 26 known BTV serotypes have been detected in the 
country and it has been found that multiple BTV serotypes co-circulate with each vector 
season (Coetzee et al., 2012): this demonstrates the necessity for use of a multivalent vaccine 
for BTV in this region.  Unfortunately, it may be distinctly unfeasible to propose using multi-
serotype VLP-based vaccines, as there would be problems producing sufficient volumes of so 
many types, and for a cost that is even remotely comparable to the live attenuated vaccine. 
The BTV structural protein VP2 is the major serotype-specific antigen of BTV (Huismans and 
Erasmus, 1981; Roy et al., 1990b).  It has been shown that ≥50 µg doses of both VP2 obtained 
from isolated and purified BTV and recombinantly-produced VP2 induced neutralising 
antibodies and protected some, but not all of the sheep that were vaccinated, against viral 
challenge.  Lower doses were shown to provide protection; however no neutralising antibodies 
were detected after vaccination (Huismans et al., 1987; Roy et al., 1990b).  Even though these 
subunit vaccines have been shown to be safe for use in sheep (Roy et al., 1990b), it is 
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desirable to enhance the immunogenicity of these vaccine candidates.  The immunogenicity 
of proteins can be increased by fusing them to other immunogenic proteins, by adding 
adjuvant to the vaccine formulation (Rybicki, 2010), or by fusion to signal sequences that drive 
assembly and sequestration of the protein into protein bodies (Torrent et al., 1994).  Particulate 
proteins with repeating sequence motifs, such as protein bodies, are favoured for uptake by 
antigen presenting cells, thereby enhancing the immune response (Whitehead et al., 2014).  
Protein bodies (PBs) are endoplasmic reticulum (ER)-derived organelles that are found in 
maize seeds.  These organelles stably store massive amounts of zeins as a source of protein 
within the ER (Müntz, 1998).  Once expressed and targeted to the ER for post translational 
modification, these zein polypeptides oligomerise in large complexes and eventually self-
associate into protein bodies (Galili, 2004; Herman and Larkins, 1999; Larkins and Hurkman, 
1978).  The proline-rich N-terminal (including a tandem-repeat domain) of one of these zeins 
- γ-zein - was shown to be important for ER retention and the formation of PBs in both maize 
seeds and a wide range of eukaryotic cells (Ludevid et al., 2004).   
Zera® (ERA Biotech, Spain) is a synthetic peptide generated from the N-terminal proline-rich 
domain of γ-zein (Ludevid et al., 2004).  The Zera® sequence (see Figure 4.1) is made up of 
112 amino acids that include the γ-zein signal peptide and the first 93 amino acids of γ-zein.  
The complete Zera® sequence contains four regions (Figure 4.1): a γ-zein ER-targeting signal 
peptide (blue box), 11 hydrophobic non-proline amino acids that contain a CGC motif that is 
important for packing of protein bodies due to the formation of inter-and intra-chain disulphide 
bonds (green box, N-term), the proline-rich repeat domain containing eight repeats of the 
hexapeptide PPPVHL (grey box) which is important for the assembly of PBs and finally, a 
proline-X (Pro-X region) sequence where proline residues alternate with other amino acids 
(Llop-Tous et al., 2010; Ludevid et al., 2004).  The main driving forces behind the self-
assembly of PBs are hydrophobic interactions between the (PPPVHL)8 repeat regions of two 
or more Zera® chains and inter-chain disulphide bond formation that stabilises and strengthens 








It has been demonstrated that fusion of Zera® to different proteins of interest results in the 
retention of recombinant proteins within PBs called StorPro® organelles (ERA Biotech, Spain).  
Zera® fused to several different proteins including red fluorescent protein (Joseph et al., 2012), 
enhanced cyan fluorescent protein (Llop-Tous et al., 2010), human growth hormone (Llompart 
et al., 2010), calcitonin (Ludevid et al., 2004) and epidermal growth factor (Torrent et al., 
2009a) has been shown to result in the formation of PBs in the leaves of both transiently and 
stably transformed tobacco plants.   
Synthetic PBs  (StorPro® organelles) retain many beneficial characteristics of natural PBs, 
including the presence of chaperones that facilitate folding of recombinant proteins, better 
accumulation within dense membrane-bound structures that allow for easier purification and 
subcellular sequestration that protects the proteins from intracellular degradation (Torrent et 
al., 2009a).   
Zera®-fused subunit vaccine proteins have been shown to induce cellular and humoral 
immune responses as well as having intrinsic adjuvancy and immunomodulatory properties 
(http://www.erabiotech.com/index.php/applications/zera-vaccines/protein-particle-vaccines).  
It has been shown that fusion of the HPV-16 E7 protein to Zera® enhanced immunogenicity of 
the protein.  The study further demonstrated the adjuvant activity of Zera®, whereby free 
protein bodies mixed with the HPV-16 E7 protein resulted in an enhanced immune response 
(Rybicki et al., 2011; Whitehead et al., 2014).  
As has been described previously, the antigenic characteristics of VP2 make it an excellent 
candidate for a BT vaccine.  By presenting VP2 to the immune system in particulate form, 
immunogenicity of the protein will probably be enhanced and less of the antigen may be 
needed for vaccination.  Therefore, the aim of this study was to develop two novel VP2-based 
BTV vaccine candidates.  For the first vaccine candidate, the putative antibody-binding 
epitopes of multiple serotypes of VP2 were predicted with in silico methods and a synthetic 
Figure 4.1:  A schematic representation of the Zera® regions, including the amino acid sequence. Image 
adapted from Llop-Tous et al. (2010). 
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peptide based on the predicted epitopes was constructed for VP2.  The second vaccine 
candidate consisted of the full-length plant codon-optimised BTV-8 VP2.  Nucleotide 
sequences representing both the synthetic epitope sequence and the full-length plant codon-
optimised BTV-8 VP2 were fused to the Zera®-encoding sequence to drive PB formation when 
the fusion protein genes were expressed in N. benthamiana.  Protein expression and 
purification of both vaccine candidates was optimised and TEM of infiltrated leaves was carried 






4.2.  Materials and Methods 
4.2.1.  In silico epitope prediction of VP2 
Eight full-length BTV VP2 amino acid sequences (Table 4.1) were selected from Genbank 
(http://www.ncbi.nlm.nih.gov/genbank/) and the most likely epitopes of each of these 
sequences was predicted with COBEpro [(Sweredoski and Baldi, 2009), 
http://scratch.proteomics.ics.uci.edu/], an online program for the prediction of continuous B-
cell epitopes.   
The VP2 amino acid sequences were aligned using ClustalW2 
(https://www.ebi.ac.uk/Tools/msa/clustalw2/) and two predicted B-cell epitope regions whose 
amino acid compositions corresponded to most of the aligned VP2 sequences - belonging to 
the eight different BTV serotypes - were selected for inclusion into the synthetic epitope-based 
vaccine.  A third homologous region was also included in the synthetic epitope-based vaccine 
sequence. 
 
Table 4.1:  The BTV serotypes used in the design of the putative VP2 epitope and their 
corresponding Genbank accession numbers.  













4.2.2.  Construction of the fusion product Zera®-VP2ep with assembly PCR 
4.2.2.1.  PCR amplification of Zera® 
The plasmid pZera®1 (Torrent et al., 2009a) obtained from ERA Biotech was used as a 
template for the PCR amplification of Zera®.  Primers were designed to introduce 5’ AgeI and 
3’ NcoI restriction enzyme sites to the gene termini (Table 4.2; Zera®-FP and Zera®-RP). The 
PCR reaction consisted of 50 ng of the template DNA, 200 μM dNTPs, 1 μM of each primer, 
1x Buffer A and 1 unit (U) KAPA Taq DNA polymerase (KAPA Biosystems).   
Zera® was amplified by initial denaturation at 94 °C for 5 min. Thereafter, 25 cycles of 
denaturation at 94 °C for 30 s, annealing at 55 °C for 60 s and elongation at 72 °C for 45 s 
were carried out followed by a final elongation step at 72 °C for 5 min.  The amplified product 
was separated on a 1% w/v TBE (89 mM Tris base, 89 mM boric acid and 2 mM EDTA [pH8]) 
agarose gel containing 2.5 mg/mL ethidium bromide and visualised under short wavelength 
ultraviolet (UV) illumination.  
The amplified Zera® fragment was purified from the agarose gels using the QIAquick® Gel 
Extraction kit (Qiagen) following the manufacturer’s instructions.  The purified DNA was used 




Table 4.2:  Primers and oligomers used for PCR of individual genes and the assembly PCR of fusion products1. 






sites           
(5’ / 3’) 
5’ – 3’ sequence2 Tm      (°C) 
Zera® 352 
Zera®-FP3, 4       
Zera®-RP 
AgeI         
NcoI 
GCACCGGTATGAGGGTGTTGCTCGTT                   
GCCCATGGCTGGCACGGGCTTGGAT 
62.7          
58.3 
VP2ep 70 
VP2ep-F          
VP2ep-R 




76.7        
79.8 
Linker   NcoI/MluI CCATGGGAAGCGGCGGCGAAAACGCGT 75.9 
  Linker-VP2ep-FP3  GAAGCGGCGGCGAAAACGCGTTTCCCAGAGCACCTT 77.3 
  Linker-Zera®-RP3  TTTCGCCGCCGCTTCCCATGGTCTGGCACGGGCTTG 81.4 









61.2      
62.3 
1. All primers and oligomers were synthesized in-house at the Department of Molecular and Cell Biology (University of Cape Town). 
2 The restriction enzyme sites are underlined and in bold. 
3, 4 Primers used for first and second stage assembly PCR of Zera®-VP2ep. 
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4.2.2.2.  Assembly of VP2ep 
The putative multi-epitope sequence - VP2ep - was designed to contain 5’ MluI and 3’ XmaI 
restriction enzyme sites.  Two oligomers - VP2ep-F and VP2ep-R (Table 4.2) - consisting of 
41 bp each were designed and synthesized with 12 complementary base pairs to facilitate 
fusion of the fragments during assembly PCR to yield VP2ep.  The assembly PCR reaction 
consisted of 1 μM each of VP2ep-F and VP2ep-R, 200 μM dNTPs, 1x Buffer A and 1 U KAPA 
Taq DNA polymerase.  The two oligomers were assembled by initial denaturation of the DNA 
at 94 °C for 5 min, followed by 20 cycles of denaturing at 93 °C for 1 min and annealing and 
elongation at 65 °C for 30 s.  A final elongation step was carried out for 5 min at 72 °C.  The 
annealed product was separated on a 2% w/v TBE agarose gel containing 2.5 mg/mL ethidium 
bromide.  
The VP2ep DNA was purified from the PCR reaction using the QIAquick® PCR purification kit 
(Qiagen) following the manufacturer’s instructions and used as template in the assembly PCR 
of Zera®-VP2ep. 
 
4.2.2.3.  Assembly PCR of Zera®-VP2ep 
For the fusion of Zera® to VP2ep a nucleotide sequence encoding a short universal peptide 
linker consisting of glutamate (E), three alanines (A) and lysine (K) - EAAAK (nucleotide 
sequence in Table 4.2) - was synthesized so as to contain 5’ NcoI and 3’ MluI restriction sites.  
Linker primers containing regions that were complementary to both the linker, Zera® and 
VP2ep were also designed and synthesized (Table 4.2; Linker-VP2ep-FP and Linker-Zera®-
RP) to further facilitate assembly of the fusion product.  
Assembly PCR of Zera®-VP2ep was carried out in two stages.  Figure 4.2 illustrates the fusion 
product Zera®-VP2ep, including the primers that were used in first and second stage assembly 














The first stage assembly PCR reaction consisted of ~50 ng of each of the following DNA 
templates:  Zera®, VP2ep and the linker.  The remainder of the reaction contained 1 μM of 
each primer (Zera®-FP, Linker-VP2ep-FP, Linker-Zera®-RP, VP2ep-RP), 200 μM dNTPs, 1x 
Buffer A and 1 U KAPA Taq DNA Polymerase.  First stage assembly PCR was carried out 
with an initial denaturing step at 94 °C for 2 min, followed by 25 cycles of denaturing at 93 °C 
for 1 min and annealing and elongation at 72 °C for 30 s.  A final elongation step was carried 
out for 5 min at 72 °C.   
The assembled PCR product was separated on a 2% w/v TBE agarose gel and purified using 
the QIAquick® Gel Extraction kit, after which the purified DNA was used as template in second 
stage PCR of the fusion product.   
The second stage PCR reaction contained 50 ng of the template DNA, 1 μM each of Zera®-
FP and VP2ep-RP, 200 μM dNTPs, 1x Buffer A and 1 U KAPA Taq DNA Polymerase.  Second 
stage cycling conditions were similar to the first stage assembly PCR conditions, however only 
20 cycles of amplification were carried out and the annealing temperature was decreased to 
65 °C.  The assembled fusion product Zera®-VP2ep was visualised and gel purified as 
described above.   
 
Figure 4.2:  Schematic representation of the primers used to create the fusion product Zera®-VP2ep. 
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4.2.3.  Cloning of Zera®-VP2ep into pEAQ-HT 
The entire volume of gel purified Zera®-VP2ep was digested for 1 hr at 37 °C with 1 U each of 
the restriction enzymes AgeI and XmaI (Fermentas), after which the DNA was gel purified as 
described above.  Similarly, 1 µg of the pEAQ-HT vector was linearized and gel purified after 
which the vector DNA was dephosphorylated using 1 U rapid alkaline phosphatase (Roche) 
according to the manufacturer’s instructions.   
Zera®-VP2ep was directionally cloned into the pEAQ-HT plant expression vector to yield 
pEAQ-HTZera®-VP2ep.  DH5-α chemically competent E. coli cells (E. cloni™, Lucigen) cells 
were transformed (Sambrook et al., 1989) with the plasmid construct and recombinant clones 
were selected using kanamycin resistance (50 μg/mL).   
pEAQ-HTZera®-VP2ep recombinant clones were screened by colony PCR using the Zera-FP 
and VP2ep-RP primers (Table 4.2).  PCR cycling conditions included an initial denaturation 
step at 94 °C for 2 min, followed by 20 cycles at 93 °C for 1 min, 65 °C for 30 s and 72 °C for 
45 s and a final elongation step at 72 °C for 5 min.  PCR products were separated on 2% TBE 
agarose gel with 2.5 mg/mL ethidium bromide.   
Recombinant clones were verified by restriction enzyme digestion of the plasmid DNA.  
Colonies were inoculated into 5 mL LB media supplemented with 50 μg/mL kanamycin and 
incubated with aeration for 16 hrs at 37 °C. Small scale plasmid isolations were performed on 
the cultures using the QIAprep® Spin Miniprep kit (Qiagen) according to the manufacturer’s 
instructions.  Recombinant plasmid DNA (~500 ng) was digested for 1 hr at 37 °C using 1 U 
each of AgeI and XhoI.  The digested DNA was separated on a 1% TBE agarose gel stained 
with 2.5 mg/mL ethidium bromide.   
The sequence of the pEAQ-HTZera®-VP2ep construct was verified using the pEAQ-FP and 
pEAQ-RP sequencing primers (Table 4.2).  Sequence data was analysed by alignment with 
the theoretical sequence in DNAMAN (Lynnon BioSoft). 
 
4.2.4.  Construction of pEAQ-HTZera®-VP2 
VP2ep was excised from the pEAQ-HTZera®-VP2ep plasmid by restriction enzyme digestion 
with 1 U each of MluI and XhoI.  Similarly, the full-length N. benthamiana codon-optimised 
VP2 was excised from the pTRAkc-rbcs1-cTPVP2co plasmid (Chapter 2).  To create the 
pEAQ-HTZera®-VP2 construct, VP2 was cloned into the MluI and XhoI sites after which it was 
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used to transform DH5-α chemically competent E. coli cells (E. cloni™, Lucigen) as described 
in Section 4.2.3.   
Recombinant pEAQ-HTZera®-VP2 clones were screened by colony PCR with the cTPVP2coF 
and cVP2coR primers (Chapter 2, Table 2.1) using the cycling conditions described in Section 
2.2.1.   
The recombinant clones were verified by digesting ~500 ng of the plasmid DNA for 1 hr at   37 
°C using 1 U each of AgeI and XhoI.  The digested DNA was separated on a 0.8% TBE 
agarose gel stained with 2.5 mg/mL ethidium bromide.   
The pEAQ-HTZera®-VP2 construct was further confirmed by sequencing and sequence 
analysis as described in Section 4.2.3. 
 
4.2.5.  Transformation of A. tumefaciens LBA4404 
Both expression constructs were transformed into electrocompetent A. tumefaciens LBA4404 
as described in Section 2.2.4.  Recombinant clones were selected on LB media plates at 27 
°C containing 30 μg/mL kanamycin and 50 μg/mL rifampicin.   
Successful transformation was confirmed by colony PCR as described in Sections 4.2.3 and 
2.2.1 for pEAQ-HTZera®-VP2ep and pEAQ-HTZera®-VP2, respectively.  Further confirmation 
was also obtained by back-transformation of the plasmid DNA into DH5-α chemically 
competent E. coli cells as described in Section 4.2.3.  Transformed E. coli was plated onto LB 
plates supplemented with the appropriate antibiotics to select for the recombinant plasmids. 
 
4.2.6.  A. tumefaciens-mediated transient expression of Zera®-VP2ep and Zera®-
VP2 
Starter cultures of A. tumefaciens harbouring the pEAQ-HTZera®-VP2ep and pEAQ-HTZera®-
VP2 plasmids were supplemented with 30 μg/mL kanamycin, 50 μg/mL rifampicin and 2 mM 
MgSO4 and grown in LB media as described by Maclean et al. (2007).   
The starter cultures were used to inoculate induction medium supplemented with 30 μg/mL 
kanamycin, 50 μg/mL rifampicin, 20 μM acetosyringone and 2 mM MgSO4.  The cultures were 
propagated O/N at 27 °C with agitation, after which the cells were prepared for syringe 
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infiltration into six-week-old N. benthamiana leaves as described in Section 2.2.5.  Time-trials 
were carried out to evaluate at what OD600 and which day the best expression of Zera®-VP2ep 
and Zera®-VP2 occurred, after which expression was scaled up.   
 
4.2.7.  In situ TEM of Zera®-VP2ep and Zera®-VP2 PBs 
A. tumefaciens cultures harbouring the pEAQ-HTZera®-VP2ep or pEAQ-HTZera®-VP2 
plasmids were syringe-infiltrated into the abaxial air spaces of six-week-old N. benthamiana 
plants and protein was expressed for 3 and 7 days, respectively.   
Embedding and sectioning of the leaf material was carried out according to the method in 
Section 3.2.3.  Grids were viewed using a Technai G2 transmission electron microscope (FEI). 
 
4.2.8.  Protein extraction  
For small-scale expression three leaf discs were harvested for each expression construct at 
2, 3, 5 and 7 dpi and ground up in liquid nitrogen.  The leaf material was resuspended in    70 
μL per disc of buffer PBP3 (100 mM Tris [pH8], 50 mM KCl, 6 mM MgCl2, 10 mM EDTA, 0.4 
M NaCl and 1x Complete Mini EDTA-free protease inhibitor cocktail [Roche]) and mixed by 
vortexing.  The leaf extracts were clarified for 5 min at 15 000 x g on a bench top centrifuge.  
After large scale expression of Zera®-VP2ep and Zera®-VP2, leaves were harvested at 3 and 
7 dpi, respectively and were either frozen at -80 °C until further processing or immediately cut 
up into fine pieces and thoroughly homogenised with a Waring-type blender in five volumes of 
ice cold PBP3 buffer containing 10% sucrose and 1 x Complete Mini EDTA-free protease 
inhibitor cocktail.  The crude plant extract was incubated at 4 °C with gentle agitation, after 
which it was filtered through four layers of Miracloth™ (Merck).  The homogenate was further 
clarified by centrifugation at 1 000 x g for 10 min at 4 °C. 
 
4.2.9.  Sucrose cushion purification of protein bodies 
The clarified crude plant extract was overlaid onto 5 mL of a 42% sucrose cushion prepared 
in buffer PBP3 and ultracentrifuged for 2 hrs at 79 000 x g in a SW 32 Ti rotor (Beckman).  
86 
 
After centrifugation the pellet was resuspended in 300 µL buffer PBP3 containing 10% 
sucrose.   
 
4.2.9.1.  Sequential extraction of purified PBs 
PBs were sequentially solubilised according to the method described by Joseph et al. (2012).  
The process was carried out by mixing 1 part of the protein body suspension in 1 part buffer 
SB1 (62.5 mM Tris-Cl [pH 6.8], 25% glycerol and 2% SDS).  The mixture was incubated at RT 
for 1 hr, after which it was centrifuged at 15 000 x g for 15 min at 4 °C.  The supernatant 
containing the soluble (S) fraction was aspirated.  The pellet was resuspended in 1 part buffer 
SB2 (buffer SB1 including 350 mM DTT), after which it was incubated and centrifuged as 
above.  The supernatant was aspirated (fraction R) and the pellet resuspended in buffer SB2.  
The resuspended pellet was incubated at 95 °C for 5 min to solubilise the PB cores and 
centrifuged as described above, after which the supernatant (H) was collected.  The remaining 
pellet was resuspended in 1 part buffer SB2 (final pellet) and analysed with western and dot 
blots.   
 
4.2.9.2.  “Washing” of PBs 
The pellet (obtained after sucrose cushion purification) was resuspended in buffer PBP3 and 
washed multiple times by centrifugation at 15 000 x g for 5 min – each time collecting the 
supernatant (wash 1, wash 2, etc.) and resuspending the pellet in 500 µL PBP3 buffer 
containing 10% sucrose.  The purified protein bodies were stored at 4 °C until further analysis.   
 
4.2.10.  Western- and dot blot analysis of Zera®-VP2ep and Zera®-VP2 
4.2.10.1.  Production of wild type BTV-8 VP2 antibodies in rabbits for use in 
western- and dot blot analysis 
Since there was no commercially available antibody for BTV VP2, antibodies were raised in 
rabbits against the wild type (wt) BTV-8 VP2 for the detection of plant-expressed proteins.  
The wtVP2 protein was expressed in E. coli DH5-α using the pCold™TF Cold Shock 
Expression System (TAKARA).  The recombinant E. coli culture was incubated for 16 hrs at 
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37 °C with agitation, after which it was used to inoculate 100 mL LB medium supplemented 
with 50 µg/mL ampicillin.  The culture was incubated with agitation at 37 °C until it reached an 
OD600 of 0.4-0.5.  The culture was refrigerated at 15 °C for 30 min after which protein 
expression was induced by the addition of 0.5 mM isopropylthio-β-D-galactoside (IPTG) and 
the culture incubated at 15 °C for 24 hrs.  After 24 hrs the cells were harvested by 
centrifugation at 1 000 x g for 5 min.   
Inclusion bodies were purified from the E. coli cell pellet using Bugbuster® (Novagen, USA) 
according to the manufacturer’s instructions.  The resuspended wtVP2 inclusion bodies were 
dialysed O/N at 4 °C using dialysis tubing with a molecular weight cut-off of 10 kDa (Thermo 
Fischer Scientific, USA) in 2 L sterile Dulbecco’s Endo-free PBS (Sigma-Aldrich, USA).   
Endotoxin levels were measured using the Limulus Amebocyte Lysate QCL-1000™ kit 
(Lonza) as per the manufacturer’s instructions.  Samples were assayed in a 96-well Maxisorp® 
microtitre plate and the absorbance readings at 405 nm were obtained using a Bio-Tek 
Powerwave XS spectrophotometer.   
The amounts of wtVP2 antigen on a 8% SDS polyacrylamide Coomassie-stained gel was 
estimated using a bovine serum albumin (BSA, Sigma-Aldrich) standard curve.  The bands 
were quantitated using a Syngene Gene Genius imaging system and GeneTools software 
(Synoptics Inc., UK).   
Deltamune (Pty) Ltd. (South Africa) carried out inoculation and production of the polyclonal 
antibody in rabbits.  For the primary inoculation rabbits were injected subcutaneously with 500 
µL of wtVP2 in the presence of Incomplete Freund’s Adjuvant (IFA) made according to the 
manufacturer’s instructions (Difco, #263910).  This was followed by three subsequent booster 
vaccinations (in the presence of IFA); the first booster was administered two weeks after the 
initial injection and thereafter the second and third boosters followed one week after the other.  
The total amount of antigen used for each dose was ~32 µg.  All protocols were approved by 
the Deltamune Animal Ethics Committee prior to being carried out.   
Rabbit serum obtained from Deltamune was used as primary antibody for western– and dot 




4.2.10.2.  Western blot and dot blot analysis of Zera®-VP2ep and Zera®-VP2 
For western blot analysis, the plant extracts were incubated at 90 °C for 10 min in 5 x DTT 
sample application buffer (250 mM Tris-Cl [pH6.8], 500 mM DTT, 10% sodium dodecyl 
sulphate [SDS], 0.3 mM bromophenol blue and 10% glycerol).  Zera®-VP2ep and Zera®-VP2 
proteins were separated on 15% and 8% SDS polyacrylamide gels, respectively.  Western 
blot analysis was carried out as described in Section 2.2.6, except that a 1:2000 dilution of the 
rabbit-raised anti-VP2 polyclonal antibody (α-VP2R) in blocking buffer was used as primary 
antibody after which the membranes were subsequently probed with a 1:5000 dilution of anti-
rabbit IgG alkaline phosphatase-conjugated secondary antibody produced in goats (Sigma-
Aldrich).   
Dot blots were done by dropping 5 µL of the purified protein wash fractions onto nitrocellulose 
membranes and letting the membranes dry completely.  The membranes were probed O/N at 
4 °C with 1:2000 dilutions of α-VP2R, BTV-8 sheep serum (raised against plant-produced 
VLPs) and BTV-10 guinea pig-produced serum (obtained from Dr Christiaan Potgieter, 
Deltamune) in blocking buffer.  The membranes were washed four times in blocking buffer for 
15 min each and afterward incubated for 1 hr at 37 °C in either a 1:5000 dilution of anti-rabbit 
alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich), 1:10 000 dilution of 
anti-goat/sheep alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich) or 
1:5000 anti-guinea-pig alkaline phosphatase-conjugated secondary antibody (Sigma-Aldrich).  
After secondary antibody incubation the dot blots were washed four times with 1x PBST, with 
15 min for each wash.  Detection was performed using BCIP/NBT (KPL) substrate.   
 
4.2.10.3.  Quantification of purified PBs 
PBs were quantified by determining the TSP present in the final pellet obtained after washing 
the PBs.  Quantification was carried out according to the method described in Section 3.2.6, 
after confirming with Coomassie-stained gels that no contaminating plant-proteins were co-




4.3.  Results 
4.3.1.  Prediction of a putative BTV VP2 epitope 
In silico prediction (data not shown) of continuous B-cell epitopes was carried out on eight  full-
length VP2 amino acid sequences that were available on Genbank 
(http://www.ncbi.nlm.nih.gov/genbank) with COBEpro (Sweredoski and Baldi, 2009) 
prediction software available from the Scratch protein server 
(http://scratch.proteomics.ics.uci.edu/).  COBEpro lists possible predicted epitopes regions 
from most likely to least likely.  The VP2 amino acid sequences were aligned and two predicted 
epitope regions that were similar for most of the serotypes was selected for the epitope-based 
vaccine sequence.   
The resulting multi-epitope (VP2ep) consisted of three discontinuous regions that were fused 
together from the VP2 amino acid sequences.  Two predicted epitope regions (Figure 4.3 A, 
blue and green boxes) that showed consensus among most of the amino acid sequences 
were selected for the design of the putative epitope-based vaccine and a homologous region 
across all the serotypes was also included in the sequence (Figure 4.3 A, purple box).  In total 
the putative predicted epitope-based oligomer consisted of 54 bp (codon optimised for N. 










4.3.2.  Assembly of the fusion product Zera®-VP2ep 
4.3.2.1.  PCR amplification of Zera® 
Zera® was amplified from the pZera™1 plasmid using the primers listed in Table 4.2.  The 
primers were designed to modify the 5’ and 3’ termini for the addition of AgeI and NcoI 
restriction enzyme sites, respectively.  Amplification resulted in an expected band at 350 bp 
(Figure 4.4).   
Figure 4.3:  (A) Two regions of the ClustalW multiple alignment of the amino acid sequences of eight 
VP2 serotypes.  The predicted epitope regions corresponding to most of the serotypes are shown below 
the alignment in bold and boxed in blue and green.  The homologous region is boxed in purple.  (B) The 













The band representing Zera® was excised and gel-purified to use as DNA template in further 
downstream reactions for assembly PCR of the fusion product.  
 
4.3.2.2.  Assembly PCR of VP2ep 
Two oligomers (VP2ep-F and VP2ep-R) containing a 12 bp complementary region were 
designed for the assembly of the synthetic putative epitope by PCR (Figure 4.5 A).  VP2ep-F 
and VP2ep-R also included 5’ MluI and 3’ XmaI restriction sites respectively, to facilitate 
cloning into the pEAQ-HT expression vector.  Addition of the restriction enzyme sites 
increased the size of the epitope from 54 bp to 70 bp.  The two oligomers were successfully 
annealed and amplified by assembly PCR, resulting in an expected fragment of 70 bp (Figure 




Figure 4.4:  PCR amplification of Zera® (white arrow) using Zera®-FP and Zera®-RP.  The negative 
control (-) was amplified with the same primer set, however the reaction contained water instead of 

















The annealed VP2ep product was purified from the PCR reaction for use as template in 
subsequent PCR reactions for assembly of the fusion product Zera®-VP2ep.   
 
4.3.2.3.  Assembly PCR of Zera®-VP2ep 
Zera® was successfully fused to VP2ep with a linker sequence (Table 4.2), as it has been 
shown that the linking of two proteins or domains with a universal peptide linker can potentially 
increase the expression of soluble proteins (Arai et al., 2001).  The fusion product Zera®-
VP2ep was assembled during first stage assembly PCR by using the nucleotide templates 
Zera®, VP2ep and the linker sequence.  These sequences were annealed and amplified with 
Figure 4.5:  (A) Schematic representation illustrating the two oligomers (VP2ep-F and VP2ep-R, with 
the restriction enzyme sites underlined) and the 12 bp complementary overlap to facilitate assembly of 
VP2ep.  (B) The assembled VP2ep (white arrow) at ~70 bp.  The negative control (-) reaction contained 
no template DNA.  Lane M represents the molecular weight marker.  
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overlapping primers (a schematic representation of first stage assembly PCR is shown in 
Figure 4.2).   
First stage assembly PCR resulted in a fragment of the expected size at 465 bp (white arrow) 
which indicated successful assembly of Zera®-VP2ep (Figure 4.6).  The smaller bands 
observed at ~350 bp and ~100 bp could possibly represent Zera® and VP2ep template DNA 
that did not anneal during assembly PCR.  
The Zera®-VP2ep DNA fragment obtained during first stage assembly PCR was gel-purified 
and used as template in second stage assembly PCR.  Second stage PCR was carried out 
with primers (Table 4.2, Zera®-FP and VP2ep-RP) that flanked the 5’ and 3’ regions of the 
complete Zera®-VP2ep fusion; these primers further ensured modification of the termini with 
AgeI and XmaI restriction enzyme sites.  Second stage assembly PCR resulted in an expected 












Figure 4.6:  First and second stage assembly PCR of Zera®-VP2ep showing a band at 465 bp (white 
arrow).  Both negative controls (-) contained water instead of DNA template.  Lane M represents the 
molecular weight marker.  
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4.3.3   Verification of pEAQ-HTZera®-VP2ep clones 
Zera®-VP2ep was successfully cloned into the pEAQ-HT plant expression vector and 
transformed into both E. coli DH5-α competent cells and A. tumefaciens LBA4404. 
Recombinant clones were screened by colony PCR using Zera®-FP and VP2ep-RP primers 
that bind the 5’ and 3’ termini of Zera®-VP2ep.  The recombinant clones produced an expected 
band at ~465 bp.  The recombinant pEAQ-HTZera®-VP2ep clone was further verified by 
restriction enzyme digestion using AgeI and XhoI restriction sites.  The AgeI restriction enzyme 
site is located at the 5’ termini of the gene, whereas the XhoI restriction site is located on the 
vector backbone just downstream of the Zera®-VP2ep XmaI 3’ site.  As expected, restriction 
enzyme digestion of the recombinant clone showed the presence of a 485 bp insert (results 
not shown). 
The pEAQ-HTZera®-VP2ep plasmid DNA was sequenced and confirmed by aligning the 
sequence data with the theoretical sequence using DNAMAN multiple alignment software 
(data not shown). 
 
4.3.4.  Construction and verification of pEAQ-HTZera®-VP2 clones 
To construct pEAQ-HTZera®-VP2, the pEAQ-HTZera®-VP2ep plasmid (Figure 4.7 A) was 
digested with the restriction enzymes MluI and XhoI.  This facilitated the removal of VP2ep 
(green box), with Zera® (pink box) and the linker (blue box) remaining on the pEAQ-HT 
backbone (Figure 4.7 B). VP2 was excised from the pTRAkc-rbcs1-cTPVP2co backbone 
(Chapter 2) using MluI and XhoI (data not shown), after which it was directionally cloned into 

















The pEAQ-HTZera®-VP2 plasmid DNA was successfully transformed into E. coli DH5-α 
competent cells and A. tumefaciens LBA4404.  The recombinant clones were screened with 
colony PCR using VP2-specific primers (Table 2.1, cTPVP2coF and cVP2coR).  Recombinant 
colonies resulted in the amplification of expected fragments at 2.8 kb.  The recombinant pEAQ-
HTZera®-VP2 clone was further verified by restriction enzyme digestion with AgeI and XhoI.  
Restriction digestion resulted in the expected banding pattern, with the VP2 insert at 2.8 kb 





Figure 4.7:  A schematic representation of the pEAQ-HTZera®-VP2ep (A) and pEAQ-HTZera®-VP2 
(C) plasmids, with the pEAQ-HTZera® (MluI / XhoI) backbone shown in (B). Zera® is represented by 
the pink box, the linker sequence by the blue box and VP2ep and VP2 is represented by the green and 
orange boxes, respectively.  A detailed map showing all the elements of the pEAQ-HT plant expression 
vector is shown in Figure 2.1 A (Chapter 2).  
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4.3.5.  Optimisation of transient Zera®-VP2ep and Zera®-VP2 expression in N. 
benthamiana 
Transient expression of Zera®-VP2ep and Zera®-VP2 in N. benthamiana was investigated 
over a 7 day period, where leaf discs were harvested at 2, 3, 5 and 7 days after infiltration.  
Plants were infiltrated at an OD600 of 0.5, 1.0 and 1.5 with Zera®-VP2ep or Zera®-VP2 to 
examine the effects of A. tumefaciens cell concentration on recombinant protein expression 
levels.  Protein accumulation was analysed with western blotting using rabbit-raised α-VP2R 
polyclonal serum produced against E. coli-expressed wtVP2.  Both proteins were detected, 
with predicted bands of Zera®-VP2ep and Zera®-VP2 at ~16 kDa and ~120 kDa, respectively 
(Figure 4.8).   
Zera®-VP2ep expression was observed on days 2, 3 and 5, with peak expression observed at 
3 dpi (Figure 4.8 A) when using an infiltration OD600 of 0.5.  The infiltrated leaves showed 
chlorosis with slight necrosis at the infiltration sites at 3 dpi (Figure 4.8 C – top panel), after 
which the infiltrated leaves became more necrotic.  When the cell concentration was increased 
to an OD600 of 1.0 and 1.5, the plants showed severe necrosis with blackening and drying out 
of the leaves (Figure 4.8 C – top panel).  In addition the increased cell concentration resulted 
in no expression of Zera®-VP2ep at any of the days sampled post infiltration (results not 
shown). 
In contrast, expression of Zera®-VP2 was only detected on western blots by using an infiltration 
OD600 of 1.5 (Figure 4.8 B).  Expression was observed from 5 dpi onward, with the highest 
levels detected at 7 dpi.  The high infiltration OD resulted in chlorosis of the leaves at 7 dpi 
(Figure 4.8 C), however it did not negatively affect expression of Zera®-VP2.  Even though the 
leaves that were infiltrated at lower cell concentrations (Figure 4.8 C) showed similar 
symptoms of chlorosis, no protein was detected using western blot analysis (results not 



































Figure 4.8:  Zera®-VP2ep (A) and Zera®-VP2 (B) expression time-trials at infiltration OD600 values of 
0.5 and 1.5, respectively.  Expressed protein in crude leaf extracts were detected by the α-VP2R 
polyclonal antibody.  Negative controls (-) were plants infiltrated with only infiltration medium.  White 
arrows indicate the position of the expressed proteins.  Lanes M represent the protein marker with sizes 
indicated in kDa.  (C) N. benthamiana leaves infiltrated with different A. tumefaciens cell concentrations.  
Leaves expressing Zera®-VP2ep and Zera®-VP2 were photographed at 3 and 7 dpi, respectively.  The 
negative control shows a leaf infiltrated with only infiltration medium at 7 dpi.   
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4.3.6.  In situ characterisation of PBs 
Having shown that optimal expression of Zera®-VP2ep and Zera®-VP2 occurred at 3 and 7 dpi 
respectively, it was undertaken to determine if these polypeptides were sequestered into PBs.  
Leaves infiltrated with A. tumefaciens harbouring the pEAQ-HTZera®-VP2ep and pEAQ-
HTZera®-VP2 plasmids were harvested at 3 dpi and 7 dpi respectively, after which the leaf 
sections were embedded in Spurr’s resin and subsequently viewed using TEM (Figure 4.9).     
Western blot analysis was carried out on the crude leaf samples with the α-VP2 antibody to 
confirm that Zera®-VP2ep and Zera®-VP2 were successfully expressed (data not shown).   
It has been shown that the Zera® domain containing the (PPPVHL)8 repeats and the Pro-X 
sequences allow for the accumulation of fusion proteins into membrane-bound protein bodies 
(Geli et al., 1994; Torrent et al., 2009a).  TEM of the embedded leaf material showed the 
presence of membrane-defined, spherical electron-dense PB-like structures ranging from 0.6 
µm to 1 µm in size in the cytoplasm of leaves expressing Zera®-VP2ep and Zera®-VP2 (Figure 
4.9 B and C, respectively).  These electron-dense structures were embedded in the cytoplasm 
along with organelles such as mitochondria and chloroplasts.  No structures resembling these 





Figure 4.9:  Transmission electron micrographs of leaf sections that were infiltrated with (A) infiltration medium, (B) pEAQ-HTZera®-VP2ep (C) and pEAQ-
HTZera®-VP2. PBs for both Zera®-VP2ep (B – green arrows) and Zera®-VP2 (C – orange arrows) were present as electron-dense structures within the cytoplasm 
(CYT) of the infiltrated leaves.  No similar structures were present in the negative control samples (A).  Scale bars:  (A):  0.2 µm; (B) and (C):  0.5 µm.  CW:  cell 







4.3.7.  Purification of PBs 
Since it was shown that Zera®-VP2ep and Zera®-VP2 successfully formed PB-like structures 
when expressed in N. benthamiana, the number of plants infiltrated was scaled up to allow 
purification of them by density gradient ultracentrifugation.   
After homogenisation, the crude plant extract was incubated at 4 °C with gentle agitation to 
facilitate sufficient extraction of the protein bodies from the plant material.  This was followed 
by clarifying the crude plant sap by filtration and low-speed centrifugation before the 
supernatant was applied to a sucrose cushion for purification.  Plant material infiltrated with 
infiltration medium only was subjected to the same extraction procedure. 
Western blot analysis of the clarified crude protein extracts obtained after low-speed 
centrifugation showed the presence of bands at ~16 kDa for Zera®-VP2ep (Figure 4.10 A[i]) 
and ~120 kDa for Zera®-VP2 when using the rabbit-raised α-VP2R polyclonal antibody (Figure 
4.10 A[ii]).  The detection of an additional band at ~26 kDa on the Zera®-VP2ep western blot 
(Figure 4.10 A[i], black arrow) could possibly represent oligomerised fusions of Zera®-VP2ep 
that did not denature completely.  No bands were detected in the crude extracts that were 
obtained from the negative control plants (Figure 4.10 A[i] and [ii]). 
Initially it was attempted to purify the PBs using discontinuous sucrose gradients (3 mL each 
of 19%, 27%, 42% and 56% sucrose in buffer PBP3), however western blot analysis of the 
fractions collected from the bottom of the tubes after ultracentrifugation showed the presence 
of Zera®-VP2ep and Zera®-VP2 in all the fractions, including the pellet (results not shown).   
Thus, instead of using discontinuous sucrose gradients for purification, the crude negative 
control, Zera®-VP2ep and Zera®-VP2 plant extracts were overlaid onto 42% sucrose cushions 
and centrifuged at 79 000 x g to facilitate collection of the dense PBs in the pellet.  The entire 
volume of the sucrose cushions was collected from the bottom of the tubes and the pellets 
resuspended in buffer PBP3.  The liquid on top (labelled TOP) of the sucrose cushions was 
also collected and analysed on dot blots probed with α-VP2R serum. 
Dot blots of the fractions collected for the negative control showed no colour development in 
either the pellet, the 42% sucrose fraction or the top fraction (Figure 4.10 B[i]).  These results 
indicate that the antibody did not react with any of the plant material.  Dot blots of Zera®-VP2ep 
and Zera®-VP2 showed a positive reaction with the pellet sample, indicating successful 
purification of the recombinant proteins after ultracentrifugation (Figure 4.10 B[ii] and [iii], 



















It was found that the purified PBs were very stable.  Western blot analysis of Zera®-VP2ep 
and Zera®-VP2 purified using 42% sucrose cushions always showed the presence of 
oligomerised proteins in the denatured samples, even after treating the purified proteins at   90 
°C with 5 x sample application buffer containing 500 mM DTT in order to denature them 
(results not shown).   
Figure 4.10:  (A) Western blot analysis of crude Zera®-VP2ep (i) and Zera®-VP2 (ii) extracted protein 
using α-VP2R as primary antibody.  White arrows indicate the respective proteins with the black arrow 
showing an oligomerised fusion of VP2ep.  In both cases the negative control (-) was plant material 
infiltrated with infiltration medium only that was extracted using the same method.  Lanes M indicate 
the molecular weight marker.  (B) Dot blots of (i) the negative control, (ii) Zera®-VP2ep and (iii) Zera®-
VP2 purified using a 42% sucrose cushion.   
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It was further investigated whether the sequential extraction process described by Joseph et 
al. (2012) would result in the solubilisation of the PBs.  The first solubilisation step facilitates 
the extraction of soluble and membrane-bound proteins, after which the second step extracts 
proteins that are linked by disulphide bridges.  The final heating step should theoretically result 
in solubilisation of the PB cores (Joseph et al., 2012).  After treatment with SDS and DTT, the 
PBs were mostly present in the final insoluble pellet as seen on the dot blot in Figure 4.11.  
For both Zera®-VP2ep and Zera®-VP2 protein was detected in the soluble fraction (S), 
however western blot analysis of these fractions still showed the presence of multiple bands 
on the blots representing oligomerised fusions of the recombinant proteins that could not be 
completely denatured (results not shown).  After the final solubilisation/centrifugation step the 
negative control contained no pellet, indicating that whatever protein was present in that 








Since the PBs were intended for immunogenic studies in mice, it was not desirable for the 
extraction buffers to contain reagents such as DTT or SDS, as these might be detrimental to 
the health of the animals.  Therefore, the pellet obtained after ultracentrifugation was washed 
with buffer PBP3 containing 10% sucrose to stabilise the PBs.   
The Zera®-VP2ep pellet was washed six times, and Zera®-VP2 and the negative control 
samples 10 times each with buffer PBP3 until the final pellet was white.  The final pellet 
obtained after washing was resuspended in 300 µL buffer PBP3 containing 10% sucrose and 
stored O/N at 4 °C in 1.5 mL microcentrifuge tubes.  For both the negative control and Zera®-
Figure 4.11:  A dot blot probed with α-VP2R showing the sequential solubilisation of PBs.  The negative 
control was plant material infiltrated with infiltration medium.  S:  soluble fraction; R:  fraction containing 
disulphide-linked proteins and H:  solubilised protein body cores.    
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VP2ep a white precipitate was present at the bottom of the tubes with green liquid (SNT) 
containing chlorophyll visible above the precipitate.  A sample of the chlorophyll-containing 
liquid was aspirated for analysis after which the white precipitate was mixed with the liquid 
resulting in a homogenous solution.  In contrast, the resuspended Zera®-VP2 final pellet 
remained in solution with no precipitate present in the tubes.   
The wash samples were analysed with dot blots that were probed with α-VP2R (Figure 4.12 
A), BTV-8 sheep serum raised against VLPs (Figure 4.12 B) and BTV-10 guinea pig serum 
(Figure 4.12 C).  Both Zera®-VP2ep and Zera®-VP2 were detected by all the sera used for dot 
blot analysis (Figure 4.12).  The green liquid (SNT) that was collected above the precipitated 
material in the negative control and Zera®-VP2ep did not react with any of the sera tested, 
suggesting that the PBs precipitated out of solution after standing O/N.   
When probing with α-VP2R (Figure 4.12 A), PBs were only detected in the final pellet for both 
Zera®-VP2ep and Zera®-VP2.  A slight colour reaction was observed for Zera®-VP2ep wash 
1, indicating that some of the PBs were solubilised after the first wash.  The negative control 
did not react with the rabbit-raised serum at all.   
The BTV-8 sheep serum (Figure 4.12 B) raised against plant-produced VLPs appeared to be 
more sensitive than the rabbit-raised serum as Zera®-VP2ep was detected in wash 1 and 2, 
as well as in the final pellet.  Zera®-VP2 protein was present in wash 1 – 7, including the final 
pellet.  The detection of the proteins in the wash fractions was possibly the result of gradual 
solubilisation of the PBs during the wash steps.   
The BTV-10 guinea pig serum (Figure 4.12 C) appeared to bind non-specifically to plant 
proteins, as it showed the presence of protein in wash 1 of the negative control sample.  
However the results obtained when probing Zera®-VP2ep and Zera®-VP2 were similar to that 
obtained with the rabbit and sheep serum, showing that the highest concentration of PBs were 




















Figure 4.12:  Dot blots of the wash fractions of the negative control, Zera®-VP2ep and Zera®-VP2 that 
were probed with 1: 2000 dilutions of α-VP2R (A), BTV-8 sheep serum raised against plant-produced 
VLPs (B) and BTV-10 guinea pig serum (C).  SNT:  green chlorophyll-containing liquid above the white 




4.3.8.  PB quantification 
The final resuspended pellets obtained for Zera®-VP2ep and Zera®-VP2 (Figure 4.12) were 
quantified for testing in subsequent animal experiments (Chapter 5).   
Even though bands representing the PBs could not be visualised on Coomassie-stained gels 
(data not shown), the gels did confirm the absence of contaminating plant proteins in the PB-
containing pellets.  
Zera®-VP2ep and Zera®-VP2 PBs were quantified by using the Bio-Rad DC Protein Assay kit.  
The TSP was determined from a standard curve of the average absorbance values obtained 
for the BSA standards (Figure 4.13).   
The TSP of Zera®-VP2ep was calculated to be ~1.39 mg/mL by using both the average 
absorbance values obtained for Zera®-VP2ep (Figure 4.13, green triangle) and the equation 
on the chart.  The total amount of Zera®-VP2ep PBs that were produced in plants was 
determined to be ~69.5 mg TSP per kilogram of fresh leaf material.   
Similarly, the TSP of Zera®-VP2 was calculated to be ~1.34 mg/mL (Figure 4.13, orange 
triangle).  The total yield of Zera®-VP2 PBs produced in plants was ~35 mg TSP per kilogram 











Figure 4.13:  TSP quantification of the Zera®-VP2ep and Zera®-VP2 PBs using BSA as a standard.  
The green and orange triangles indicate the average absorbance values obtained for Zera®-VP2ep and 
Zera®-VP2, respectively.  The error bars indicate the standard deviation. 




















4.4.  Discussion 
VP2 is the outermost exposed protein of the BTV virion and it is the most variable protein 
across the BTV serotypes (DeMaula et al., 2000).  Immunologically, VP2 is the most important 
BTV protein (Cowley and Gorman, 1987; Hassan and Roy, 1999; Marshall and Roy, 1990; 
Pierce et al., 1995; Urakawa et al., 1994), and VP2 on its own or together with VP5 have been 
tested as possible vaccine candidates with variable results (Noad and Roy, 2009a; Roy et al., 
2009).  The aims of this study was to investigate the production of two novel VP2-based 
vaccine candidates for BTV in N. benthamiana that would be cost-effective to produce, easy 
to purify and DIVA-compliant.   
The vaccine candidates designed in this study consisted of a synthetic peptide - VP2ep - 
constructed from in silico epitope predictions of VP2 and the full-length BTV-8 plant codon-
optimised VP2.  Both the VP2ep and BTV-8 VP2 sequences were fused to Zera® to direct the 
formation of PBs as both vaccine candidates were aimed at presenting the antigens to the 
immune system in a particulate form, thereby enhancing the extent of the immune response.  
In addition, these particular Zera®-fused PB vaccine candidates will allow for DIVA as the 
commercially available BTV diagnostic tests are mostly based on the detection of the group-
specific antigen VP7 (MacLachlan, 1994; Vellema, 2008).   
Epitopes are localised regions on the surfaces of antigens that are involved in its recognition 
by antibodies.  These peptide regions also have the ability to elicit an immune response and 
represent the smallest subunits that can be used therapeutically (Santi et al., 2006; Toussaint 
et al., 2008).  Many advantages such as safety, ease of production and analytical control are 
associated with the use of epitope-based vaccines:  with the presentation of specific epitopes 
a precise immune response can be directed at conserved and highly immunogenic regions of 
antigens of interest (Toussaint et al., 2008).  B-cell epitopes are parts of antigens that are 
recognised by the variable regions of antibodies (Sweredoski and Baldi, 2009).  Several 
epitope-based vaccines have been developed for the treatment of various cancers and the 
prevention of infectious diseases.  Epitope-based vaccines for the treatment of ovarian 
carcinoma, end-stage cervical cancer and melanoma have been successful and have entered 
or completed phase I and II clinical trials.(Chianese-Bullock et al., 2008; Kenter et al., 2008; 
Slingluff et al., 2003)  Furthermore, an epitope-based vaccine derived from the Epstein-Barr 
virus latency antigens has been shown to be immunogenic in pre-clinical trials in mice (Depil 
et al., 2007).   
For the Zera®-VP2ep vaccine candidate, the putative B-cell epitopes of VP2 from eight BTV 
serotypes was predicted using a computational system.  Two predicted epitope regions that 
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were similar for the eight VP2 amino acid sequences were included in design of the epitope-
based peptide.  Furthermore, to enable detection of the recombinantly expressed fusion 
protein with the antibodies used in this study, a homologous region consisting of eight 
conserved amino acids was also included in the peptide sequence.  The complete synthetic 
multi-epitope-based peptide - VP2ep - consisted of a total of 18 amino acids (Figure 4.3).   
The VP2ep sequence was successfully synthesized with assembly PCR yielding a final 
product of ~70 bp (Figure 4.5).  VP2ep was fused downstream of the Zera® sequence using 
assembly PCR, yielding Zera®-VP2ep (Figure 4.6), after which it was successfully cloned into 
the pEAQ-HT plant expression vector (Figure 4.7).   
Initial attempts to create a fusion product of Zera® with the full-length plant codon-optimised 
BTV-8 VP2 gene by assembly PCR was not successful (results not shown).  This was possibly 
due to the size of the gene (2.8 kb) and the extreme difference in annealing temperatures of 
the primers used for assembly PCR.  Therefore, to make the second vaccine candidate - 
Zera®-VP2 - VP2ep was excised from the recombinant pEAQ-HTZera®-VP2ep plasmid 
(Figure 4.7 A) and replaced with the full-length BTV-8 codon-optimised VP2, yielding the 
construct pEAQ-HTZera®-VP2 (Figure 4.7 C).   
Agrobacterium-mediated expression time-trials – where the cell concentration used for 
infiltration was also analysed - were carried out in N. benthamiana for both Zera®-VP2ep and 
Zera®-VP2.  From the time-trials it was determined that the highest levels of Zera®-VP2ep 
accumulation was achieved at 3 dpi using an infiltration OD600 of 0.5 (Figure 4.8 A).  Infiltration 
using an OD600 of 0.5 resulted in chlorosis of the infiltrated leaves (Figure 4.8 C – top panel).  
In contrast, higher cell concentrations (OD600 of 1.0 and 1.5) resulted in severe necrosis of the 
infiltrated leaves at 3 dpi.  Moreover, no expression of Zera®-VP2ep was detected after 
infiltration with the increased cell densities.  The fact that the polyclonal rabbit anti-VP2 serum 
(α-VP2R) that was made against full-length wtVP2 successfully detected the Zera®-VP2ep 
(Figure 4.8 A) fusion product was very promising.  These results confirmed that the epitopes 
selected for construction of the synthetic epitope-based vaccine were recognised by the 
antibodies that were present in the serum raised against the “natural” protein.   
In contrast to the expression of Zera®-VP2ep, the highest levels of Zera®-VP2 accumulation 
were observed at 7 dpi (Figure 4.8 B) after using an infiltration OD600 of 1.5.  The high cell 
density resulted in chlorosis of the infiltrated leaves (Figure 4.8 C – bottom panel), however it 
did not negatively affect protein expression.  The leaves infiltrated with lower cell densities 
(OD600 of 0.5 and 1.0) developed chlorosis, suggesting expression of proteins, however no 
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protein could be detected on western blots.  It is possible that protein was indeed expressed; 
however, the levels were too low to be detected using western blots.  
When comparing the visible effects of the two fusion products in plants (Figure 4.8 C), it was 
shown that expression of the epitope-based construct was more detrimental to the plants than 
expression of the full-length Zera®-VP2 fusion protein.  It has been shown that VP2 contains 
cytotoxic T-lymphocyte epitopes (Andrew et al., 1995): it is possible that some of these 
cytotoxic epitopes were selected in the design of the epitope-based vaccine and that over-
expression of these resulted in necrosis of the plants.  Furthermore, it has been postulated 
that recombinant fusion proteins are accumulated and concentrated to high levels within PBs  
(Llop-Tous et al., 2010); therefore it is possible that the concentration of the Zera®-VP2ep 
fusion protein within PBs resulted in necrosis when plants were infiltrated with higher A. 
tumefaciens cell concentrations (OD600 of 1.0 and 1.5).   
It was shown that transient expression of Zera®-VP2ep and Zera®-VP2 resulted in the 
formation of intact PBs that were present within the cytoplasm of plant cells as membrane-
defined electron-dense vesicles of different sizes (Figure 4.9).  These structures were similar 
in size and morphology to epidermal growth factor PBs produced in SF9 insect cells (Torrent 
et al., 2009a).  Two steps have been described for the formation of PBs:  (i) early synthesized 
Zera® fusion polypeptide chains promote self-assembly of Zera®, resulting in the origin of PBs 
and thereafter (ii) the continued synthesis of the fusion protein at later stages results in the PB 
growing by incorporating Zera® fusions into the PBs that were formed during the early stages 
of expression (Llop-Tous et al., 2010).  The different sizes that were observed for the Zera®-
VP2ep and Zera®-VP2 PBs (Figure 4.9 B and C, respectively) could be attributed to the 
occurrence of the two-step process described above.   
It was further undertaken to purify Zera®-VP2ep and Zera®-VP2 PBs on a discontinuous 
sucrose gradient.  Analysis of the fractions collected after ultracentrifugation showed that the 
proteins of interest were present in all the fractions, including the pellet (data not shown).  
These results could be attributed to the different sizes and therefore densities of early and 
mature protein bodies.  Similar results were obtained by Geli et al. (1994) after subcellular 
fractionation of transgenic plants expressing γ-zein.  Therefore, instead of purifying the fusion 
proteins on a discontinuous gradient, a 42% sucrose cushion was used to separate out 
contaminating plant proteins form the PBs in the plant extract.   
The crude Zera®-VP2ep and Zera®-VP2 plant extracts were analysed with western blotting 
before purification on the sucrose cushion (Figure 4.10 A).  A band of ~16 kDa (Figure 4.10 
A[i] – white arrow) confirmed the presence of Zera®-VP2ep in the crude plant sap, an additional 
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band (almost double the size of Zera®-VP2ep) representing oligomerised fusions of Zera®-
VP2ep was detected at ~26 kDa (Figure 4.10 A[i] – black arrow).  Western blot analysis of the 
Zera®-VP2 crude extract showed a single band at ~120 kDa (Figure 4.10 A[ii] – white arrow).  
Oligomerised fusions were not observed for Zera®-VP2 as an oligomer approximately double 
the size (~ 240 kDa) of Zera®-VP2 was not visualised on an 8% acrylamide gel.  Purification 
of Zera®-VP2ep and Zera®-VP2 PBs on a sucrose cushion resulted in the sedimentation of 
the PBs in the pellet (Figure 4.10 B), with no fusion proteins detected in the sucrose cushion 
or the top fractions.  The PBs in the pellet were shown to be very stable (Figure 4.11), as they 
remained insoluble and oligomerised even after subjection to the sequential extraction 
process using SDS, DTT and heating as described by Joseph et al. (2012).   
Recombinantly expressed VP2 is a complex protein that forms multimers stabilised by 
disulphide bonds (Hassan and Roy, 1999), resulting in the protein being insoluble when 
expressed in mammalian cells (Capocefalo et al., 2010) and E. coli (results not shown).  It is 
possible that the insoluble nature of VP2 combined with the stabilisation afforded by fusion of 
the protein to Zera®, rendered the fusion proteins completely insoluble and protected them 
against degradation.  
After sucrose cushion purification the pellet containing the PBs was washed multiple times 
with buffer PBP3 containing 10% sucrose until the resulting pellet was white and free of 
chlorophyll.  The addition of the sucrose further aided in stabilising the PBs during the wash 
steps.  For both the Zera®-VP2ep and Zera®-VP2 wash fractions, dot blots (Figure 4.12) were 
carried out using α-VP2R (rabbit raised serum against wtVP2), BTV-8 sheep serum (obtained 
from sheep vaccinated with BTV-8 VLPs) and BTV-10 guinea pig serum.  All the antibodies 
mainly detected the fusion proteins within the final pellet obtained after numerous wash steps.  
Even though washing of the PB pellets resulted in removal of the chlorophyll present after 
sucrose cushion purification, it did not result in the solubilisation of either Zera®-VP2ep or 
Zera®-VP2.   
Using TSP quantification, it was shown that ~69.5 mg of Zera®-VP2ep and 35 mg of Zera®-
VP2 per kilogram of fresh leaf material was purified from plant material after transient 
expression in N. benthamiana.  It is possible that the lower yields obtained for Zera®-VP2 could 
be attributed to the larger size of VP2 (111 kDa) compared to the small 2 kDa size of the 
synthetic epitope; furthermore the extremely insoluble nature of Zera®-VP2 possibly resulted 
in an under-estimation of the total TSP present in the sample.  
In conclusion, two novel particulate VP2-based vaccine candidates were successfully 
expressed in N. benthamiana and purified using ultracentrifugation.  A novel synthetic epitope 
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based on the amino acid sequences of eight BTV serotypes was synthesized from predictions 
obtained using computational software.  The Zera®-VP2ep and Zera®-VP2 fusion proteins 
were successfully detected with rabbit raised serum against the full-length wtVP2, BTV-8 
sheep serum raised against BTV-8 VLPS and BTV-10 guinea pig serum.  These results 
showed that antibodies in the sera were able to recognise and bind to the synthetic epitope, 
suggesting that regions encoding immunogenic epitopes were accurately selected for design 
of this vaccine candidate.  These results are promising, as success of the epitope-based 
vaccine could obviate the need for vaccination with a mixture of multiple serotypes since it 
contains putative epitopes for at least eight BTV serotypes.  Furthermore, it was shown that 
the fusion of both VP2ep and BTV8-VP2 to the Zera® sequence resulted in the formation of 
electron-dense PBs, or StorPro® organelles, when expressed in N. benthamiana.  The 
particulate nature of both Zera®-VP2ep and Zera®-VP2 makes these fusion proteins easy to 
purify and could possibly enhance their immunogenicity (Torrent et al., 1994). 
Since both vaccine candidates were shown to be particulate and both antigens could be 
detected with antisera raised against full-length wtVP2, BTV-8 VLPs and BTV-10, it was 
undertaken to preliminarily investigate the immunogenicity of these fusion proteins in mice 





Preliminary investigation of the immunogenicity of novel plant-produced 
candidate vaccines 
 
5.1.  Introduction 
The existence of 26 serotypes of Bluetongue virus (Maan et al., 2011a; Maan et al., 2011b) 
complicates control of the disease as animals need to be vaccinated against whichever strains 
are co-circulating in affected areas.  Even though VLP-based vaccines are excellent vaccine 
candidates, they are not DIVA vaccines, ie. naturally infected animals cannot be distinguished 
from vaccinated animals with the commercially available competitive enzyme linked 
immunosorbent assays (cELISA) that detects the presence of VP7 group-specific antibodies 
in sera (MacLachlan, 1994; Vellema, 2008).   
Vaccine antigens are selected by their ability to be immunogenic.  VP2 is the major serotype-
specific antigen of BTV and a very important component of the vaccines against BTV.  Studies 
have shown that a subunit VP2 vaccine was able to induce neutralising antibodies in sheep 
(Huismans et al., 1987; Roy et al., 1990b).  Chapter 4 of this thesis describes the development 
of a multivalent DIVA vaccine based on the fusion of three putative B-cell VP2 epitopes 
predicted for eight BTV serotypes using in silico methods.  The putative predicted epitopes 
(VP2ep) and full length VP2 sequences were successfully fused to Zera® to direct protein body 
formation and these PBs could potentially enhance the immune response.  
According to ERA Biotech (http://www.erabiotech.com/index.php/applications/zera-
vaccines/protein-particle-vaccines) vaccine antigens fused to Zera® have the ability to induce 
humoral immunity.  Moreover, these antigens have been shown to have intrinsic adjuvant 
properties, suggesting that the administration of adjuvant with the vaccine formulation is not 
needed (Whitehead et al., 2014).  It was shown in Chapter 4 that the epitope-based vaccine 
antigen (Zera®-VP2ep) could be detected using rabbit-raised serum obtained from animals 
inoculated with full-length BTV-8 wtVP2 as well as BTV-8 VLP-vaccinated sheep serum.   
BTV is an interferon alpha (IFN-α) inducer in adult mice, which plays an essential role in the 
antiviral innate immune response.  A BTV infection model was established in mice that are 
deficient in the alpha/beta interferon receptor (IFNAR (-/-)) making the mice unable to establish 
an antiviral state, therefore rendering them susceptible to BTV infection (Calvo-Pinilla et al., 
2009). This is a very useful system, especially when performing challenge experiments which 
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involve live BTV.  However, in the present study BALB/c mice were used as test animals since 
this preliminary study was aimed at evaluating the ability of the plant-produced VLPs, Zera®-
VP2ep and Zera®-VP2 candidate vaccines to stimulate humoral anti-VP2 immune responses.  





5.2.  Materials and Methods 
5.2.1.  Immunisation of mice 
Female BALB/c mice obtained from South African Vaccine Producers (SAVP, Johannesburg, 
South Africa) were housed in filter top micro-isolator cages under Biosafety Level 2 (BSL-2) 
conditions in the Animal Unit at the Health Science Faculty, University of Cape Town.  
Approval for this study was granted by the Animal Research Ethics Committee at the 
University of Cape Town (AEC# 011-016).   
Female mice (6-8 weeks old) were immunised with the vaccine candidates prepared as 
described in Chapters 3 and 4 to evaluate the immunogenicity of the plant-produced BTV-8 
VLPs and the particulate Zera®-VP2ep and Zera®-VP2 candidate vaccines. Dulbecco’s 
Phosphate Buffered Saline (DPBS, Sigma) was used as a negative control.  Vaccination 
details are shown in Table 5.1 below.  
 







BTV-8 VLPs G1 N/A 10 
BTV-8 VLPs G2 IFA 10 
Zera®-VP2ep G3 N/A 10 
Zera®-VP2 G4 N/A 10 
DPBS G5 N/A N/A 
1.  n = number of mice 
 
The immunogenicity study was carried out in duplicate (Experiment 1 and 2), with each 
experiment containing a total of 25 mice, divided into 5 groups (G1-G5) of 5 mice each.  The 
TSP of the vaccine candidates (VLPs:  Chapter 3, Section 3.3.5; Zera®-VP2ep and Zera®-
VP2:  Chapter 4, Section 4.3.8) was determined using the Bio-Rad DC Protein Assay kit.   The 
vaccine candidates (G1, G3 and G4) were prepared so as to contain 10 μg antigen in 100 µL 
DPBS.  Only one vaccine candidate, BTV-VLPs (G2), was administered in the presence of 
Incomplete Freund’s Adjuvant (IFA, Sigma-Aldrich).  This vaccine was adjusted to contain 10 
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μg antigen in 50 µL DPBS, after which IFA in a 1:1 ratio was added and the emulsion 
homogenised by vortexing.   
Pre-bleeds were collected from each mouse via the saphenous vein three days prior (Day -3) 
to vaccination.  The vaccine candidates were administered by subcutaneous injection into both 
the right and left flanks (50 µL each) on Day 0.  The mice were boosted on Day 28 with doses 
containing 10 µg of the appropriate antigens.  Final bleeds were obtained via cardiac puncture 
at Day 56.  Serum was isolated from the blood and stored at -80 °C.   
 
5.2.2.  ELISA detection of antibodies in mouse sera 
5.2.2.1.  Indirect ELISA for detection of anti-VP2 antibodies 
The anti-VP2 response was determined by indirect ELISA.  96-well Maxisorp® microtitre plates 
(Nunc) were coated with 100 μL/well (1 μg) of E. coli-produced BTV-8 wtVP2 (Chapter 4, 
Section 4.2.10.1) diluted in coating buffer (10 mM Tris, pH 8.5) and incubated O/N at 4 °C. 
The plates were blocked with TBS blocking buffer (5% non-fat dry milk in 1x TBS [50 mM Tris, 
150 mM NaCl, pH 7.5]) for 2 hrs at RT after which it was washed four times with 1x TST buffer 
(1x TBS [pH 7.5], 0.05% Tween®20).   
To evaluate the anti-VP2 immune response elicited by each mouse, the pre- and final bleed 
sera were diluted 1:50 in 100 μL TBS blocking buffer and added to each well, after which the 
plates were incubated for 2 hrs at RT.  Blank wells containing no antibody were included as 
background control.  The plates were washed four times with 1x TST buffer and 100 μL of 
goat anti-mouse IgG alkaline phosphatase conjugate (1:10 000, Sigma) diluted in blocking 
buffer was added per well and incubated for 1 hr at 37 °C.  After incubation the plates were 
washed four times with 1x TBS (pH 9) buffer and 200 μL SIGMAFAST™ p-Nitrophenyl 
phosphate (pNPP, Sigma) was added per well.  The plates were developed in the dark for 30 
min after which the absorbance was detected at 405 nm on a BIO-TEK® Powerwave XS 
microtitre plate reader.   
To determine the anti-VP2 binding titres, mouse sera from each group were pooled into 
vaccine groups (5 mice/vaccine) for analysis.  Final bleed mouse sera were diluted in TBS 
blocking buffer in a 4-fold series in triplicate ranging from a 1:50 dilution to 1:51 200. Mouse 
sera from the mice vaccinated with DPBS served as a negative control. Positive control wells 
to confirm that the ELISA was successful contained sheep serum that was isolated from sheep 
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previously inoculated with plant-produced BTV-8 VLPs and blank wells with no antibody were 
included for background control in all the ELISAs.  The indirect ELISA was carried out as 
described above and the anti-VP2 binding titres were expressed as a reciprocal of the 
maximum serum dilution which produced absorbance values that were three times greater 
than the corresponding pre-bleed serum diluted at 1:50.   
 
5.2.2.2.  Statistical analysis 
To calculate the statistical significance of the final bleed anti-VP2 responses between the 
vaccines and the negative control, a Kruskal-Wallis (KW) test was performed (due non-normal 
and heteroscedastic data) to compare medians among groups.  Statistical analysis was 
carried out using STATISTICA 64 (StatSoft, Inc.). 
 
5.2.2.3.  cELISA for detection of VP7 serogroup-specific antibodies 
Final bleed sera for all the vaccine candidates were analysed with the commercially available 
competitive ELISA (cELISA) BTV Antibody Test Kit (VMRD, Inc.).  For this assay plates are 
coated with VP7, the serogroup-specific BTV antigen. In the cELISA the VP7 serogroup-
specific antibodies present in the test sera compete with the horseradish peroxidase (HRP)-
conjugated monoclonal VP7 antibody for binding to the antigen (www.cabi.org/ahpc. 
www.vmrd.com).   
The cELISA was carried out according to the manufacturer’s instructions, each final bleed 
serum sample was analysed in triplicate.  Positive and negative control samples were included 
in the test kit.  Sera obtained from the Zera®-VP2ep, Zera®-VP2 and DPBS vaccinated mice 
served as additional negative controls for the cELISA, since the inocula did not contain VP7.  
The absorbances were determined at 620 nm on a BIO-TEK® Powerwave XS microtitre plate 
reader. 
 
5.2.3.  Western blot detection of anti-VP2 antibodies 
E. coli-produced BTV-8 wtVP2 antigen (Chapter 4, Section 4.2.10.1) or plant-produced BTV-
8 VP3 (Chapter 2, Section 2.3.5) was incubated at 90 °C for 10 min in sample application 
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buffer (Sambrook et al., 1989).  The proteins (~3 µg TSP each of the E. coli-expressed wtVP2 
and plant-expressed wtVP3) were separated on 8% SDS polyacrylamide gels, after which 
they were transferred onto nitrocellulose membranes as described in Chapter 2, Section 2.2.6.   
After transferring the proteins onto nitrocellulose membranes, the sections incorporating the 
100 kDa to 170 kDa proteins (where VP2 and VP3 were expected to be visualised) were 
incubated in blocking buffer for 4 hrs at RT.  Individual pre- and final bleed sera from both 
experiments were pooled into vaccine groups (10 mice per vaccine) and diluted 1:100 in 
blocking buffer.  The membrane strips were probed O/N at 4 °C with 1:100 dilution of BTV-8 
VLP sheep serum as positive control and the pooled mouse sera.   
Following incubation in the primary antibody the strips were washed four times, 15 min each, 
in blocking buffer.  The strips were probed for 1 hr at 37 °C with either anti-goat/sheep alkaline 
phosphatase-conjugated secondary antibody (1:10 000, Sigma-Aldrich) or anti-mouse IgG 
alkaline phosphatase-conjugated secondary antibody (1:10 000, Sigma) for the positive 
control or mouse sera, respectively.  The strips were washed four times, 15 min per wash, 






5.3.  Results 
5.3.1.  Humoral immune response against BTV-8 VP2 
5.3.1.1.  Indirect ELISA detection of anti-VP2 antibodies 
The humoral anti-VP2 immune responses elicited in the mice were analysed by indirect ELISA, 
using E. coli-produced BTV-8 wtVP2 as coating antigen.  Initial analysis of the pre-and final 
bleed sera of the individual mice showed the presence of anti-VP2 antibodies in only the final 
bleed sera of mice vaccinated with the Zera®-VP2ep and Zera®-VP2 candidate vaccines, 
therefore mouse sera from each group were pooled (5 mice/vaccine) for analysis of the anti-
VP2 binding titres.  In contrast, mice vaccinated with the VLP-based candidate vaccines 
showed no anti-VP2 response since the absorbance values obtained for the final bleed sera 
were similar to those obtained for the pre-bleed sera as well as the values obtained for the 
DPBS vaccinated control mice (Figure 5.1). 
The anti-VP2 titres of the mouse sera were determined for the VLP (with and without IFA), 
Zera®-VP2ep and Zera®-VP2 vaccinated mice. The antibody binding titres were expressed as 
the reciprocal of the maximum serum dilution containing absorbance values that were three 
times greater than the corresponding pre-bleed serum at 1:50.   
No anti-VP2 response was detected for the vaccine pre-bleeds (Figure 5.1 A) and the negative 
control vaccine (DPBS, Figure 5.1 C).  The positive control indirect ELISA using sheep serum 
(from sheep vaccinated with plant-produced VLPs) showed a good anti-VP2 response (Figure 
5.1 B), thereby validating the indirect ELISA.  The VLP vaccine candidates administered in the 
absence and presence of IFA (Figure 5.1 C; yellow and green lines, respectively) elicited no 
anti-VP2 immune response with titres similar to the values obtained for the pre-bleed sera and 
DPBS negative control (Figures 5.1 A and C). However, the Zera®-VP2ep vaccine elicited anti-
VP2 titres of 800, with an OD405 of ~0.177 (Figure 5.1 C, blue line) compared to an OD405 of 
~0.0039 obtained for the corresponding pre-bleed serum (Figure 5.1 A, blue marker).  In 
addition, the Zera®-VP2 vaccine candidate elicited anti-VP2 binding titres of 3200 at an OD405 
of ~0.0097 (Figure 5.1 C, pink line), compared to an OD405 value of ~0.0016 obtained for the 
























A box whisker plot statistical analysis (Figure 5.2) of the anti-VP2 responses elicited by the 
Zera®-VP2ep and Zera®-VP2 vaccine candidates, showed that the antibody levels were 
significantly higher for both vaccines compared to the DPBS negative control (Figure 5.2: KW; 
H = 22.002, N = 30,  p < 0.0001).  Since no anti-VP2 immune response was detected for VLP 
vaccinated mice, therefore these sera were not included in statistical analysis. 
 
Figure 5.1.  Indirect ELISA of mouse sera using E. coli-produced wtVP2 as antigen.  (A) Absorbance 
values of the vaccine pre-bleeds at 1:50 dilution.  (B) Titration of the ELISA positive control sheep serum 
produced against BTV-8 VLPs to validate the indirect ELISA.  (C) Titration of the mouse antisera 
produced against the VLPs (yellow line), VLPs+IFA (green line), Zera®-VP2ep (blue line), Zera®-VP2 
(pink line) and DPBS (negative control, grey line) vaccine candidates.  The markers indicate the mean 













5.3.1.2.  Western blot detection of E. coli-expressed wtVP2 
The ability of the antibodies produced against the two significant test vaccines (Zera®-VP2ep 
and Zera®-VP2) to recognise BTV-8 wtVP2 was further analysed by evaluating the anti-VP2 
humoral immune response of the Zera®-VP2ep and Zera®-VP2 vaccine candidates on western 
blots using E. coli produced BTV-8 wtVP2 as antigen.  This BTV-8 wtVP2 protein (~163kDa, 
Section 4.2.10.1) was expressed as a fusion product with a trigger factor chaperone and a 
translation enhancing element to achieve high level, soluble expression in E. coli 
(http://www.takara-bio.com).   
Individual pre-and final bleed mice sera from both experiments were pooled for each vaccine 
candidate and analysed for anti-VP2 responses (Figure 5.3).  
In Figure 5.3 E. coli-expressed wtVP2 (~163kDa, white arrow) was detected with the positive 
control sheep serum raised against plant-produced BTV-8 VLPs and the final bleed sera 
obtained from Zera®-VP2ep and Zera®-VP2 vaccinated mice.  Non-specific protein bands 
smaller than the ~163 kDa wtVP2 band were detected with all the serum samples, including 
the positive control.  These bands possibly represent truncated versions of the E. coli-
expressed wtVP2.  It has been shown that heterologous expression in E. coli often results in 
Figure 5.2:  A box whisker plot comparing the results of the Zera®-VP2ep (blue box) and Zera®-VP2 
(pink box) vaccines with the DPBS (grey box) vaccinated mice to determine the statistical significance 
of the immune responses.  The boxes (blue, pink and grey) indicate the values within which 25-75% of 
the data are confined.  The black boxes indicate the median values and the minimum and maximum 
values are displayed by the whiskers (vertical bars).  
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the expression of truncated versions of the expressed proteins due to abundant codons found 
in heterologous genes which cause translational stalling and termination of protein expression 







5.3.2.  Analysis of the humoral immune response elicited by the VLP-based 
vaccine candidates 
5.3.2.1.  cELISA detection of anti-VP7 antibodies 
Since no anti-VP2 response was detected for the VLP-based vaccines (in the absence and 
presence of IFA), it was proposed that this was a result of instability of the VLPs and that the 
outer capsid proteins, VP2 and VP5, had degraded or dissociated from the CLPs by the time 
the mice were vaccinated.  To determine if CLPs, consisting of VP3 and VP7, were present in 
the vaccine dose at the time of vaccination a cELISA (VMRD, Inc) was carried out on the 
pooled final bleed sera of all the vaccine candidates using the commercially available cELISA 
kit (Figure 5.4).  
This cELISA is based on antibodies in the test sera competing with the HRP-conjugated 
monoclonal VP7 antibody for binding to the antigen.  Therefore, sera containing anti-VP7 
antibodies produces lower OD620 values than 50% of the mean negative as the antibodies in 
the sera outcompete the HRP-labelled antibody for binding to the antigen.  
Figure 5.3:  Western blot detection of E. coli-expressed wtVP2 with 1:100 dilution of pooled mice sera 
from animals vaccinated with the Zera®-VP2ep and Zera®-VP2 vaccines.  Lane M represents the 
molecular weight marker.  The negative control (-) was performed with no primary antibody and sheep 
serum obtained from BTV-8 VLP vaccinated sheep was used as the positive control (+).  Lanes PB and 
FB represent the pre-and final bleed sera respectively.  The white arrow indicates E. coli-expressed 
wtVP2 at ~163 kDa.  
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cELISA analysis of the test sera indicated that mice vaccinated with VLPs (Figure 5.4, without 
[yellow bar] and with IFA [green bar]) produced antibodies against VP7.  Lower absorbance 
values were obtained with the sera of mice vaccinated with VLPs in the presence of IFA, 
suggesting that the presence of adjuvant enhanced the immune response. As expected, no 
anti-VP7 response was measured in the kit negative control (light blue bar) as well as the sera 











5.3.2.2.  Western blot detection of plant-expressed BTV-8 VP3 
Since it was shown with the commercial cELISA that VP7 was present in the VLP vaccines, it 
was undertaken to determine if VP3 was still present in the vaccine candidate.  These 
experiments were carried out as there were concerns that the VLPs had degraded after 
storage at 4 °C.  Pooled antisera from mice vaccinated with the VLP candidate vaccine 
(without and with IFA) was analysed with western blots where plant-expressed BTV-8 VP3 
was used as antigen (Figure 5.5) 
Figure 5.4:  Commercial cELISA of mouse sera using VP7 (www.cabi.org/ahpc; www.vmrd.com) as 
antigen.  The dotted line at OD620 = ~0.26 represents 50% of the mean values obtained for the negative 
control.  Samples are positive for anti-VP7 antibodies if OD620 ˂ 50% of the mean negative control and 
negative samples have OD620 values ≥ 50% of the mean negative control.  Positive and negative 
controls were included in the cELISA kit.  Error bars indicate the standard deviation. 
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The VLP-based vaccines - administered without and with IFA - elicited an anti-VP3 immune 
response, as VP3 bands were detected at ~102 kDa (Figure 5.5, white arrow) using the 
antisera and positive control sheep serum.  The anti-VP3 immune response in mice vaccinated 
with only VLPs was weaker than that of the mice vaccinated with VLPs in the presence of IFA 








Figure 5.5:  Western blot detection of plant-expressed VP3 with 1:100 dilution of pooled mice sera from 
animals vaccinated with the VLP-based vaccines (without and with IFA).  Lane M represents the 
molecular weight marker.  The negative control (-) was performed with no primary antibody and sheep 
serum obtained from BTV-8 VLP vaccinated sheep was used as the positive control (+).  Lanes PB and 
FB represent the pre-and final bleed sera respectively.  The white arrow indicates plant-expressed VP3 
at ~102 kDa. 
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5.4.  Discussion 
The most effective means of controlling BT is through vaccination and many vaccine 
candidates have been developed against BT – with varying degrees of success (Stewart et 
al., 2012).  Recombinant vaccines are promising vaccine candidates as they have the potential 
to be safer than attenuated vaccines with no risk of reassortment and they can be DIVA 
compliant (Calvo-Pinilla et al., 2012; Noad and Roy, 2003)   
In this study, a preliminary investigation of the immunogenicity of three novel plant-produced 
vaccine candidates was carried out.  BALB/c mice were subcutaneously vaccinated with    10 
µg each of the VLP vaccine (without and with IFA) and the protein body (Zera®-VP2ep and 
Zera®-VP2) vaccine candidates.  The mice received booster vaccinations containing 10 µg of 
plant-produced antigen after 28 days.  
The detection of anti-VP2 antibodies in mouse antisera was done by indirect ELISA and 
western blotting using E. coli-produced wtVP2 as antigen.  The vaccine pre-bleeds and 
negative control vaccine (DPBS) gave no anti-VP2 responses (Figure 5.1 A and C, 
respectively).  For the VLP vaccine candidate no anti-VP2 immune response was detected in 
mice vaccinated with either the VLPs on their own or in the presence of IFA (Figure 5.1 C), 
suggesting that the outer capsid protein – VP2 – was not present at the time of vaccination.   
To explain this result, we propose that the lack of anti-VP2 immune responses in VLP-
vaccinated mice could have been a result of the vaccine doses not consisting of intact VLPs 
as the particles were not stable during storage at 4 °C, which resulted in the dissociation and 
degradation of the outer capsid proteins, VP2 and VP5, from the scaffolding provided by CLPs.  
For VLPs to be suitable as vaccines, it is vital that their structural integrity is preserved during 
purification and storage and that conditions for maintaining this need to be resolved.  Stability 
of the BTV VLPs could possibly be enhanced by storage in polyols such as sorbitol and 
trehalose; which are natural substances found in plants, fungi and algae (Bolen, 2004). These 
polyols have been shown to be safe for use as stabilisers in Norwalk VLP (Kissmann et al., 
2008) and the rotavirus VLP vaccine  (Peixoto et al., 2007) preparations.  Furthermore, it has 
been reported by Lynch et al. (2012) that the addition of 15% trehalose to human 
immunodeficiency virus (HIV) VLPs resulted in the particles retaining their original appearance 
over a period of 12 months.  The temperature at which VLPs are stored can also play a role 
in maintaining their structural integrity and it is important that stability studies are carried out 
at different temperatures over a period of time.  
Further analysis of the serum from mice inoculated with VLPs using the cELISA kit (VMRD, 
Inc) showed the presence of anti-VP7 antibodies (Figure 5.4).  Furthermore antibodies in this 
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serum was also successful in detecting plant-produced VP3 antigen (~102 kDa) with western 
blot analysis (Figure 5.5).  Antisera from mice vaccinated with VLPs showed that the immune 
response was enhanced when VLPs were administered in the presence of IFA (Figures 5.4 
and 5.5).  These results further support the abovementioned proposition that the VLPs used 
for vaccination of the mice were not stable and that the outer capsid proteins had dissociated 
and degraded leaving only intact CLPs (VP3 and VP7) in the vaccine preparation.   
Both the Zera®-VP2ep and Zera®-VP2 vaccine candidates successfully detected E. coli-
expressed BTV-8 wtVP2 indicating the stimulation of production of antibodies against this 
protein.  The Zera®-VP2ep and Zera®-VP2 vaccine candidates elicited anti-VP2 immune 
responses with binding titres of 800 and 3200, respectively (Figure 5.1 C).  Furthermore, the 
anti-VP2 responses measured for antisera from both protein body vaccine candidates were 
shown to be significant (p < 0.0001) in comparison to the negative control (Figure 5.2).   
Zera®-VP2ep and Zera®-VP2 antisera successfully detected E. coli-expressed BTV-8 wtVP2 
(Figure 5.3) on a western blot.  The final bleed antisera from both vaccine candidates and the 
positive control sheep serum detected wtVP2 at ~163 kDa; bands representing truncated 
versions of the E. coli-expressed wtVP2 was also detected.  No non-specific bands were 
detected with the pre-bleed sera. 
Unfortunately, the lack of an anti-VP2 response in mice inoculated with VLPs (with and without 
IFA) precluded the comparison of the immune responses measured in mice vaccinated with 
Zera®-VP2ep and Zera®-VP2.   
In conclusion, Zera®-VP2ep and Zera®-VP2 - the two novel protein body vaccine candidates 
encoding the predicted putative B-cell epitopes of VP2 and full-length codon-optimised VP2 
fused to Zera® to make particulate vaccines – were successful in eliciting anti-VP2 humoral 
immune responses in mice.  Results from the indirect ELISA and western blots showed that 
antibodies raised against the putative multi-epitope, VP2ep (predicted using in silico methods, 
Chapter 4) were able to bind the full length recombinant wtVP2, further supporting the findings 
(Chapter 4) that immunogenic-specific epitope sequences were successfully predicted and 
included in the design of this vaccine.  Moreover, the reaction of the antibodies in both ELISA 
and western blots means the antibodies elicited in vaccinated mice would almost certainly 
bind native protein as well as denatured protein, meaning they have the potential to protect 
against infection.  
Future research of the Zera®-VP2ep vaccine should include studies to determine if the 
antiserum produced in this study is successful in detecting VP2 from other BTV serotypes, 
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thereby confirming the multivalency of the epitope-based vaccine candidate.  The Zera®-
VP2ep vaccine candidate shows potential for further development as a BTV vaccine that is 




Chapter 6:   
General discussion and conclusions 
 
6.1.  General discussion 
The incursion of BTV-8 into northern Europe in 2006 resulted in significant economic losses 
due to mortality of affected livestock, but more importantly due to the ban of ruminant trade 
between affected and non-affected regions (Maan et al., 2010).  In an effort to limit the direct 
losses incurred with BTV infection and to minimize circulation of the virus, vaccination of 
livestock was undertaken by European countries (Noad and Roy, 2009a; Savini et al., 2008).  
The types of BTV vaccines that are currently available for use in the European community and 
in South Africa include inactivated virus vaccines and MLV vaccines (Coetzee et al., 2012; 
Dungu et al., 2004b; Niedbalski, 2011; Noad and Roy, 2009a; Savini et al., 2008).  The 
disadvantages associated with these vaccines include: high cost of production, the risks of 
reassortment with wild type field strains or reversion to virulence, and lastly, the inability to 
distinguish naturally infected from vaccinated animals with current serological methods 
(Batten et al., 2008b; Di Emidio et al., 2004; Roy et al., 2009; Savini et al., 2008).  
The problems associated with the use of MLV and inactivated vaccines have led to the 
consideration of recombinant vaccines for the control of BTV.  Various recombinant vaccines 
have been developed, with VLP-based vaccines being the most promising candidate (Noad 
and Roy, 2003; Roy and Noad, 2008; Stewart et al., 2013).  Even though the insect cell-
produced VLPs are effective they are not commercially available, possibly because their cost 
of production is very high and production of vaccines for different serotypes requires different 
clones, therefore this system is not economically feasible for producing vaccines against 
multiple serotypes.  Alternative methods for the large scale production of these vaccines is 
desirable.  Plant-based protein expression provides a cost-effective method for large scale 
production of vaccine antigens (Fischer et al., 2004; Rybicki, 2010; Sainsbury and 
Lomonossoff, 2008). Recently BTV-8 VLPs were successfully produced via transient 
expression in N. benthamiana, and were shown to elicit protective immunity in vaccinated 
sheep (Thuenemann et al., 2013).  The promise of plant-produced VLPs, led to the present 
study which investigated optimisation of transient expression of BTV-8 VLPs, as well as the 
expression of two novel recombinant BTV vaccine candidates that presents VP2 to the 
immune system in particulate form.  
127 
 
The aims of this study were to compare transient expression of the BTV-8 plant codon-
optimised capsid protein genes using different plant expression vectors with a view to forming 
VLPs which could be potentially used as a vaccine.  The best expression vector from this 
study was selected for further optimisation to increase VLP expression levels and subsequent 
purification which would be appropriate for dosing and which would facilitate quantitation and 
characterisation of the VLPs.  This study was taken further to produce two novel second 
generation plant-produced vaccines that utilise the immunogenic capacity of VP2.  These 
vaccine candidates were based on the fusion of multiple B-cell epitopes predicted for VP2 and 
the full length BTV-8 VP2 fused to a signal peptide that facilitates protein body (PB) formation.  
The epitope-based vaccine would be simpler and more cost-effective to produce at a large 
scale as it requires expression of only one recombinant A. tumefaciens construct, compared 
to two or four A. tumefaciens constructs required for heterologous expression of VLPs.  Lastly, 
it was undertaken to analyse the immunogenicity of the VLP and PB vaccine candidates in 
mice.    
Expression levels of proteins can be increased by using vectors that target expressed proteins 
to different organelles within the plant cell (Maclean et al., 2007).  Therefore, A. tumefaciens-
mediated transient co-expression of the BTV-8 capsid proteins in N. benthamiana was 
compared using several different expression vectors available in-house.  Expression with the 
pTRA vectors, which target heterologous proteins to the cytoplasm, chloroplast and apoplast 
(Maclean et al., 2007), was compared to expression with the pEAQ-HT vector, which targets 
expressed proteins to the cytoplasm (Sainsbury et al., 2009).  This is the first study which 
directly compares co-expression of the four BTV-8 plant codon-optimised capsid proteins 
using different plant expression vectors.  By adjusting the infiltration ratio of the recombinant 
A. tumefaciens constructs harbouring the four capsid genes to 1:1:2:1 (VP2:VP3:VP5:VP7) 
and by increasing the cell concentration used for infiltration, it was shown that the pEAQ-HT 
vector was the only vector that could successfully co-express all four capsid proteins at 
detectable levels.  Although the pTRA vectors were able to express the proteins separately, 
none were able to co-express all four capsid proteins simultaneously.  Thus, the pEAQ-HT 
vector was therefore selected as the most suitable vector for co-expression of BTV-8 VLPs.  
Agrobacterium-mediated transient expression of BTV-8 VLPs with the pEAQ-HT vector 
construts was further optimised by investigating longer expression times as well as the ratios 
used for infiltration of the four A. tumefaciens constructs harbouring the recombinant pEAQ-
HT plasmids.  The best co-expression and purification of VLPs were found to be after 9 days 
using a relative vector infiltration ratio of 1:1:2:1 (VP2:VP3:VP5:VP7). Both continuous and 
discontinuous iodixanol gradients were investigated for the purification of VLPs, and it was 
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shown with TEM that discontinuous gradients were important for the purification of structurally 
intact VLPs.  These results were similar to sucrose gradient purification experiments 
performed for insect cell-produced VLPs (Stewart et al., 2010). It was further undertaken to 
determine where in the plant cell the VLPs were localised.  TEM analysis of infiltrated leaf 
sections showed that co-expression of the four capsid proteins resulted in assembly of higher 
order structures.  Mixed populations consisting of large numbers of CLPs and VLPs were 
present as paracrystalline arrays within the cytoplasm of plant cells. To the best of our 
knowledge, this is the first report showing assembled CLPs and VLPs within plant cells. 
Similarly, French and Roy (1990) showed that CLPs aggregated as paracrystalline arrays 
within the cytoplasm of insect cells co-expressing VP3 and VP7.  The final yield of purified 
VLPs using the optimised protocol was ~27 mg TSP per kilogram of fresh leaf tissue.  This 
was 2.5 times less than the ~70 mg VLPs per kilogram of fresh weight plant material obtained 
by expression with the pEAQexpress vector (Thuenemann et al., 2013).  However, these 
yields were sufficient to provide doses for testing the immunogenicity of the VLP vaccine 
candidate.    
Even though recombinant VLPs are excellent vaccine candidates (Crisci et al., 2012), they 
can only provide protection against one of the 26 serotypes of BTV, unless they are 
administered as a cocktail containing VLPs representing multiple serotypes of the virus.  The 
possibility of instability of the VLPs could result in the existence of a mixture of CLPs and VLPs 
within a vaccine preparation which presents a problem when vaccinating animals, as these 
vaccines cannot be tested by the user for the presence of all four proteins in the field prior to 
vaccination.  Furthermore, even though VLP vaccines are DIVA compliant when using nucleic-
acid type assays (Hofmann et al., 2008; Mayo et al., 2010), at present the commercially 
available serological BTV diagnostic tests are mostly based on the detection of the group-
specific antigen, VP7 (MacLachlan, 1994; Vellema, 2008).  Thus, when animals are 
vaccinated with recombinantly produced VLPs, antibodies against VP7 will react with the 
group-specific antigen in the serological diagnostic tests resulting in the inability to distinguish 
between vaccinated and naturally infected animals.   
Therefore, in an effort to find alternative, possibly multivalent vaccine candidates for BTV it 
was undertaken to design and express two novel second-generation vaccines in N. 
benthamiana.  The first vaccine is based on synthetic B-cell epitopes predicted for multiple 
serotypes of VP2 by using online computational methods; the second vaccine is based on 
incorporation of the full length BTV-8 VP2 only.  By utilising the immunogenic properties of 
only VP2, these vaccine candidates were aimed at being DIVA-compliant using current 
commercially available serological diagnostic tests which are dependent on detecting the 
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presence of VP7.  The putative multi-epitope (VP2ep) and full length BTV-8 VP2 were both 
fused to a synthetic peptide, Zera®, to induce accumulation of the proteins in dense PBs called 
StorPro® organelles (ERA Biotech, Spain).  PBs have been shown to enhance immunogenicity 
of the fusion proteins by presenting the recombinant protein to the immune system in 
particulate form.  Both Zera®-VP2ep and Zera®-VP2 proteins were successfully expressed in 
plants and it was shown with TEM that both these constructs directed the accumulation of 
proteins in electron-dense granules – StorPro® organelles – that were surrounded by a 
membrane, within the cytoplasm of plant cells.  Antibodies raised against the full length wild 
type BTV-8 VP2, BTV-8 sheep serum raised against VLPs (Thuenemann et al., 2013) and 
BTV-10 guinea pig antiserum were able to detect Zera®-VP2ep with western– and dotblot 
analysis. These results were very promising, as it suggested that the predicted putative VP2 
multi-epitope contained regions that were able to bind to the antibodies produced against 
native VP2 in the antisera and it can potentially be used to stimulate antibodies against BTV 
VP2 representing other serotypes.     
It was further demonstrated that the PBs were easily purified on a sucrose cushion due to their 
dense nature.  The purified PBs were extremely stable and insoluble, even after treatment 
with SDS, DTT and heat.  The sequestration of proteins in PBs that are membrane-delimited 
has been shown to protect fusion proteins from proteolytic degradation (Torrent et al., 2009a).  
The stability of the PBs is ideal for vaccines, as it means the vaccine candidates can be stored 
at 4 °C for extended periods of time without the risk of degradation or proteolysis.  Expression 
and purification of the two PB candidate vaccines, Zera®-VP2ep and Zera®-VP2, resulted in 
yields of ~69.5 mg and ~35 mg TSP per kilogram of fresh leaf material. Another major 
advantage of using the Zera®-VP2ep and Zera®-VP2 vaccines is the ability to distinguish 
vaccinated from infected animals by using the commercially available cELISA.   
Preliminary tests to analyse the immunogenicity of the VLPs, Zera®-VP2ep and Zera®-VP2 
candidate vaccines were carried out in BALB/c mice.  It was shown by Thuenemann et al. 
(2013) that VLPs produced using the pEAQexpress expression vector were stable and they 
were able to elicit neutralising antibody responses in sheep.  However, in our study, analysis 
of the VLP vaccine candidates with and without adjuvant showed that the particles produced 
were not stable as they had degraded to their core components, VP3 and VP7, by the time of 
vaccination.  It is possible that the VLPs produced by Thuenemann et al. (2013) were more 
stable than the VLPs produced in this study because both inner and both outer capsid genes 
were expressed from the same T-DNA, ensuring that stable protein complexes from within the 
plant cells expressing these genes.  In contrast, this proof of concept study showed that both 
the Zera®-VP2ep and Zera®-VP2 candidate vaccines elicited significant anti-VP2 humoral 
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immune responses in the vaccinated mice.  Both these vaccines were administered without 
adjuvant as it has been shown that Zera® has adjuvanting properties and that it is able to 
enhance antibody responses in subunit vaccines (Whitehead et al., 2014).  These novel PB 
vaccine candidates have great potential for the use of BTV vaccines, as they are quick and 
simple to produce and purify.  Furthermore, it was shown that these PB vaccine candidates 
are extremely stable, making them ideal as rapid response vaccines.   
 
6.2.  Future research and conclusions 
This study was successful in achieving the primary aims of this study, which included 
identifying the best plant expression vector available to us for the production of BTV-8 VLPs.  
A purification method was developed to produce sufficient levels of particles for testing in mice. 
Moreover, two novel PB vaccine candidates, Zera®-VP2ep and Zera®-VP2, were designed 
and successfully tested for expression in N. benthamiana.  Continued research is required to 
determine the efficacy of these novel PB vaccine candidates. This could include investigating 
alternative expression vectors, such as the MagnICON® expression system to increase 
expression levels of the PB vaccine candidates.  
VLPs were successfully produced in this study; however they were not stable. It is suggested 
that the pEAQexpress plant expression system described by Thuenemann et al. (2013) - 
where two proteins are expressed from a single T-DNA - be investigated further as a rapid 
response system for the production of VLP vaccines for BTV.  This could possibly be achieved 
by always using the more conserved proteins VP3, VP5 and VP7 as a “universal core” and 
interchanging the variable, serotype specific protein, VP2, with VP2 from whichever strain of 
BTV is circulating at the time of an outbreak.   
It is important to determine if the epitope-based vaccine candidate, Zera®-VP2ep, is able to 
bind antibodies from different BTV serotypes, this would be done by serum neutralisation 
assays and ELISAs to determine if the predicted epitope is able to cross-react with other BTV 
serotypes, including BTV-8.  By incorporating a wider range of the predicted VP2 B-cell 
epitopes within the synthetic peptide, cross-reactivity of the candidate vaccine with more 
serotypes could be achieved.  Should the Zera®-VP2ep vaccine candidate be successful, it 
could obviate the need for vaccination with a cocktail of BTV serotypes, resulting in “broad-
spectrum” protection.   
Similar to the VLP-based vaccine, the Zera®-VP2 candidate vaccine should also be 
investigated as a rapid response vaccine, as it is straightforward to replace the current BTV-8 
131 
 
VP2.  It was shown by Roy et al. (1990b) that vaccination of sheep with both recombinant VP2 
and VP5 resulted in complete protection of vaccinated animals, suggesting it could be possible 
to further enhance the immune response obtained with Zera®-VP2ep and Zera®-VP2 by 
creating fusion proteins that include VP5.   
In conclusion, to the best of our knowledge, this is the first study that directly compares co-
expression of the BTV capsid proteins using different expression vectors in plants.  This is 
also the first report that provides TEM evidence of the accumulation of assembled CLPs and 
VLPs within the cytoplasm of plant cells co-expressing the four BTV-8 capsid proteins.  
Additionally, this is the first study to investigate the design, expression and immunogenicity of 
two novel BTV PB vaccine candidates.  Importantly, Zera®-VP2ep is the first multi-epitope-
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